

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁵ : C12N 15/55, 15/62, A23K 1/165 C12N 1/15 // (C12N 1/15 C12R 1:885)</p>	<p>A1</p>	<p>(11) International Publication Number: WO 94/03612 (43) International Publication Date: 17 February 1994 (17.02.94)</p>
<p>(21) International Application Number: PCT/FI93/00310 (22) International Filing Date: 30 July 1993 (30.07.93) (30) Priority data: 923,724 31 July 1992 (31.07.92) US (71) Applicant (for all designated States except US): ALKO LTD. [FI/FI]; Salmisaarenranta 7H, FIN-00180 Helsinki (FI). (72) Inventors; and (75) Inventors/Applicants (for US only): NEVALAINEN, Hele- na, K., M. [FI/FI]; Elsankuja 2 K 81, FIN-02230 Espoo (FI). PALOHEIMO, Marja, T. [FI/FI]; Töölönkatu 32 b A 7, FIN-00260 Helsinki (FI). MIETTINEN-OINON- EN, Arja, S., K. [FI/FI]; Nissnikuntie 1 F 22, FIN-02430 Masala (FI). TORKKELI, Tuula, K. [FI/FI]; Koillisväy- lä 17 C 27, FIN-00200 Helsinki (FI). CANTRELL, Mi- chael [US/US]; 1204 B 36th N.E., Seattle, WA 98125 (US). PIDDINGTON, Cristopher [US/US]; 736 N 70th Street, Seattle, WA 98103 (US). RAMBOSEK, John, A. [US/US]; 7701 17th Avenue, N.E., Seattle, WA 98115 (US). TURUNEN, Marja, K. [FI/FI]; Raisiontie 7 A 3, FIN-00280 Helsinki (FI). FAGERSTRÖM, Richard, B. [FI/FI]; Kielotie 18 A, FIN-02260 Espoo (FI).</p>		<p>(74) Agent: PAPULA REIN LAHTELA OY; Box 981, Salom- onkatu 17 B, FIN-00101 Helsinki (FI). (81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: PRODUCTION OF PHYTATE DEGRADING ENZYMES IN <i>TRICHODERMA</i> (57) Abstract A highly efficient overexpression system for phytase and pH 2.5 acid phosphatase in <i>Trichoderma</i> is described. This sys- tem results in enzyme compositions that are especially useful in the animal feed industry.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TC	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

TITLE OF THE INVENTION**PRODUCTION OF PHYTATE DEGRADING ENZYMES
IN *TRICHODERMA***BACKGROUND OF THE INVENTION

5 The mesophilic filamentous fungus *Trichoderma reesei* is very efficient in secreting cellulase enzymes into the growth medium. In optimized cultivation conditions amounts, up to 40 g/l of extracellular cellulase have been reported (Durand *et al.*, *Enzyme Microb. Technol.* 10:341-346 (1988); Durand *et al.*, in *Biochemistry and Genetics of Cellulose-Degradation*.
10 Academic Press, 1988, pp. 135-151).

 Development of transformation systems for *T. reesei* (Knowles *et al.*, EP244,234; Penttilä *et al.*, *Gene* 61:155-164 (1987); Berka *et al.*, EP215,594) has made possible the application of genetic engineering methods to the fungus. By genetic engineering, production profiles of different cellulase
15 enzymes have been modulated e.g., to give strains with improved levels of the endoglucanase I enzyme. The strong *cbh1* promoter has been applied to promote endoglucanase expression (Nevalainen *et al.*, "The molecular biology of *Trichoderma* and its application to the expression of both homologous and heterologous genes." in *Molecular Industrial Mycology*, Leong and Berka.
20 eds., Marcel Dekker Inc., New York, pp. 129-148 (1991); and Harkki, A. *et al.*, *Enzyme Microb. Technol.* 13:227-233 (1991)).

 In addition to tailoring the production profiles of homologous proteins, the production potential of *T. reesei* has been harnessed to express various heterologous proteins in the fungus. So far examples are few and include
25 e.g., calf chymosin (Knowles *et al.*, EP244,234; Berka *et al.*, EP215,594; Harkki, A. *et al.*, *Bio/Technol.* 7:596-603 (1989); Uusitalo, J.M. *et al.*, *J. Biotechnol.* 17:35-50 (1991)), CBH1-Fab fusion antibodies raised against 2-phenyl-oxazolone (Nyyssönen *et al.*, WO92/01797) and a fungal ligninolytic

enzyme (Saloheimo, M. and Niku-Paavola, M.-L. *Bio/Technol.* 9:987-990 (1991)). For improved expression the desired gene has been inserted into a *cbh1* expression cassette and introduced into *T. reesei* by protoplast transformation (Harkki, A. *et al.*, *Bio/Technol.* 7:596-603 (1989); Nyyssönen *et al.*, WO92/01797; Saloheimo, M. and Niku-Paavola, M.-L. *Bio/Technol.* 9:987-990 (1991)). Even though heterologous filamentous fungal promoters such as *Aspergillus amdS*, *argB* and glucoamylase (GA) can function in *T. reesei* at least to some extent (Penttilä *et al.*, *Gene* 61:155-164 (1987); Knowles *et al.*, EP244,234) efficient expression requires the use of a homologous promoter. In addition, better yields have been obtained in some cases by producing the desired gene product as a fusion protein (Harkki, A. *et al.*, *Bio/Technol.* 7:596-603 (1989); Nyyssönen *et al.*, WO92/01797). The yields of heterologous proteins obtained from *T. reesei* have varied between 10 - 150 mg/l.

Phytate, a storage form of phosphorus in plant seeds, is part of human and animal diets. Phytate phosphorus is poorly available to monogastrics, because it forms complexes with multivalent metal ions and binds to proteins. Thus degradation of phytate is of interest. Plant phytin degrading enzymes phytase and acid phosphatase for the conversion of phytate to inositol and inorganic phosphorus are produced e.g., by bacteria (Powar, V.K. and Jagannathan, V.J., *J. Bacteriol.* 15:1102-1108 (1982); Cosgrove, D.J., *Aust. J. Biol. Sci.* 23:1207-1220 (1970) and Cosgrove, D.J. *et al.*, *Aust. J. Biol. Sci.* 23:339-343 (1970); yeasts (Nayini, N.R. and Markakis, P., *Lebensmittel Wissenschaft und Technologie.* 17:24-26 (1984)) and filamentous fungi comprising several *Aspergillus* species such as *A. terreus* (Yamada *et al.*, *Agric. Biol. Chem.* 32:1275-1282 (1968), *A. ficuum* (Gibson, D.M. *Biotechnol. Lett.* 9:305-310 (1987) and *A. niger* (Shieh, T.R. and Ware, J.H., *Appl. Microbiol.* 16:1348-1351 (1968)). For complete degradation of plant phytin, both phytase and pH 2.5 acid phosphatase are needed.

Industrial applications involve remarkable higher production yields than the amounts produced by the natural reported strains. The gene coding for

phytase has been recently isolated and characterized from *A. ficuum* (Van Gorcom *et al.*, EP420.358 or WO91/05053) and the production of phytase has been improved in *A. niger* by multiplying the copy number of the gene in an expression cassette containing a strong homologous *Aspergillus* promoter e.g., GA (Van Gorcom *et al.*, EP420.358 or WO91/05053). A gene coding for acid phosphatase has been isolated and characterized from *A. niger* (MacRae *et al.*, *Gene* 71:339-348 (1988)).

SUMMARY OF THE INVENTION

Recognizing the need for better production methods of phytase and pH2.5 acid phosphatase, and for compositions containing the same, the inventors have developed highly efficient methods for the recombinant production thereof.

According to the invention, there is first provided a method for overexpressing phytate degrading enzymes in *Trichoderma*.

There are further provided methods for overexpressing recombinant *Aspergillus niger* phytase and pH2.5 acid phosphatase enzymes in *Trichoderma* and secreting such enzymes therefrom.

There are further provided expression vectors containing genetic sequences encoding such enzymes, and *Trichoderma* host cells transformed with such expression vectors.

There are further provided compositions comprising one or more of the *Trichoderma*-synthesized, recombinant phytase-degrading enzymes of the invention.

There are further provided methods for the use of such compositions in feed and other such methods comprising food compositions, especially for animals.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Sequence of peptide #816 ([SEQ ID No. :57:]), oligo PHY-31 ([SEQ ID No. :64:]), peptide #1110 ([SEQ ID No. :62:]), oligo PHY-34 ([SEQ ID No. :65:]), and oligo PHY-35 ([SEQ ID No. :52:]). pH2.5 acid phosphatase oligonucleotide PHY-31 is a 17mer mixture with 64 fold degeneracy and a single inosine. Peptide #816 is derived from an endoproteinase Lys-C digestion of purified native acid phosphatase. PHY-34 is a 17mer mixture with 128 fold degeneracy. PHY-35 is a 17mer mixture with 64 fold degeneracy. Both PHY-34 and PHY-35 are necessary for complete representation of Peptide #1110. Peptide #1110 is derived from a trypsin digestion of purified native acid phosphatase.

Figure 2. Nucleotide sequence from the 2.1 kb *SphI* fragment containing the pH 2.5 acid phosphatase gene [SEQ ID No. :1:] with deduced amino acid translation [SEQ ID No. :2:]. The intron donor, lariat and acceptor sequence as determined by cDNA sequencing are overlined. The nucleotide sequence corresponding to peptides #816 ([SEQ ID No. :57:]) and #1110 ([SEQ ID No. :62:]) is underlined. The genomic nucleotide sequence was determined by the M13-dideoxy method (Sanger, F., *et al.*, *Proc. Natl. Acad. Sci. USA* 74:5463-5467 (1977) with the use of the United States Biochemical Sequencase II kit.

Figure 3. The amino acid sequences of the phytase tryptic peptides #792 [SEQ ID No. :43:] and #420 [SEQ ID No. :23:] and the deduced oligonucleotides [SEQ ID Nos. :3:, :4:, :5: and :6:] used in the production of the phytase probe by nested PCR amplification.

Figure 4. Plasmid pALK169. The map of pALK169 containing the 2.4 kb *SphI* insert and showing the restriction map of the insert. The location of the phytase gene is shown by an arrow. The hybridization site for the 350 bp PCR fragment in the phytase sequence is shown by an intensified line.

Figure 5. The nucleotide sequence of the phytase gene. [SEQ ID Nos. :7: (DNA) and :8: (amino acid)].

Figure 6. The PCR primers used for making the *cbh1*-phytase fusion fragments [SEQ ID Nos. :9: and :10: and :11: and :12:].

Figure 7. Construction of pALK171. The phytase gene with its own signal sequence was fused to the *cbh1* promoter. Only the relevant restriction sites are shown.

Figure 8. Construction of pALK172. The phytase gene was fused to the *cbh1* signal sequence. Only the relevant restriction sites are shown.

Figure 9. Plasmids pALK173A and pALK173B. The maps of the plasmids containing the phytase gene with its own promoter and the selection marker, *amdS* gene, are shown. In the plasmid, pALK173A the transcriptional orientation of the phytase and *amdS* genes is the same; and in the plasmid pALK173B, the transcriptional orientation of these two genes is opposite to each other.

Figure 10. Western blots of the samples from the culture supernatants of the *Trichoderma* host strains and transformants producing phytase. Lane 1: 50 ng of purified *Aspergillus* ALKO 243 phytase; Lane 2: 15 ng of endoF-treated *Aspergillus* ALKO 243 phytase; Lanes 3 and 10: *T. reesei* ALKO 233; Lanes 4-5 and 11-12: *T. reesei* ALKO 233 transformant 171FR/ A4 and A13, respectively; Lanes 6 and 13: *T. reesei* ALKO 2221; Lanes 7-8 and 14-15: *T. reesei* ALKO 2221 transformant 171FR/A5 and A9, respectively; Lane 9: *T. reesei* ALKO 2221 transformant D2; Lane 16: *T. reesei* ATCC56765; Lanes 17, 18, 19: *T. reesei* ATCC56765 transformants 171FR/A21, A11, and A23, respectively. In each case 2 μ l of 1:10 dilution of the culture supernatant were run in the gel. 171FR: the host transformed with the *Xba*I fragment from the plasmid pALK171.

Figure 11. The PCR primers used for making the *cbh1* - pH 2.5 acid phosphatase fusion fragments [SEQ ID Nos. :13: and :14: and :15:].

Figure 12. Construction of the plasmid pALK533. The pH 2.5 acid phosphatase gene with its own signal sequence was fused to the *cbh1* promoter.

Figure 13. Construction of the plasmid pALK532. The pH 2.5 acid phosphatase gene was fused to the *cbhl* signal sequence and promoter.

Figure 14. Western blot of the *Trichoderma* transformants producing pH 2.5 acid phosphatase. Lane 1: 10ng of purified *Aspergillus* ALKO 243 pH 2.5 acid phosphatase; Lane 2: 10ng of endoF treated *Aspergillus* ALKO 243 pH 2.5 acid phosphatase; and Lanes 3-9: 60ng of protein from the each of the culture supernatants of *Trichoderma reesei* ALKO 2221 transformants SC-9, KA-31, KA-17, KB-44, KB-18, SB-4 and KA-28, respectively.

DETAILED DESCRIPTION OF THE INVENTION

10 I. DEFINITIONS

In the description that follows, a number of terms used in recombinant DNA (rDNA) technology are extensively utilized. In order to provide a clear and consistent understanding of the specification and claims, including the scope to be given such terms, the following definitions are provided.

15 Gene. A DNA sequence containing a template for an RNA polymerase. The RNA transcribed from a gene may or may not code for a protein. RNA that codes for a protein is termed messenger RNA (mRNA) and, in eukaryotes, is transcribed by RNA polymerase II. A gene containing a RNA polymerase II template (as a result of a RNA polymerase II promoter)
20 wherein an RNA sequence is transcribed which has a sequence complementary to that of a specific mRNA, but is not normally translated may also be constructed. Such a gene construct is herein termed an "antisense RNA gene" and such an RNA transcript is termed an "antisense RNA." Antisense RNAs are not normally translatable due to the presence of translational stop codons
25 in the antisense RNA sequence.

A "complementary DNA" or "cDNA" gene includes recombinant genes synthesized by, for example, reverse transcription of mRNA, thus lacking

intervening sequences (introns). Genes clones from genomic DNA may or may not contain introns.

Cloning vehicle. A plasmid or phage DNA or other DNA sequence which is able to carry genetic information, specifically DNA, into a host cell.

5 A cloning vehicle is often characterized by one or a small number of endonuclease recognition sites at which such DNA sequences may be cut in a determinable fashion without loss of an essential biological function of the vehicle, and into which a desired DNA may be spliced in order to bring about its cloning into the host cell. The cloning vehicle may further contain a
10 marker suitable for use in the identification of cells transformed with the cloning vehicle, and origins of replication that allow for the maintenance and replication of the vehicle in one or more prokaryotic or eukaryotic hosts. Markers, for example, are tetracycline resistance or ampicillin resistance. The word "vector" is sometimes used for "cloning vehicle." A "plasmid" is a
15 cloning vehicle, generally circular DNA, that is maintained and replicates autonomously in at least one host cell.

Expression vehicle. A vehicle or vector similar to a cloning vehicle but which supports expression of a gene that has been cloned into it, after transformation into a host. The cloned gene is usually placed under the
20 control of (i.e., operably linked to) certain control sequences such as promoter sequences, that may be provided by the vehicle or by the recombinant construction of the cloned gene. Expression control sequences will vary depending on whether the vector is designed to express the operably linked gene in a prokaryotic or eukaryotic host and may additionally contain
25 transcriptional elements such as enhancer elements (upstream activation sequences) and termination sequences, and/or translational initiation and termination sites.

Host. A host is a cell, prokaryotic or eukaryotic, that is utilized as the recipient and carrier of recombinant material.

30 Eukaryotic host. A "eukaryotic host" may be any cell from a eukaryotic organism, including, for example, animal, plant, fungi and yeast.

Host of the Invention. The "host of the invention" is a filamentous fungus host that has been engineering to produce recombinant phytase and/or pH 2.5 acid phosphatase according to the methods of the invention.

Functional Derivative. A "functional derivative" of a protein or
5 nucleic acid, is a molecule that has been chemically or biochemically derived from (obtained from) such protein or nucleic acid and which retains a biological activity (either functional or structural) that is a characteristic of the native protein or nucleic acid. A "mutant" of a protein or nucleic acid is a biochemical or chemical derivative of such protein or nucleic acid. The term
10 "functional derivative" is intended to include "mutants," "fragments," "variants," "analogues," or "chemical derivatives" of a molecule that retain a desired activity of the native molecule.

As used herein, a molecule is said to be a "chemical derivative" of another molecule when it contains additional chemical moieties not normally
15 a part of the molecule. Such moieties may improve the molecule's solubility, absorption, biological half life, etc. The moieties may decrease the toxicity of the molecule, or eliminate or attenuate any undesirable side effect of the molecule, etc. Moieties capable of mediating such effects are disclosed in *Remington's Pharmaceutical Sciences* (1980). Procedures for coupling such
20 moieties to a molecule are well known in the art.

Fragment. A "fragment" of a molecule such as a protein or nucleic acid is meant to refer to a portion of the native amino acid or nucleotide genetic sequence, and in particular the functional derivatives of the invention.

Variant or Analog. A "variant" or "analog" of a protein or nucleic
25 acid is meant to refer to a molecule substantially similar in structure and biological activity to either the native molecule, such as that encoded by a functional allele.

II. THE HOSTS OF THE INVENTION

T. reesei does not produce endogenous phytase. Instead, other enzyme components such as β -glucan degrading activity, important in e.g. feed applications, are produced in high amounts. Thus the use of *T. reesei* as a production host for fungal phytase and pH 2.5 acid phosphatase results in secretion of a totally different enzyme composition when compared to that secreted from *Aspergillus*. In addition, by using *Trichoderma* as a source of a composition containing phytate degrading enzymes, some difficult problems in downstream processing that occur with similar *Aspergillus* compositions (e.g., in filtration) are avoided. This is because the mode of growth of the recombinant *T. reesei* is different than that of *Aspergilli*, the mycelium being most often fluid and easily separable. Thus, by producing these enzymes in the hosts of the invention, no problems in subsequent filtration of the secreted material is seen, as is the case with the often slimy and thick mycelium of *Aspergilli*.

Improved amounts of phytase and pH 2.5 acid phosphatase (as compared to synthesis in *Aspergillus*) can be produced in the *T. reesei* expression system by inserting a DNA sequence obtained from *A. niger*, coding for phytase or pH 2.5 acid phosphatase activity, into a *T. reesei* expression cassette containing the *cbh1* promoter and the *Aspergillus amdS* gene as a transformation marker. Transformation of the construct to *T. reesei* hosts results in stable transformants expressing the phytase or pH 2.5 acid phosphatase in high amounts in a novel background of accompanying enzyme activities.

The mixture produced by *T. reesei* contains high β -glucanase activity and low glucoamylase activity. Moreover, the amount of phytase produced by recombinant *T. reesei* strains in shake flask cultivations is comparable to the level of which the main cellulase, the endogenous cellobiohydrolase I, is expressed, more than 1 g/l. The amount of the pH 2.5 acid phosphatase

produced by the recombinant strains in shake flask cultivations is less than 0.5 g/l.

Aspergillus niger var. *awamori* ALKO 243 (ATCC 38854) (IFO4033) phytase and acid phosphatase (optimum pH 2.5) were overexpressed in
5 *Trichoderma reesei* under the control of the *Trichoderma* cellobiohydrolase I (*cbh1*) promoter. In addition, the phytase gene was expressed from its own promoter.

For both the genes, two constructions utilizing the *cbh1* promoter were made: in one construction the phytase or acid phosphatase signal sequence was
10 used and in the other construction the *cbh1* signal sequence was used. In all cases, the fusions were made precise by using PCR and the plasmids were constructed so that the expression cassette could be separated from the vector backbone prior to transformations. Thus it was possible to transform strains with only the desired sequences (and not the entire vector used for maintaining
15 the sequences) and thus to obtain strains that did not contain any "foreign" sequences; such strains were suitable for industrial purposes.

Three *Trichoderma reesei* strains, ATCC 56765 (RutC-30), ALKO 233 (VTT-D-79125) and a low aspartyl protease producing strain ALKO 2221 were used as hosts for phytase expression. For acid phosphatase expression,
20 only *T. reesei* ALKO 2221 was transformed. When phytase was expressed under the *cbh1* promoter in *Trichoderma*, the best transformation with no *E. coli* sequences produced in shake flask cultivations about 3.600 fold more phytase than the nontransformed *A. niger* ALKO 243. When the phytase promoter was used, the best yield obtained in shake flask cultivations of *T.*
25 *reesei* transformants was about 120 fold that obtained with *A. niger* ALKO 243. The best acid phosphatase activities obtained were about 240 fold higher compared to the levels produced by the *A. niger* ALKO 243 strain.

The molecular weights (in SDS-PAGE) of the phytase and pH 2.5 acid phosphatase secreted by *Trichoderma* were different from those secreted by
30 *Aspergillus*. The difference seemed to be due to different glycosylation.

The production level of phytase obtained when the *Aspergillus* gene was expressed in *Trichoderma* under the control of a *Trichoderma* promoter was surprisingly high.

5 The use of *T. reesei* as a production host for fungal phytase and pH 2.5 acid phosphatase results in totally different enzyme preparations as compared to that from *Aspergillus*. When compared to *Aspergillus* preparations, the mixtures produced by *T. reesei* contain substantially higher β -glucanase and proportionally lower glucoamylase activities thus making *T. reesei* preparations preferable to be used e.g. in animal feed.

10 The hosts of the invention are meant to include all *Trichoderma*. *Trichoderma* are classified on the basis of morphological evidence of similarity. *T. reesei* was formerly known as *T. viride* Pers. or *T. koningii* Oudem; sometimes it was classified as a distinct species of the *T. longibrachiatum* group. The entire genus *Trichoderma*, in general, is
15 characterized by rapidly growing colonies bearing tufted or pustulate, repeatedly branched conidiophores with lageniform phialides and hyaline or green conidia borne in slimy heads (Bissett, J., Can. J. Bot. 62:924-931 (1984)).

The fungus called *T. reesei* is clearly defined as a genetic family
20 originating from the strain QM6a, that is, a family of strains possessing a common genetic background originating from a single nucleus of the particular isolate QM6a. Only those strains are called *T. reesei*.

Classification by morphological means is problematic and the first recently published molecular data from DNA-fingerprint analysis and the
25 hybridization pattern of the cellobiohydrolase 2 (*cbh2*) gene in *T. reesei* and *T. longibrachiatum* clearly indicates a differentiation of these strains (Meyer, W. et al., Curr. Genet. 21:27-30 (1992); Morawetz, R. et al., Curr. Genet. 21:31-36 (1992)).

However, there is evidence of similarity between different *Trichoderma*
30 species at the molecular level that is found in the conservation of nucleic acid

and amino acid sequences of macromolecular entities shared by the various *Trichoderma* species. For example, Cheng, C., *et al.*, *Nucl. Acids. Res.* 18:5559 (1990), discloses the nucleotide sequence of *T. viride cbh1*. The gene was isolated using a probe based on the *T. reesei* sequence. The authors note
5 that there is a 95% homology between the amino acid sequences of the *T. viride* and *T. reesei* gene. Goldman, G.H. *et al.*, *Nucl. Acids Res.* 18:6717 (1990), discloses the nucleotide sequence of phosphoglycerate kinases from *T. viride* and notes that the deduced amino acid sequence is 81% homologous with the phosphoglycerate kinase gene from *T. reesei*. Thus, the species
10 classified to *T. viride* and *T. reesei* must genetically be very close to each other.

In addition, there is a high similarity of transformation conditions among the *Trichoderma*. Although practically all the industrially important species of *Trichoderma* can be found in the formerly discussed *Trichoderma*
15 section *Longibrachiatum*, there are some other species of *Trichoderma* that are not assigned to this section. Such a species is, for example, *Trichoderma harzianum*, which acts as a biocontrol agent against plant pathogens. A transformation system has also been developed for this *Trichoderma* species (Herrera-Estrella, A. *et al.*, *Molec. Microbiol.* 4:839-843 (1990)) that is
20 essentially the same as that taught in the application. Thus, even though *Trichoderma harzianum* is not assigned to the section *Longibrachiatum*, the method used by Herrera-Estrella in the preparation of spheroplasts before transformation is the same. The teachings of Herrera-Estrella show that there is not a significant diversity of *Trichoderma* spp. such that the transformation
25 system of the invention would not be expected to function in all *Trichoderma*.

Further, there is a common functionality of fungal transcriptional control signals among fungal species. At least three *A. nidulans* promoter sequences, *amdS*, *argB*, and *gpd*, have been shown to give rise to gene expression in *T. reesei*. For *amdS* and *argB*, only one or two copies of the
30 gene are sufficient to being about a selectable phenotypes (Penttilä *et al.*, *Gene* 61:155-164 (1987). Grüber, F. *et al.*, *Curr. Genetic* 18:71-76 (1990) also

- 13 -

notes that that fungal genes can often be successfully expressed across different species.

Many species of *Trichoderma* are available from a wide variety of resource centers that contain fungal culture collections. In addition, 5 *Trichoderma* species are catalogued in various databases. These resources and databases are summerized by O'Donnell, K. *et al.*, in *Biochemistry of Filamentous Fungi: Technology and Products*, D.B. Finkelstein *et al.*, eds., Butterworth-Heinemann, Stoneham, MA, USA, 1992, pp. 3-39.

III. CONSTRUCTION OF THE HOSTS OF THE INVENTION

10 The process for genetically engineering the hosts of the invention, according to the invention, is facilitated through the isolation and partial sequencing of pure protein encoding an enzyme of interest or by the cloning of genetic sequences which are capable of encoding such protein with polymerase chain reaction technologies; and through the expression of such 15 genetic sequences. As used herein, the term "genetic sequences" is intended to refer to a nucleic acid molecule (preferably DNA). Genetic sequences which are capable of encoding a protein are derived from a variety of sources. These sources include genomic DNA, cDNA, synthetic DNA, and combinations thereof. The preferred source of genomic DNA is a fungal 20 genomic library. The preferred source of the cDNA is a cDNA library prepared from fungal mRNA grown in conditions known to induce expression of the desired mRNA or protein.

The genomic DNA of the invention may or may not include naturally occurring introns. Moreover, such genomic DNA may be obtained in 25 association with the 5' promoter region of the gene sequences and/or with the 3' transcriptional termination region. Further, such genomic DNA may be obtained in association with the genetic sequences which encode the 5' non-translated region of the mRNA and/or with the genetic sequences which

encode the 3' non-translated region. To the extent that a host cell can recognize the transcriptional and/or translational regulatory signals associated with the expression of the mRNA and protein, then the 5' and/or 3' non-transcribed regions of the native gene, and/or, the 5' and/or 3' non-translated
5 regions of the mRNA may be retained and employed for transcriptional and translational regulation. Genomic DNA can be extracted and purified from any host cell, especially a fungal host cell, which naturally expresses the desired protein by means well known in the art.

For cloning into a vector, such suitable DNA preparations (either
10 genomic DNA or cDNA) are randomly sheared or enzymatically cleaved, respectively, and ligated into appropriate vectors to form a recombinant gene (either genomic or cDNA) library.

A DNA sequence encoding a desired protein or its functional derivatives may be inserted into a DNA vector in accordance with
15 conventional techniques, including blunt-ending or staggered-ending termini for ligation, restriction enzyme digestion to provide appropriate termini, filling in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and ligation with appropriate ligases. Techniques for such manipulations are disclosed by Maniatis, T., (Maniatis, T. *et al.*, *Molecular*
20 *Cloning (A Laboratory Manual)*, Cold Spring Harbor Laboratory, second edition, 1988) and are well known in the art.

Libraries containing sequences coding for the desired gene may be screened and the desired gene sequence identified by any means which specifically selects for a sequence coding for such gene or protein such as, for
25 example, a) by hybridization with an appropriate nucleic acid probe(s) containing a sequence specific for the DNA of this protein, or b) by hybridization-selected translational analysis in which native mRNA which hybridizes to the clone in question is translated *in vitro* and the translation products are further characterized, or, c) if the cloned genetic sequences are
30 themselves capable of expressing mRNA, by immunoprecipitation of a translated protein product produced by the host containing the clone.

- 15 -

Oligonucleotide probes specific for a certain protein which can be used to identify clones to this protein can be designed from the knowledge of the amino acid sequence of the protein or from the knowledge of the nucleic acid sequence of the DNA encoding such protein or a related protein.

5 Alternatively, antibodies may be raised against purified forms of the protein and used to identify the presence of unique protein determinants in transformants that express the desired cloned protein. The sequence of amino acid residues in a peptide is designated herein either through the use of their commonly employed three-letter designations or by their single-letter

10 designations. A listing of these three-letter and one-letter designations may be found in textbooks such as *Biochemistry*, Lehninger, A., Worth Publishers, New York, NY (1970). When the amino acid sequence is listed horizontally, unless otherwise stated, the amino terminus is intended to be on the left end and the carboxy terminus is intended to be at the right end. Similarly, unless

15 otherwise stated or apparent from the context, a nucleic acid sequence is presented with the 5' end on the left.

Because the genetic code is degenerate, more than one codon may be used to encode a particular amino acid (Watson, J.D., In: *Molecular Biology of the Gene*, 3rd Ed., W.A. Benjamin, Inc., Menlo Park, CA (1977), pp. 356-

20 357). The peptide fragments are analyzed to identify sequences of amino acids which may be encoded by oligonucleotides having the lowest degree of degeneracy. This is preferably accomplished by identifying sequences that contain amino acids which are encoded by only a single codon.

Although occasionally an amino acid sequence may be encoded by only

25 a single oligonucleotide sequence, frequently the amino acid sequence may be encoded by any of a set of similar oligonucleotides. Importantly, whereas all of the members of this set contain oligonucleotide sequences which are capable of encoding the same peptide fragment and, thus, potentially contain the same oligonucleotide sequence as the gene which encodes the peptide fragment, only

30 one member of the set contains the nucleotide sequence that is identical to the exon coding sequence of the gene. Because this member is present within the

- 16 -

set. and is capable of hybridizing to DNA even in the presence of the other members of the set. it is possible to employ the unfractionated set of oligonucleotides in the same manner in which one would employ a single oligonucleotide to clone the gene that encodes the peptide.

5 Using the genetic code, one or more different oligonucleotides can be identified from the amino acid sequence, each of which would be capable of encoding the desired protein. The probability that a particular oligonucleotide will, in fact, constitute the actual protein encoding sequence can be estimated by considering abnormal base pairing relationships and the frequency with
10 which a particular codon is actually used (to encode a particular amino acid) in eukaryotic cells. Using "codon usage rules," a single oligonucleotide sequence, or a set of oligonucleotide sequences, that contain a theoretical "most probable" nucleotide sequence capable of encoding the protein sequences is identified.

15 The suitable oligonucleotide, or set of oligonucleotides, which is capable of encoding a fragment of a certain gene (or which is complementary to such an oligonucleotide, or set of oligonucleotides) may be synthesized by means well known in the art (see, for example, *Synthesis and Application of DNA and RNA*, S.A. Narang, ed., 1987, Academic Press, San Diego, CA)
20 and employed as a probe to identify and isolate a clone to such gene by techniques known in the art. Techniques of nucleic acid hybridization and clone identification are disclosed by Maniatis, T., *et al.*, in: *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY (1982)), and by Hames, B.D., *et al.*, in: *Nucleic Acid*
25 *Hybridization, A Practical Approach*, IRL Press, Washington, DC (1985)). Those members of the above-described gene library which are found to be capable of such hybridization are then analyzed to determine the extent and nature of coding sequences which they contain.

30 To facilitate the detection of a desired DNA coding sequence, the above-described DNA probe is labeled with a detectable group. Such detectable group can be any material having a detectable physical or chemical

property. Such materials have been well-developed in the field of nucleic acid hybridization and in general most any label useful in such methods can be applied to the present invention. Particularly useful are radioactive labels, such as ^{32}P , ^3H , ^{14}C , ^{35}S , ^{125}I , or the like. Any radioactive label may be employed which provides for an adequate signal and has a sufficient half-life. If single stranded, the oligonucleotide may be radioactively labelled using kinase reactions. Alternatively, polynucleotides are also useful as nucleic acid hybridization probes when labeled with a non-radioactive marker such as biotin, an enzyme or a fluorescent group.

Thus, in summary, the elucidation of a partial protein sequence, permits the identification of a theoretical "most probable" DNA sequence, or a set of such sequences, capable of encoding such a peptide. By constructing an oligonucleotide complementary to this theoretical sequence (or by constructing a set of oligonucleotides complementary to the set of "most probable" oligonucleotides), one obtains a DNA molecule (or set of DNA molecules), capable of functioning as a probe(s) for the identification and isolation of clones containing a gene.

In an alternative way of cloning a gene, a library is prepared using an expression vector, by cloning DNA or, more preferably cDNA prepared from a cell capable of expressing the protein into an expression vector. The library is then screened for members which express the desired protein, for example, by screening the library with antibodies to the protein.

The above discussed methods are, therefore, capable of identifying genetic sequences which are capable of encoding a protein or biologically active or antigenic fragments of this protein. In order to further characterize such genetic sequences, and, in order to produce the recombinant protein, it is desirable to express the proteins which these sequences encode. Such expression identifies those clones which express proteins possessing characteristics of the desired protein. Such characteristics may include the ability to specifically bind antibody, the ability to elicit the production of antibody which are capable of binding to the native, non-recombinant protein, the ability to

provide a enzymatic activity to a cell that is a property of the protein, and the ability to provide a non-enzymatic (but specific) function to a recipient cell, among others.

A DNA sequence may be shortened by means known in the art to
5 isolate a desired gene from a chromosomal region that contains more information than necessary for the utilization of this gene in the hosts of the invention. For example, restriction digestion may be utilized to cleave the full-length sequence at a desired location. Alternatively, or in addition, nucleases that cleave from the 3'-end of a DNA molecule may be used to digest a certain
10 sequence to a shortened form, the desired length then being identified and purified by gel electrophoresis and DNA sequencing. Such nucleases include, for example, Exonuclease III and *Bal31*. Other nucleases are well known in the art.

If the coding sequence and an operably linked promoter are introduced
15 into a recipient eukaryotic cell as a non-replicating DNA (or RNA), non-integrating molecule, the expression of the encoded protein may occur through the transient (nonstable) expression of the introduced sequence.

Preferably the coding sequence is introduced on a DNA (or RNA) molecule, such as a closed covalent circular molecule that is incapable of
20 autonomous replication, or preferable a linear molecule that integrates into the host chromosome. Genetically stable transformants may be constructed with vector systems, or transformation systems, whereby a desired DNA is integrated into the host chromosome. Such integration may occur *de novo* within the cell or, be assisted by transformation with a vector which
25 functionally inserts itself into the host chromosome, for example, transposons or other DNA elements which promote integration of DNA sequences in chromosomes. A vector is employed which is capable of integrating the desired gene sequences into a fungal host cell chromosome.

The genes coding for phytase or pH 2.5 acid phosphatase under the
30 control of suitable promoters may be combined in one plasmid construction and introduced into the host cells by transformation. The nature of the

plasmid vector will depend on the host organism. In the practical realization of the invention the filamentous fungus *Trichoderma* has been employed as a model. Thus, for *Trichoderma* and especially for *T. reesei*, vectors incorporating DNA that provides for integration of the sequences encoding the
5 phytase or pH 2.5 acid phosphatase genes into the host's chromosome are preferred. Such targeting to, for example, the *cbh1* locus may be achieved by providing *cbh1* coding or flanking sequences on the recombinant construct, in an amount sufficient to direct integration to this locus at a relevant frequency.

Cells which have stably integrated the introduced DNA into their
10 chromosomes are selected by also introducing one or more markers which allow for selection of host cells which contain the expression vector in the chromosome, for example the marker may provide biocide resistance, e.g., resistance to antibiotics, or heavy metals, such as copper, or the like. The selectable marker gene can either be directly linked to the DNA gene
15 sequences to be expressed, or introduced into the same cell by co-transfection. A genetic marker especially for the transformation of the hosts of the invention is *amdS*, encoding acetamidase and thus enabling *Trichoderma* to grow on acetamide as the only nitrogen source.

To express a desired protein and/or its active derivatives,
20 transcriptional and translational signals recognizable by an appropriate host are necessary. The cloned coding sequences, obtained through the methods described above, and preferably in a double-stranded form, may be operably linked to sequences controlling transcriptional expression in an expression vector, and introduced into a host cell, either prokaryote or eukaryote, to
25 produce recombinant protein or a functional derivative thereof. Depending upon which strand of the coding sequence is operably linked to the sequences controlling transcriptional expression, it is also possible to express antisense RNA or a functional derivative thereof.

Expression of the protein in different hosts may result in different post-
30 translational modifications which may alter the properties of the protein.

Preferably, the present invention encompasses the expression of the protein or a functional derivative thereof, in eukaryotic cells, and especially in fungus.

A nucleic acid molecule, such as DNA, is said to be "capable of expressing" a polypeptide if it contains expression control sequences which contain transcriptional regulatory information and such sequences are
5 "operably linked" to the nucleotide sequence which encodes the polypeptide.

An operable linkage is a linkage in which a sequence is connected to a regulatory sequence (or sequences) in such a way as to place expression of the sequence under the influence or control of the regulatory sequence. Two
10 DNA sequences (such as a coding sequence and a promoter region sequence linked to the 5' end of the coding sequence) are said to be operably linked if induction of promoter function results in the transcription of mRNA encoding the desired protein and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation,
15 (2) interfere with the ability of the expression regulatory sequences to direct the expression of the protein, antisense RNA, or (3) interfere with the ability of the DNA template to be transcribed. Thus, a promoter region would be operably linked to a DNA sequence if the promoter was capable of effecting transcription of that DNA sequence.

20 The precise nature of the regulatory regions needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribing and 5' non-translating (non-coding) sequences involved with initiation of transcription and translation respectively, such as the TATA box, capping sequence, CAAT sequence, and the like. Especially,
25 such 5' non-transcribing control sequences will include a region which contains a promoter for transcriptional control of the operably linked gene. Such transcriptional control sequences may also include enhancer sequences or upstream activator sequences, as desired.

30 Expression of a protein in eukaryotic hosts such as fungus requires the use of regulatory regions functional in such hosts, and preferably fungal regulatory systems. A wide variety of transcriptional and translational regu-

- 21 -

latory sequences can be employed, depending upon the nature of the host. Preferably, these regulatory signals are associated in their native state with a particular gene which is capable of a high level of expression in the host cell.

In eukaryotes, where transcription is not linked to translation, such control regions may or may not provide an initiator methionine (AUG) codon, depending on whether the cloned sequence contains such a methionine. Such regions will, in general, include a promoter region sufficient to direct the initiation of RNA synthesis in the host cell. Promoters from filamentous fungal genes which encode a mRNA product capable of translation are preferred, and especially, strong promoters can be employed provided they also function as promoters in the host cell. Preferred strong eukaryotic promoters for use in *Trichoderma* include the *T. reesei cbh1* gene promoter or a promoter of another cellulase gene such as that for the *cbh2*, *egl1* or *egl2* gene may be used. In addition to the use of *Trichoderma* regulatory elements, the expression of proteins may be placed under the control of regulatory elements from *Aspergillus nidulans* (for example, the *argB* gene promoter and the *amdS* gene promoter), *Aspergillus niger* (for example, the phytase promoter or the glucoamylase gene promoter) However, expression under non-*Trichoderma* regulatory elements such as these may be very low as compared to the use of *Trichoderma* elements, and especially those of *T. reesei*.

As is widely known, translation of eukaryotic mRNA is initiated at the codon which encodes the first methionine. For this reason, it is preferable to ensure that the linkage between a eukaryotic promoter and a DNA sequence which encodes the desired protein, or a functional derivative thereof, does not contain any intervening codons which are capable of encoding a methionine. The presence of such codons results either in a formation of a fusion protein (if the AUG codon is in the same reading frame as the protein-coding DNA sequence) or a frame-shift mutation (if the AUG codon is not in the same reading frame as the protein-coding sequence).

It may be desired to construct a fusion product that contains a partial coding sequence (usually at the amino terminal end) of a protein and a second coding sequence (partial or complete) of a phytase degrading enzyme of the invention. The sequence that does not encode the phytase degrading enzyme
5 may or may not function as a signal sequence for secretion of the protein from the host cell. For example, the sequence coding for desired protein may be linked to a signal sequence which will allow secretion of the protein from, or the compartmentalization of the protein in, a particular host. Such fusion protein sequences may be designed with or without specific protease sites such
10 that a desired peptide sequence is amenable to subsequent removal. In a preferred embodiment, the native signal sequence of a fungal protein is used, or a functional derivative of that sequence that retains the ability to direct the secretion of the peptide that is operably linked to it. *Aspergillus* leader/secretion signal elements also function in *Trichoderma*.

15 Transcriptional initiation regulatory signals can be selected which allow for repression or activation, so that expression of the operably linked genes can be modulated. For example, regulatory signals may be temperature-sensitive so that by varying the temperature, expression can be repressed or initiated, or are subject to chemical regulation, e.g., metabolite. Translational
20 signals are not necessary when it is desired to express antisense RNA sequences.

If desired, the non-transcribed and/or non-translated regions 3' to the sequence coding for a desired protein can be obtained by the above-described cloning methods. The 3'-non-transcribed region may be retained for its
25 transcriptional termination regulatory sequence elements, or for those elements which direct polyadenylation in eukaryotic cells. Where the native expression control sequences signals do not function satisfactorily in a host cell, then sequences functional in the host cell may be substituted.

The vectors of the invention may further comprise other operably
30 linked regulatory elements such as DNA elements which confer antibiotic

resistance, or origins of replication for maintenance of the vector in one or more host cells.

5 In another embodiment, especially for maintenance of the vectors of the invention in prokaryotic cells, or in yeast *S. cerevisiae* cells, the introduced sequence is incorporated into a plasmid or viral vector capable of autonomous replication in the recipient host. Any of a wide variety of vectors may be employed for this purpose. In *Bacillus* hosts, integration of the desired DNA may be necessary.

10 Factors of importance in selecting a particular plasmid or viral vector include: the ease with which recipient cells that contain the vector may be recognized and selected from those recipient cells which do not contain the vector; the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to "shuttle" the vector between host cells of different species.

15 Preferred *S. cerevisiae* yeast plasmids include those containing the 2-micron circle, etc., or their derivatives. Such plasmids are well known in the art (Botstein, D., *et al.*, *Miami Wntr. Symp.* 19:265-274 (1982); Broach, J.R., in: *The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, p. 20 445-470 (1981); Broach, J.R., *Cell* 28:203-204 (1982); Bollon, D.P., *et al.*, *J. Clin. Hematol. Oncol.* 10:39-48 (1980); Maniatis, T., In: *Cell Biology: A Comprehensive Treatise*, Vol. 3, Gene Expression, Academic Press, NY, pp. 563-608 (1980)), and are commercially available.

25 Once the vector or DNA sequence containing the construct(s) is prepared for expression, the DNA construct(s) is introduced into an appropriate host cell by any of a variety of suitable means, including transformation. After the introduction of the vector, recipient cells are grown in a selective medium, which selects for the growth of vector-containing cells. Expression of the cloned gene sequence(s) results in the production of the 30 desired protein, or in the production of a fragment of this protein. This

expression can take place in a continuous manner in the transformed cells, or in a controlled manner, for example, by induction of expression.

Fungal transformation is carried out also accordingly to techniques known in the art, for example, using, for example, homologous recombination
5 to stably insert a gene into the fungal host and/or to destroy the ability of the host cell to express a certain protein.

IV. PREPARATION OF ANTIBODIES

In the following description, reference will be made to various methodologies well-known to those skilled in the art of immunology. Standard
10 reference works setting forth the general principles of immunology include the work of Catty, D. (*Antibodies. A Practical Approach*, Vol. 1, IRL Press, Washington, DC (1988)); Klein, J. (*Immunology: The Science of Cell-Noncell Discrimination*, John Wiley & Sons, New York (1982)); Kenneff, R., *et al.* in *Monoclonal Antibodies, Hybridoma: A New Dimension in Biological*
15 *Analyses*, Plenum Press, New York (1980)); Campbell, A. ("Monoclonal Antibody Technology," in: *Laboratory Techniques in Biochemistry and Molecular Biology*, Volume 13 (Burdon, R., *et al.*, eds.), Elsevier, Amsterdam (1984)); and Eisen, H.N., in: *Microbiology*, 3rd Ed. (Davis, B.D., *et al.*, Harper & Row, Philadelphia (1980)).

20 An antibody is said to be "capable of binding" a molecule if it is capable of specifically reacting with the molecule to thereby bind the molecule to the antibody. The term "epitope" is meant to refer to that portion of a hapten which can be recognized and bound by an antibody. An antigen may have one, or more than one epitope. An "antigen" is capable of inducing an
25 animal to produce antibody capable of binding to an epitope of that antigen. The specific reaction referred to above is meant to indicate that the antigen will react, in a highly selective manner, with its corresponding antibody and not with the multitude of other antibodies which may be evoked by other antigens.

The term "antibody" (Ab) or "monoclonal antibody" (Mab) as used herein is meant to include intact molecules as well as fragments thereof (such as, for example, Fab and F(ab')₂ fragments) which are capable of binding an antigen. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody. clear more rapidly from the circulation, and may have less non-specific tissue binding of an intact antibody (Wahl *et al.*, *J. Nucl. Med.* 24:316-325 (1983)).

The antibodies of the present invention are prepared by any of a variety of methods. Preferably, purified phytase or pH 2.5 acid phosphatase protein, or a fragment thereof, (treated or not treated with endoF or its equivalent to remove sugar moieties), is administered to an animal in order to induce the production of sera containing polyclonal antibodies that are capable of binding such phytase or pH 2.5 acid phosphatase.

Cells expressing phytase or pH 2.5 acid phosphatase protein, or a fragment thereof, or, a mixture of proteins containing phytase or pH 2.5 acid phosphatase or such fragments, can also be administered to an animal in order to induce the production of sera containing polyclonal antibodies, some of which will be capable of binding phytase or pH 2.5 acid phosphatase protein. If desired, such phytase or pH 2.5 acid phosphatase antibody may be purified from the other polyclonal antibodies by standard protein purification techniques and especially by affinity chromatography with purified phytase or pH 2.5 acid phosphatase or fragments thereof.

A phytase or pH 2.5 acid phosphatase protein fragment may also be chemically synthesized and purified by HPLC to render it substantially free of contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of high specific activity.

Monoclonal antibodies can be prepared using hybridoma technology (Kohler *et al.*, *Nature* 256:495 (1975); Kohler *et al.*, *Eur. J. Immunol.* 6:511 (1976); Kohler *et al.*, *Eur. J. Immunol.* 6:292 (1976); Hammerling *et al.*, in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981)). In general, such procedures involve immunizing an animal with phytase or pH 2.5 acid phosphatase protein antigen. The splenocytes of such

animals are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention: however, it is preferable to employ the parent myeloma cell line (SP₂O), available from the American Type Culture Collection, Rockville, Maryland. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands, J.R., *et al.*, *Gastroenterology* 80:225-232 (1981), which reference is herein incorporated by reference. The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the phytase or pH 2.5 acid phosphatase protein antigen.

Through application of the above-described methods, additional cell lines capable of producing antibodies which recognize epitopes of the phytase or pH 2.5 acid phosphatase protein can be obtained.

Antibodies against both highly conserved and poorly conserved regions of the phytase or pH 2.5 acid phosphatase protein are useful for studies on the control of biosynthesis and catabolism of phytase or pH 2.5 acid phosphatase protein, and for studies wherein it is necessary to identify or quantitate the presence and/or of the protein antigen in a composition.

V. PRODUCTION OF PHYTASE AND ACID PHOSPHATASE

The best phytase production levels are obtained when *Trichoderma* are transformed with linear DNA using the *cbh1* promoter (about 3.800 PNU/ml, see Table 8). About 3.500 and 3.600 PNU/ml culture medium was obtained with the best *T. reesei* ALKO2221 and ALKO233 transformants containing no *E. coli* sequences. Both the phytase and the *cbh1* signal sequence seemed to work equally well and the same levels in phytase production could be achieved when using *T. reesei* ALKO 2221 or ATCC56765 as a host strain. In *T. reesei* ALKO 233 the level of phytase activity produced was higher when the phytase signal sequence was used.

- 27 -

Phytase is expressed from the *Trichoderma* hosts of the invention into the supernatant of the culture medium. The amount of phytase in the culture medium is generally higher than any hitherto reported amount of a heterologous protein that was expressed in *Trichoderma*.

5 The spectrum of enzymes that accompany phytase in the *Trichoderma* strains of the invention is greatly different and advantageous over that of similar preparations of *Aspergillus* culture supernatants. Both endoglucanase and cellobiohydrolase activities are generally substantially higher using the *Trichoderma* hosts of the invention. The glycosylation pattern of the phytase
10 is also different when it is expressed from *Trichoderma*, resulting in a phytase protein that migrates as multiple bands on Western analysis.

The best production of pH 2.5 acid phosphatase from the *Trichoderma* transformants of the invention resulted in 240 APNU/ml culture medium, in shake flask cultivation and in lactose based medium. As with the phytase, both
15 the acid phosphatase and the *cbh1* signal sequence worked equally well.

The compositions of the invention that contain phytase may be used directly for the removal of phytic acid, or inositol hexaphosphoric acid, from raw material, especially phytin-containing raw material, and especially plant material. Phytase removes the phosphate groups from phytic acid and destroys
20 its ability to interfere with mineral absorption. When used as an animal feed additive, the phytase compositions of the invention release phosphate bound to phytin in grain and thus dramatically reduce the need for doses of additional phosphate in feed formulations and lessen environmental loads.

The phytase and pH 2.5 acid phosphatase produced according to the
25 invention may be purified by protein purification methods known in the art.

Having now generally described the invention, the same will become better understood by reference to certain specific examples that are included herein for purposes of illustration only and are not intended to be limiting unless otherwise specified.

EXAMPLES

EXAMPLE I

Method of Assay of Phytase Activity

Principle Phytase acts on phytate (inositol hexaphosphate) to release
 5 inorganic phosphate. The determination of released inorganic phosphate is based on the color formed by the reduction of a phosphomolybdate complex.

Unit of Activity One phytase unit (PU) is the amount of enzyme which liberates, under standard conditions, 1 nmol of inorganic phosphate from sodium phytate in one minute.

10 Assay conditions

Substrate	Sodium phytate
pH	5.0
incubation temperature	37°C ± 0.5°C
incubation time	15 minutes

15 Equipment

Water bath	37°C
Water bath	50°C
Spectrophotometer	
Test tube mixer (vortex)	
20 Phosphate Free Glassware	

Reagents All solutions are prepared in deionized water, Milli-Q or equivalent.

1. Citrate Buffer (0.2 M, pH 5.0). Prepare 0.2 M solutions of both sodium citrate ($C_6H_5O_7Na \cdot 2 H_2O$, 58.8 g/l, Merck 6448) and citric acid
 25 ($C_6H_8O_7 \cdot H_2O$, 42.0 g/l, Merck 244) in water. Adjust the pH of the citrate solution (1 liter) to 5.0 with 0.2 M citric acid (the consumption of citric acid solution should be about 385 ml).

2. Substrate. Dissolve 1.00 g of sodium phytate (Sigma P-3168) in about 70 ml citrate buffer. Adjust the pH to 5.0 with 0.2 M citric acid and

adjust the volume to 100 ml with citrate buffer. Fresh substrate solution must be prepared daily.

3. 15% (w/v) TCA Solution. Prepare from trichloroacetic acid (Merck 807).

5 4. 10% (w/v) Ascorbic Acid Solution. Prepare from ascorbic acid (Merck 127). Store under refrigeration. The solution is stable for seven days.

5. 2.5% (w/v) Ammonium Molybdate Solution. Dissolve 2.5 g $(\text{NH}_4)_6\text{Mo}_7\text{O}_{24} \cdot 4\text{H}_2\text{O}$ (Merck 1182) in water and make up to 100 ml.

10 6. 1 M Sulfuric Acid. Add 55.6 ml of concentrated H_2SO_4 (Merck 731) to about 800 ml of water, with stirring. Allow to cool and make up to 1000 ml with water.

7. Reagent C. Mix 3 volumes of 1 M sulfuric acid with 1 volume of 2.5% ammonium molybdate, then add 1 volume of 10% ascorbic acid and mix well. Fresh reagent C must be prepared daily.

15 Sample dilution Samples are diluted in citrate buffer. Make duplicate dilutions of each sample. In case of enzyme powder weigh accurately about 250 mg of sample, dissolve in the buffer and fill to 25 ml in a volumetric flask, dilute further if necessary.

20

25

Dilution table:		
Estimated activity PU/ml	Recommended dilution	Dilution factor
2000	1 + 19	20
20000	1 + 199	200
40000	1 + 399	400
100000	1 + 999	1000
500000	1 + 4999	5000

Assay

Hydrolysis Pipette 1.0 ml of sample dilution containing 20-190 PU in two test tubes. Add 2.0 ml of 15% TCA to one of the tubes (blank) and mix.

30 Put the tubes without TCA in a water bath at 37°C and let them equilibrate for

5 minutes. Using a stopwatch start the hydrolysis by adding sequentially at proper intervals 1.0 ml of substrate (equilibrated for about 10 minutes at 37°C) to each tube and mix. After exactly 15 minutes incubation stop the reaction by adding 2.0 ml of TCA to each tube. Mix and cool to room temperature. Add 1.0 ml substrate to the blank tubes (kept at room temperature) also and mix. If precipitate occurs it must be separated by centrifugation for 10 minutes at 2000-g.

Released orthophosphate Pipette 0.4 ml of each sample after hydrolysis in test tubes. Add 3.6 ml of water to each tube. Add 4.0 ml of reagent C and mix. Incubate at 50°C for 20 minutes and cool to room temperature. Measure the absorbance against that of reagent blank (see below) at 820 nm.

Standard Prepare a 9.0 mM phosphate stock solution. Dissolve and dilute 612.4 mg KH_2PO_4 (Merck 4873, dried in desiccator with silica) to 500 ml with water in a volumetric flask. Make the following dilutions in water from the stock solution and use these as standards.

Dilution	Phosphorus concentration nmol/ml	Phytase activity PU/ml*
1:100	90	240
1:200	45	120
1:400	22.5	60

* The corresponding phytase activity (PU/ml) is obtained by dividing the phosphorous concentration (nmol/ml) by the time of hydrolysis (15 minutes) and multiplying by four (total volume after hydrolysis reaction / sample volume) and by 10 (dilution before analysis of inorganic phosphorous).

Pipette 4.0 ml of each dilution to two test tubes. Pipette also 4.0 ml of water in one tube (reagent blank). Add 4.0 ml of reagent C and mix. Incubate at 50°C for 20 minutes and cool to room temperature. Measure the absorbances at 820 nm against that of reagent blank. Prepare a standard curve by blotting the absorbances against phytase activity (PU/ml). A new standard line must be constructed with each series of assays.

- 31 -

Calculation Subtract the blank absorbance from the sample absorbance (the difference should be 0.100 - 1.000). Read the phytase activity (PU/ml) from the standard line and multiply by the dilution factor. To calculate the activity (PU/g) of enzyme powders the result (PU/ml) is further multiplied by 25 (ml) and divided by the exact weight of the sample (g).

Preparation of feed and other insoluble samples for phytase analysis

Weigh accurately about 2.5 g of ground sample in two 50 ml beakers. Add 20.0 ml of citrate buffer. Mix using a magnetic stirrer for 30 minutes at room temperature. Transfer about 10 ml of each in centrifuge tubes and separate the solid matter by centrifugation for 10 minutes at 2000·g. Apply 2.5 ml of supernatant on PD-10 gel filtration columns (Sephadex G-25M, Pharmacia 17-0851-01) equilibrated with 25 ml citrate buffer. Discard the eluate. Then apply 3.5 ml citrate buffer on the column and collect the eluate in a graduated cylinder. Fill the volume to 5.0 ml with citrate buffer (dilution factor 2) and assay for phytase activity. The activity PU/g is obtained by multiplying the measured activity (PU/ml) by 40 (dilution factor · volume of extraction buffer) and dividing by the exact weight of sample (g). Reference: Chen *et al. Anal. Chem.* 28:1756-1758 (1956).

EXAMPLE 2

Assay of Acid Phosphatase Activity

Principle. Acid phosphatase acts on p-nitrophenyl phosphate to release inorganic phosphate. The determination of released inorganic phosphate is based on the color formed by the reduction of phosphomolybdate complex.

Unit of activity. One acid phosphatase unit (HFU) is the amount of enzyme which liberates, under standard conditions, 1 nmol of inorganic phosphate from p-nitrophenyl phosphate in one minute.

- 32 -

Assay conditions.

	Substrate	p-nitrophenyl phosphate
	pH	2.5
	Temperature	37°C ± 0.5°C
5	Incubation time	15 min

Equipment.

	Water bath	37°C
	Water bath	50°C
10	Spectrophotometer	
	Test tube mixer (vortex)	
	Centrifuge (Hereaus Biofuge	
	17S. 3090 or equivalent	
	Phosphate Free Glassware	

15 Reagents. All solutions are prepared in deionized water, Milli-Q or equivalent.

1. Glycine Buffer (0.2 M, pH 2.5)
Dissolve 15.014 g glycine (Merck 4201) in about 800 ml of water. Adjust the pH to 2.5 with 1 M hydrochloric acid (consumption should be about 80 ml) and dilute to 1000 ml with water.
- 20 2. Substrate (30 mM)
Dissolve 1.114 g *p*-nitrophenyl phosphate (Boehringer, 738 352) in glycine buffer and adjust the volume to 100 ml with the buffer. Fresh substrate solution must be prepared daily.
- 25 3. 15% (w/v) TCA Solution
Prepare from trichloroacetic acid (Merck 807).
4. 10% (w/v) Ascorbic Acid Solution
Prepare from ascorbic acid (Merck 127). Store under refrigeration. The solution is stable for 7 days.
- 30 5. 2.5% (w/v) Ammonium Molybdate Solution
Dissolve 2.5 g (NH₄)₆Mo₇O₂₄·4H₂O. Merck 1182) in water and make up to 100 ml.

- 33 -

6. 1 M Sulphuric Acid

Add 55.6 ml of concentrated H_2SO_4 (Merck 731) to about 800 ml of water. with stirring. Allow to cool and make up to 1000 ml with water.

5 7. Reagent C

Mix 3 volumes of 1 M sulphuric acid with 1 volume of 2.5% ammonium molybdate, then add 1 volume of 10% ascorbic acid and mix well. Fresh reagent C must be prepared daily.

Sample dilution. Samples are diluted in glycine buffer. Make
10 duplicate dilutions of each sample. In case of enzyme powder weigh accurately about 250 mg of sample, dissolve in the buffer and fill to 25 ml in a volumetric flask, dilute further if necessary.

Dilution table:

15	Estimated activity HFU/ml	Recommended dilution	Dilution factor
	20000	1 + 19	20
	200000	1 + 199	200
	400000	1 + 399	400
	1000000	1 + 999	1000
20	5000000	1 + 4999	5000

Assay.

Hydrolysis: Pipette 1.9 ml of substrate in two test tubes. Add 2.0 ml of 15% TCA to one of the tubes (blank) and mix. Put the tubes without TCA in a water bath at 37°C and let them equilibrate for 5 min.
25 Using a stopwatch start the hydrolysis by adding sequentially at proper intervals 0.1 ml of enzyme dilution to each tube and mix. After exactly 15 min incubation stop the reaction by adding 2.0 ml of TCA to each tube. Mix and cool to room temperature. Add 0.1 ml of sample to the blank tubes (kept at room temperature) also and mix. If precipitate occurs it must be separated
30 by centrifugation for 10 min at 2000 g.

Released orthophosphate: Pipette 0.4 ml of each sample after hydrolysis in test tubes. Add 3.6 ml of water to each tube. Add 4.0 ml of

- 34 -

reagent C and mix. Incubate at 50°C for 20 min and cool to room temperature. Measure the absorbance against that of reagent blank (see below) at 820 nm.

Standard. Prepare a 9.0 mM phosphate stock solution. Dissolve and dilute 612.4 mg KH_2PO_4 (Merck 4873, dried in dessicator with silica) to 500 ml with water in a volumetric flask. Make the following dilutions in water from the stock solution and use these as standards.

Dilution	Phosphorus concentration nmol/ml	Acid phosphatase activity HFU/ml*
1:100	90	2400
1:200	45	1200
1:400	22.5	600

*The corresponding acid phosphatase activity (HFU/ml) is obtained by dividing the phosphorus concentration (nmol/ml) by the time of hydrolysis (15 min) and multiplying by 40 (total volume after hydrolysis reaction / sample volume) and by 10 (dilution before analysis of inorganic phosphorus).

Pipette 4.0 ml of each dilution to two test tubes. Pipette also 4.0 ml of water in one tube (reagent blank). Add 4.0 ml of reagent C and mix. Incubate at 50°C for 20 min and cool to room temperature. Measure the absorbances at 820 nm against that of reagent blank. Prepare a standard curve by blotting the absorbances against acid phosphatase activity (HFU/ml). A new standard line must be constructed with each series of assays.

Calculation. Subtract the blank absorbance from the sample absorbance (the difference should be 0.100-1.000). Read the acid phosphatase activity (HFU/ml) from the standard line and multiply by the dilution factor. To calculate the activity (HFU/g) of enzyme powders the result (HFU/ml) is further multiplied by 25 (ml) and divided by the exact weight of the sample (g).

Preparation of feed and other insoluble samples for acid phosphatase analysis. Weigh accurately about 2.5 g of ground sample in two 50 ml beakers. Add 20.0 ml of glycine buffer. Mix using a magnetic stirrer for 30

- 35 -

min at room temperature. Transfer about 10 ml of each in centrifuge tubes and separate the solid matter by centrifugation for 10 min at 2000-g. Apply 2.5 ml of supernatant on PD-10 gel filtration columns (Sephadex G-25M, Pharmacia 17-0851-01) equilibrated with 25 ml glycine buffer. Discard the
5 eluate. Then apply 3.5 ml of glycine buffer on the column and collect the eluate in a graduated cylinder. Fill the volume to 5.0 ml with glycine buffer (dilution factor 2) and assay for acid phosphatase activity. The activity HFU/g is obtained by multiplying the measured activity (HFU/ml) by 40 (dilution factor · volume of extraction buffer) and dividing by the exact weight of
10 sample (g). Reference: Chen, P.S., *et al.*, *Anal. Chem.* 28:1756-1758 (1956).

EXAMPLE 3

Purification of Phytase and pH 2.5 Acid Phosphatase

For reference to how the skilled artisan would purify phytase and pH 2.5 acid phosphatase, the following are provided.

5 I. PHYTASE

Enzyme purification. Steps were done at 4 to 8 °C unless otherwise stated. The starting material was the cell-free culture medium concentrate produced by *Aspergillus niger* var. *awamori* ALKO 243.

Ammonium sulphate precipitation. The culture filtrate concentrate (990
10 ml) was kept on an ice bath and 0.436 g ammonium sulphate per ml was added (70% saturation). After 30 minutes the precipitate was separated by centrifugation for 15 minutes at 10000-g and discarded.

Hydrophobic interaction chromatography. The supernatant (1070 ml) was applied to an Octyl-Sepharose CL-4B (Pharmacia) column (5 cm x 17 cm)
15 equilibrated with a solution containing 0.436 g (NH₄)₂SO₄ per ml of 20 mM bis-Tris/HCl (pH 6.2). The column was washed with 500 ml of the equilibration solution and then developed with a linear gradient of 500 ml containing 70→0% ammonium sulfate in 20 mM bis-Tris/HCl (pH 6.2).

- 36 -

Fractions of 10 ml were collected and analyzed for phytase and acid phosphatase activity. Most of the phytase activity eluted in the beginning of the gradient. The fractions were pooled for the next step. The fractions eluting after phytase activity and containing most of the acid phosphatase activity were pooled for acid phosphatase purification (see below).

Anion exchange chromatography. The pooled phytase fractions (129 ml) were concentrated by ultrafiltration using an Amicon PM 10 membrane. The residual ammonium sulphate was removed by PD 10 (Pharmacia) gel filtration columns equilibrated with 50 mM bis-Tris/HCl (pH 6.2). The sample, in 24.5 ml, was applied to a DEAE-Sepharose (Pharmacia) column (5 cm x 7 cm) equilibrated with 50 mM bis-Tris/HCl (pH 6.2). The column was washed with the equilibrium buffer (100 ml) and developed by a linear gradient of 200 ml containing 0→0.5 M NaCl in equilibrium buffer.

Gel filtration. The pooled active fractions were concentrated using a Centricon -30 microconcentrator to a total volume of 600 μ l. Portions of 100 μ l were run at about 23°C and 0.3 ml/min through a Superose 12-HR 10/30 HPLC column (Pharmacia) equilibrated with 50 mM bis-Tris/HCl (pH 6.2).

Cation exchange. The pooled active fractions were transferred to 50 mM sodium formate (pH 3.8) using a Centricon -30 microconcentrator. The sample was applied in two portions of 2 ml to a Mono S HR 5/5 FPLC column (Pharmacia) equilibrated with 50 mM sodium formate (pH 3.8) at about 23°C. The column was washed with the equilibration buffer (10 ml) and the bound protein was eluted at 60 ml/h with a linear gradient of 20 ml containing 0→430 mM NaCl in equilibration buffer.

II. ACID PHOSPHATASE

Gel filtration. The pooled fractions containing most of the acid phosphatase activity from the hydrophobic interaction chromatography step were concentrated by ultrafiltration using an Amicon PM 10 membrane. The concentrated sample (25 ml) was run through a Sephacryl S-200 (Pharmacia)

- 37 -

column (2.6 cm x 94 cm) equilibrated with 50 mM bis-Tris/HCl (pH 6.2) at 20 ml/h.

Anion exchange chromatography. The pooled fractions (48 ml) were applied to a DEAE-Sepharose (Pharmacia) column (5 cm x 7 cm) equilibrated with 50 mM bis-Tris/HCl (pH 6.2). The column was washed with 100 ml of equilibration buffer and developed with a linear gradient of 200 ml containing 0→0.5 M NaCl in equilibration buffer.

Anion exchange chromatography. The pooled active fractions were concentrated and transferred to 20 mM bis-Tris/HCl (pH 6.0) by ultrafiltration using an Amicon PM 10 membrane. The sample was run in four portions of 3.5 ml on Mono Q HR 5/5 HPLC column (Pharmacia) equilibrated with 20 mM bis-Tris/HCl (pH 6.0) at about 23°C and 60 ml/h. The column was washed with 10 ml of the equilibrium buffer and the bound protein was eluted with a linear gradient of 20 ml containing 0→350 mM NaCl in equilibrium buffer.

Gel filtration. The active fractions were pooled, concentrated and transferred to 20 mM bis-Tris/HCl (pH 6.2) containing 150 mM NaCl with Centricon -30 microconcentrator to total volume of 400 µl. Portions of 100 µl were run at about 23°C and 18 ml/h through a Superose 12 HR 10/30 HPLC column (Pharmacia) equilibrated with the sample buffer.

Anion exchange chromatography. The pooled active fractions were transferred to 20 mM histidin/HCl (pH 5.8) with a PD 10 gel filtration column. The sample was run in four portions of 1 ml on Mono Q HR 5/5 HPLC column (Pharmacia) equilibrated with the sample buffer at about 23°C and 60 ml/h. The column was washed with 5 ml of the sample buffer and the bound protein was eluted with a linear gradient of 20 ml containing 0→350 mM NaCl in equilibrium buffer.

Table 1. Summary of purification of phytase from *Aspergillus niger*

Step	Total activity (PU)	Total protein (mg)	Specific activity (PU/mg)	Yield (%)	Purification (fold)
Culture filtrate	4486680	2119	2117	100	1
Ammonium sulfate supernatant	3771750	1263	2986	84.1	1.4
Octyl Sepharose	1765881	32.3	54671	39.4	26
DEAE-Sepharose	1453470	8.4	173032	32.4	82
Superose 12	1010888	5.7	177349	22.5	84
Mono S	827566	3.0	275822	18.4	130

Table 2. Summary of purification of acid phosphatase from *Aspergillus niger*

Step	Total activity (HFU)	Total protein (mg)	Specific activity (HFU/mg)	Yield (%)	Purification (fold)
Culture filtrate	116523000	2119	54990	100	1
Ammonium sulphate supernatant	88275000	1263	69893	75.8	1.3
Octyl Sepharose	68296470	583	117147	58.6	2.1
Sephacryl	52237600	97.9	533581	44.8	9.7
DEAE-Sepharose	46127692	54.6	844830	39.6	15.4
Mono Q	19326753	3.28	5892303	16.6	107
Superose	16876978	nd	nd	14.5	nd
Mono Q	15197050	2.2	6907750	13.0	126

nd = not determined

EXAMPLE 4

Characterization of Purified Phytase and
pH 2.5 Acid Phosphatase Peptide Digestions

Native purified phytase (70 μ g) in 50 mM Tris-HCl pH 7.9 was
 5 digested with 2% (w/w) trypsin (TPCK-treated, Sigma) for 2 hours at 37°C
 and then with a further 2% (w/w) trypsin for 21 hours. One lot of native
 purified phosphatase in 100 mM Tris-HCl pH 8.0 was treated with 2% (w/w)

- 39 -

trypsin for 20 hours at 37°C and then with a further 2% (w/w) trypsin for 6 hours. The peptides were purified as described below.

Another lot of purified native phosphatase was alkylated using 4-vinyl pyridine as follows: To lyophilized phosphatase (75 µg) was added 40 µl 0.5 M Tris-HCl pH 7.5 containing 6 M guanidium hydrochloride, 2 mM EDTA and 34 mM DTT. After addition of 1 µl 4-vinyl pyridine (Sigma), the reaction mixture was kept at room temperature (22°C) for 1 hour. The reaction was stopped by addition of 10 µl 1.4 M DTT. Alkylated phosphatase was then purified on HPLC with a C-1 reverse-phase column (TSK TMS 250: 0.46 x 4 cm) using a 20% to 70% ACN/0.06% TFA gradient (80% to 30% 0.1% TFA) in 30 minutes. The fractions absorbing at 218 nm were pooled and evaporated in a Speed-Vac vacuum centrifuge. The dried sample was resuspended in 60 µl 70 mM Tris-HCl pH 9.1 and digested with 2% (w/w) lysylendopeptidase C (Wako Chemicals) for 2 hours at 37°C. After addition of a further 2% (w/w) lysyl endopeptidase C, the incubation at 37°C was prolonged to 26 hours. The peptides were purified as described below.

Peptide purification and amino terminal sequencing

The peptides obtained by digestions were separated by HPLC on a C-18 reverse-phase column (Vydac 218 TP B5; 0.46 x 25 cm) with a 90 minute gradient from 0 to 60% ACN/0.06% TFA (100 to 40% of 0.1% TFA). Absorbance at 218 nm was used for detection of peptides.

Amino terminal sequencing of the purified peptides, as well as the native proteins, was done by degrading them in a gas-pulsed-liquid-phase sequencer (Kalkkinen and Tilgmann, *Journal of Protein Chemistry* 7:242-243 (1988)). The released PTH-amino acids were analyzed on-line by using narrow-bore reverse-phase HPLC.

- 40 -

Carboxy terminal sequencing of phytase

One lot of purified phytase (53 μ g) was digested with carboxypeptidase Y (Sigma, 0.6 U) in 50 mM sodium acetate pH 5.6 containing 10% urea and 0.05% SDS at room temperature (22°C). Samples of the digestion were withdrawn at various time points. These were dried in a Speed-Vac vacuum centrifuge and derivatized with phenylisothiocyanate (PITC) according to the amino acid analyzing kit Pico-Tag (Waters association). Analysis of the derivatized amino acids was performed by reverse-phase HPLC with the Pico-Tag C-18 column, and quantified by identically derivatized amino acid standards.

Results and Discussion

Sequences could be extracted from the peptides showing "double sequences" (for both phytase and phosphatase, Tables 3 and 4) since they were quantitatively different and/or the other sequence was already known from peptides sequenced. Native phosphatase seemed to be somewhat resistant to lysylendopeptidase C digestion. After alkylation however, peptides of phosphatase were nicely obtained with lysyl-endopeptidase C.

The amino terminal sequence obtained from phytase (Nphy. #1081: [SEQ. ID NO.:50:]) was similar, but not identical, to the amino terminal sequence of *A. ficuum* phytase (LAVPASRNQSSGDT) [SEQ ID No.:17:] reported by Ullah, A. H.J. *Prep. Biochem.* 18:459-471 (1988). Peptides resulting from trypsin digestions are shown in Table 3. One peptide (10 phy) [SEQ ID NO.:23:] had identical sequences with the internal peptide of *A. ficuum* phytase (MMQCQAEQEPLVRVLVNDNR); Ullah, A.H.J. *Prep. Biochem.* 18:459-471 (1988). Carboxyterminal sequencing of phytase gave the sequence XSA-OH.

No results were obtained from amino terminal sequencing of native and alkylated phosphatase (Table 4). One peptide (7Lpho, #817 [SEQ. ID NO.:53:]) was, however, identical with the amino terminal sequence from

- 41 -

A. ficuum acid phosphatase (pH optimum 2.5: FSYGAAIPQSTQEK QFSQEFRDG) published by Ullah, A.H.J. and Cummings, B.J., *Prep. Biochem.* 17:397-422 (1987) and another (10 Lpho. #941 [SEQ. ID NO.:54:]) seems to be a continuation of this. Peptide 3Tpho (peptide #1106 in Table 4: 5 SEQ ID No.:61:) could also be a continuation of peptide 11Lpho (peptide #943-2 in Table 4: SEQ ID No.:60:) since it has four overlapping amino acids: FSSG.

Peptide 1Lpho (peptide #816 in Table 4: SEQ ID No. :57:) contains the active site consensus sequence RHGXRXP [SEQ ID No. :18:] of phytases and phosphatases proposed by Ullah, A.H.J. *et al.*, *Biochem. Biophys. Res. 10 Comun.* 178:45-53 (1991). The peptide was highly homologous, but not identical. One peptide of phytase (#675, [SEQ. ID NO.:37:], LKDPR) again contained part of the KDPRA [SEQ ID No.:19:] homologous sequence between *A. ficuum* phytase and different phosphatases reported by Ullah, A.H.J. *et al.*, 15 *Biochem. Biophys. Res. Comun.* 178:45-53 (1991).

The results indicate that *A. niger* phytase is homologous to *A. ficuum* phytase, but not identical. The same conclusion is reached in the case of acid phosphatase (pH optimum 2.5).

TABLE 3

Amino acid sequence of isolated peptides of phytase

Amino acid sequences of phytase peptides obtained as indicated in the text. In the case of uncertainty of the sequence, amino acids are shown in brackets. X, stands for undetected amino acids. The peptides are numbered (Xphy) according to appearance (retention times) in the HPLC runs. Phytase peptides (phy) obtained by trypsin digestion.

[SEQ ID No.:]	Peptide No. (name)	Amino Acid Sequence* sequence]	Amino Acid Sequence, Deduced from DNA
[:20:]	132 (12 phy)	Tyr-Tyr-Gly-His(Leu)-Gly-Ala-Gly-Asn-Pro-Leu-Gly-Pro-Thr-Gln	
[:21:]	133	[Tyr-Tyr-Gly-His-Gly-Ala-Gly-Asn-Pro-Leu-Gly-Pro-Thr-Gln]	
[:22:]	242 (1 phy)	Thr-Gly-Tyr-Val-Gln(Asn)-Tyr-Val-Gln-Met-(Gln)	[not found in DNA]
[:23:]	420 (10 phy)	Ala-Gln-Pro-Gly-Gln-Ala-Ala-Pro-Lys	[Ala-Gln-Pro-Gly-Gln-Ser-Ser-Pro-Lys]
[:24:]	410 (13 phy)	Leu-Tyr-Val-Glu-Met-Met-Gln-(Asn)-Gln-Ala-(Gln)-Gln(Thr)-Pro-Leu-Val	
[:25:]		[Leu-Tyr-Val-Glu-Met-Met-Gln-Cys-Gln-Ala-Glu-Gln-Glu-Pro-Leu-Val]	
[:26:]		Phe-Ile-Glu-Gly-Phe-Gln-Ser-Asp-Lys	
[:27:]	416 (7 phy)	[Phe-Ile-Glu-Gly-Phe-Gln-Ser-Asp-Lys]	
[:28:]	659 (6 phy)	Tyr-Ala-Phe-Leu-Lys	[Tyr-Ala-Phe-Leu-Lys]
[:29:]	670 and 796 (2 phy)	Gly-Leu-Ser-Phe-Ala-Arg	[Gly-Leu-Ser-Phe-Ala-Arg]
[:30:]		Val-Ile-Ala-Ser-Gly-Glu-Lys	[Val-Ile-Ala-Ser-Gly-Glu-Lys]

-43-

TABLE 3

Amino acid sequence of isolated peptides of phytase

Amino acid sequences of phytase peptides obtained as indicated in the text. In the case of uncertainty of the sequence, amino acids are shown in brackets. X, stands for undetected amino acids. The peptides are numbered (Xphy) according to appearance (retention times) in the HPLC runs. Phytase peptides (phy) obtained by trypsin digestion.

[SEQ ID No.:]	Peptide No. (name)	Amino Acid Sequence* [sequence]
[:30:]	418 (3 phy)	Phe-Tyr-Gln-Arg [Phe-Tyr-Gln-Arg]
[:31:]	785 (not pure) (11 phy)	Phe-Tyr-Gln-Arg [=418, 3phy, above] and Asp-Ser-Phe Val-Arg
[:32:]		[Asp-Ser-Phe-Val-Arg]
[:33:]	248 (not pure)	Val-Leu-Val-Asn-Asp [not possible to compare to DNA]
[:34:]		Tyr Glu Ser Leu Gln
[:35:]	784 (9 phy)	Tyr-Glu-Ser-Leu-Thr-Arg [Tyr-Glu-Ser-Leu-Thr-Arg]
[:36:]	675 (not pure)	Ser-Ala-Ala-Ser-Leu-Asn-Ser (a fragment of the trypsin enzyme)
[:37:]		Leu-Lys-Asp-Pro-Arg [Leu-Lys-Asp-Pro-Arg]
[:38:]	783 (not pure)	Val-Ile-Ala-Ser-Gly-Glu-Lys [small amount =#670 and 796, above]
[:39:]	(4 phy)	Tyr-Pro-Thr-Glu-Ser-Lys [Tyr-Pro-Thr-Glu-Ser-Lys]
[:40:]	244 (not pure)	Tyr Phe Asn X Gly [not possible to compare to DNA]
		Asp Pro Ala X

TABLE 3

Amino acid sequence of isolated peptides of phytase

Amino acid sequences of phytase peptides obtained as indicated in the text. In the case of uncertainty of the sequence, amino acids are shown in brackets. X, stands for undetected amino acids. The peptides are numbered (Xphy) according to appearance (retention times) in the HPLC runs. Phytase peptides (phy) obtained by trypsin digestion.

[SEQ ID NO.:]	Peptide No. (name)	Amino Acid Sequence* [sequence]	Amino Acid Sequence Deduced from DNA
[:41:]	793		Leu-Glu-Asn/Pro-Asp/Phe-Leu-Asp/Ser-Gly/Leu-Phe/Val-Thr-Leu-)
[:42:]			[Leu-Glu-Asn-Asp-Leu-Ser-Gly-Val-Thr-Leu-Thr]
[:43:]	792 (doubt. sequence)		Tyr-Tyr-Gly-His-Gly-Ala-Gly-Asn-Pro-Leu-Gly-Pro-Thr-Gln-Gly Val Gly/Tyr-Ala-Asn-Glu-
[:44:]	(15 phy)		Leu-Ile-Ala (= #132 (half of above)) and
			From this double sequence, the following sequences can be deduced
[:45:]			Val-Thr-Phe-Ala-Gln-Val-Leu-Ser [Val-Thr-Phe-Ala-Gln-Val Leu-Ser] and Tyr-Tyr-Gly-His-Gly-Ala-Gly-Asn-Pro-Leu-Gly-Pro-Thr-Gln-Gly- Val-Gly
			[Tyr-Tyr-Gly-His-Gly-Ala-Gly-Asn-Pro-Leu-Gly-Pro-Thr-Gln-Gly-Val Gly]
			Tyr-Ala-Asn-Glu-Leu-Ile-Ala [Tyr-Ala-Asn-Glu-Leu-Ile-Ala]
[:46:]	800 (13 phy)		Phe-Ile-Glu-Gly-Phe-Gln-Ser-Thr [Phe-Ile-Glu-Gly-Phe-Gln-Ser Thr]
[:47:]	797 (13 phy)		Asp/Asn-Tyr-Leu-Gln-Ser-Leu-Lys [Asp-Tyr-Leu-Gln-Ser-Leu-Lys]
[:48:]	795		(Odd behavior in peptide sequencing) Asn-Ile-Glu-Pro-Phe Gln-Val Asn
			[not found in DNA sequence.]

-45-

TABLE 3

Amino acid sequence of isolated peptides of phytase

Amino acid sequences of phytase peptides obtained as indicated in the text. In the case of uncertainty of the sequence, amino acids are shown in brackets. X, stands for undetected amino acids. The peptides are numbered (Xphy) according to appearance (retention times) in the HPLC runs. Phytase peptides (phy) obtained by trypsin digestion.

[SEQ ID No.:_:]	Peptide No. (name)	Amino Acid Sequence ^a sequence]	Amino Acid Sequence Deduced from DNA
[:49:]	799 (8 phy)	Val-Leu-Val-Asn-Asp-Arg Arg]	[Val-Leu-Val-Asn-Asp-
[:50:]	1081 (Nphy)	Leu-Ala-Val-Pro-Ala-Ser- (Arg) -Asp-Gln-Ser-Thr X-Asp-Thr	
		[Leu-Ala-Val-Pro-Ala-Ser-Arg-Asn-Gln-Ser-Thr-Cys-Asp-Thr]	
[:51:]	C-terminal (Cphy)	- (Arg) -Ser-Ala-OH [Cys-Ser-Ala-End]	

^a peptide sequence X = amino acid not determined; slash (/) = either one or the other of the two indicated amino acids may be present, the assay was not definitive, () = the presence of the amino acids in parenthesis is subject to question because of a weak signal of the PTH amino acid; [] = peptide sequence deduced from DNA sequence.

Table 4. pH 2.5 acid phosphatase peptide sequences generated by either trypsin (T) or endoproteinase Lys-C digestion (L) of purified enzyme. Corresponding nucleotide positions are also listed.

Peptide Number	Peptide Sequence	Nucleotide Position
N-terminal #817: 7Lpho [SEQ ID No.:53:]	FSYGAAIPQSTQEK	193...234
#941: 10Lpho [SEQ ID No.:54:]	QFSQEFRDGY	235...264
#938: 2Lpho [SEQ ID No.:55:]	YGGNGPY	280...300
#1111: 4Tpho [SEQ ID No.:56:]	VSYGIA	310...327
#816: 1Lpho [SEQ ID No.:57:]	RHGERYPSPSAGK	376...414
#847: 5Lpho [SEQ ID No.:58:]	DIEEALAK	415...438
#943-1: 11Lpho [SEQ ID No.:59:]	ARYGHLWNGET	595...627
#943-2: 11Lpho [SEQ ID No.:60:]	VVPFFSSG	628...651
#1106: 3Tpho [SEQ ID No.:61:]	FSSGYGR	640...660
#1110-1: 6Tpho [SEQ ID No.:62:]	QLPQFK	826...843
#1108: 9Tpho [SEQ ID No.:63:]	VAFGNPY	1384...1404

- 47 -

EXAMPLE 5
The Cloning and Sequencing of the
pH 2.5 Optimum Acid Phosphatase Gene
from *Aspergillus niger*

5 I. SUMMARY

The gene for pH 2.5 optimum acid phosphatase has been cloned and sequenced from *Aspergillus niger*. Translated nucleotide sequence yielded a polypeptide of 479 amino acids for the pH 2.5 acid phosphatase. The gene for this protein was isolated using oligonucleotide probes based on the peptide
10 sequence of the purified protein.

II. EXPERIMENTAL AND DISCUSSION

A. Design of oligonucleotide probes.

Isolation of the gene encoding pH 2.5 acid phosphatase (AP) was made through hybridization of degenerate oligonucleotides designed from peptide
15 sequences. Several internal peptide fragments had been isolated previously and sequenced from purified pH 2.5 AP from *A. niger* var. *awamori* strain ALKO 243 (ATCC 38854) as described earlier in this patent.

A 17mer degenerate oligonucleotide, PHY-31, was designed from acid phosphatase peptide #816 (1Lpho in Table 4 [SEQ. NO.:57:]). Through the
20 incorporation of a neutral inosine, one perfect match out of 64 possible combinations exists in PHY-31. The nucleotide sequence of oligonucleotide PHY-31 and corresponding peptide sequence is shown in Figure 1.

B. Hybridization specificity of the oligonucleotide probes

In order to evaluate the specificity of the degenerate oligonucleotides, they were end labelled with [$\gamma^{32}\text{P}$]-ATP to a high specific activity using *E. coli* polynucleotide T4 kinase (BRL) and used to probe total genomic DNA from ALKO 243. Genomic DNA was isolated by a neutral lysis method. Briefly, 5 finely ground frozen dried mycelia was lysed with a 4% SDS-TE buffer. Cell debris was removed and supernatant was removed and extracted twice with an equal volume of Tris-saturated phenol:chloroform (1:1). Genomic DNA was precipitated with NH_4OAc and EtOH. Pelleted DNA was purified by 10 ultracentrifugation through CsCl and recovered as described by Maniatis *et al.* *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA (1982)). Hybridization to genomic DNA with [$\gamma^{32}\text{P}$] ATP labelled degenerate oligonucleotides Maniatis *et al.* *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring 15 Harbor, NY, USA (1982) was done at 42°C over night on filters in oligonucleotide hybridization solution (6X SSPE, 0.5% SDS, 3X Denhardt's, 100 $\mu\text{g/ml}$ tRNA). Non-specific binding was removed by washing the filters twice for 30 minutes at room temperature with 2XSSC, 0.1% SDS, and once for 5 minutes at 42°C in fresh solution. Overnight exposure on Kodak X- 20 Omat AR film with intensifying screens revealed positively hybridizing bands.

A. niger ALKO 243 genomic DNA was probed with pH 2.5 oligonucleotide PHY-31. Hybridization was performed as in genomic hybridization. Among the oligonucleotides for pH 2.5 AP, only PHY-31 gave relatively specific hybridization to genomic DNA. Hybridization to one 25 predominant and one minor band indicated sufficient specificity to use for screening the libraries.

- 49 -

C. Isolation and characterization of the pH 2.5 Acid Phosphatase gene

Genomic DNA was partially digested with *Sau3A* in order to produce fragments 10-23kb in length. Digested DNA was ligated to *Bam*HI-cut
5 dephosphorylated Lambda Dash II vector arms (Stratagene). The ligated DNA was packaged *in vitro* using Gigapack Gold packaging extracts (Stratagene). Packaged phage was used to infect *E. coli* strain P2392. The lambda library was screened with oligonucleotide PHY-31 for the pH 2.5 AP gene under the conditions established with genomic hybridizations in section (B). Twelve
10 hybridizing plaques were picked for further characterization. Bacteriophage DNA isolated from each of the candidates was digested with restriction endonucleases and probed with either PHY-31 or a mixture of PHY-34 and PHY-35 which were derived from an independent pH 2.5 AP peptide (Figure 1). One of the clones, AP99, contained a 2.1 kb *Sph*I fragment previously
15 identified in genomic Southern analysis, that hybridized strongly to both probes. Strong hybridization to two oligonucleotides derived from different peptide sequences suggested that AP99 contained pH 2.5 AP coding sequences. This 2.1 kb *Sph*I fragment was therefore subcloned into M13mp18 and M13mp19 for sequencing. Translation of the nucleotide sequence of this
20 subclone revealed the peptide sequences including the N-terminal peptide (Table 4). Immediately upstream of the N-terminal peptide is a typical fungal secretion signal sequence beginning with a methionine initiation codon at position 136. All of the peptide sequences were present in a single ORF except #1108 (peptide 9Tpho in Table 4 [SEQ. ID NO.:63:]) which begins at
25 nucleotide position 1384. Termination codons were identified in all three reading frames between nucleotides 1151 and 1384. These results necessitated the inclusion of an intron(s) in the 3' portion of the gene.

Identification of intron boundaries was made through the isolation and sequencing of pH 2.5 AP cDNA. The 3' region of pH 2.5 AP gene was
30 isolated from the corresponding cDNA by PCR amplification using pH 2.5 AP specific primers. *A. niger* var. *awamori* ALKO 243 was grown in RNA broth media consisting per liter of 2.0% corn starch (Sigma), 1.0% protease peptone

(Difco). 30.0g glucose. 5.0g NH_4NO_3 . 0.5g $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$. 0.5g KCl. 0.183g $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$. Total RNA was isolated essentially by the LiCl precipitation method of McAda and Douglas (McAda, P.C. *et al.*, *Meth. Enzymol.* 97:337-344 (1983)). Polyadenylated messenger RNA was affinity purified from total
5 RNA by the use of oligonucleotide(dT)-cellulose columns (Pharmacia) as specified by the manufacturer. Oligonucleotide PCR primers UPPHOS (5'-GAATTCCGAGTCCGAGGTCATGGGCGCG-3') [SEQ ID No.:66:] and DOWNPHOS (5'-GAATTCCCGGGACCTACCCCTCTGCAT-3') [SEQ ID No.:16:] were synthesized according to genomic sequences with flanking
10 *EcoRI* restriction sites. UPPHOS and DOWNPHOS are inversely oriented and are separated by 978 bases in the genomic clone. First strand synthesis was performed with the BMB cDNA kit according to the manufacturer's recommendations with 1.0 μg mRNA and DOWNPHOS. PCR amplification of the cDNA-mRNA complex with oligonucleotide primers UPPHOS and
15 DOWNPHOS yielded a specific product of approximately 850 bps. PCR amplification of pAP-1 plasmid DNA with the same primers yielded the expected product of 1006 bps. Gel purified cDNA PCR product was cut with *EcoRI* and subcloned into pUC-18 for double-stranded sequencing using the United States Biochemical Sequencase II kit. The primers amplified an 850
20 bp fragment from the cDNA and the expected 1006 bp fragment from cloned genomic DNA. Sequencing of the amplified cDNA fragment revealed the presence of three short introns, each exhibiting consensus fungal donor, lariat and acceptor sequences. The coding sequence is derived by splicing the nucleotides 136-916, 971-1088, 1141-1245, and 1305-1740. The resulting
25 translated sequence codes for a protein of 479 aa as shown in Figure 2.

The pH 2.5 AP polypeptide predicted from the nucleotide sequence has a calculated M_r of 52.678. The 2.1 kb *SphI* fragment in pUC18 (pAP-1) contained 135 bp of upstream pH 2.5 AP sequence.

- 51 -

EXAMPLE 6

Aspergillus niger Phytase Production in Trichoderma reesei

II. EXPERIMENTAL PROTOCOLS

1. Bacterial strains, phage and plasmids

5 For subcloning and sequencing, the *E. coli* strains DH5 α (Hanahan, D., "Techniques for transformation of *E. coli*," in *DNA Cloning*, vol. 1, Glover, D.M., ed., IRL Press, Oxford, pp. 109-135 (1985); Bethesda Research Laboratories, Gaithersburg, MD, USA) and XL-1-Blue (Bullock, W.O., *et al.*, *BioTechniques* 5:376-378 (1987); Stratagene, La Jolla, CA, USA) were used. *E. coli* Y1090 (r) (Huynh, D.S., *et al.*, "Constructing and screening cDNA libraries in λ gt1 and λ gt11," *DNA Cloning*, vol. 1, Glover, D.M., ed., IRL Press, Oxford, pp. 49-57 (1985); Promega Biotec Protoclone GT System, Madison, WI, USA) was used as a host in λ gt11 phage growing.

10 *Aspergillus niger* var. *awamori* ALKO 243 (ATCC 38854) was used as a donor of the phytase gene. *T. reesei* strains ATCC56765 (RutC-30), ALKO 233 (VTT-D-791256, Bailey and Nevalainen, *Enzyme Microb. Technol.* 3:153-157 (1981)) and ALKO 2221 were used as recipients for the phytase gene. ALKO 2221 is a low aspartyl protease mutant derived from the strain ALKO 233 by UV-mutagenesis.

20 The phage λ gt11 (Promega) was used for making the gene library. The phages were grown by the standard methods described by Silhavy *et al.* (Silhavy, T.J., *et al.*, *Experiments with Gene Fusions*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA (1984)).

25 As vectors for subcloning, pUC9 (Boehringer, Mannheim, FRG) and pALK307, a derivative of pIBI76 (IBI, New Haven, Conn., USA) were used. To obtain pALK307, an approximately 940 bp *NaeI*-*PvuI* fragment (actually 941 bp) has been deleted from pIBI76. This the only change in pIBI76. The plasmid pAMH110 (Nevalainen, H., *et al.*, "The molecular biology of *Trichoderma* and its application to the expression of both homologous and heterologous genes," in *Molecular Industrial Mycology*, Leong and Berka,

30

- 52 -

eds., Marcel Dekker Inc., New York, pp. 129-148 (1991)) contains the *Trichoderma reesei cbh1* promoter and terminator areas. The plasmid p3SR2 (Kelly and Hynes, *EMBO J.* 4:475-479 (1985)) contains the *Aspergillus nidulans* acetamidase gene. p3SR2 has been kindly donated by Dr. M. Hynes (University of Melbourne, Australia).

2. Growth media and culture conditions

E. coli cultivations were carried out at 37°C overnight and cultivations of filamentous fungi at 30°C for 5 to 7 days for enzyme production and for 2 days when mycelia was grown for DNA isolation.

E. coli were grown in L-broth (Maniatis, T., *et al.*, *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA (1982)) supplemented with ampicillin (50 - 100 µg/ml) when needed. PD agar slants (Potato Dextrose broth by Difco, Detroit, MI, USA) were used for growing the *Aspergillus* and the *Trichoderma* strains. *Aspergillus niger* ALKO 243 mycelium for DNA extraction was grown in complete *Aspergillus* medium containing 2% (w/v) malt extract (Difco), 0.1% (w/v) Bacto-peptone (Difco) and 2% (w/v) glucose. The plates and media for *T. reesei* transformations were as in Penttilä *et al.* (Penttilä, M., *et al.*, *Gene* 61:155-164 (1987)). The transformants were purified on selective acetamide - CsCl medium (Penttilä, M., *et al.*, *Gene* 61:155-164 (1987)) before transferring to PD slants.

For plate screening of high phytase producers, *T. reesei* clones transformed with the *cbh1* promoter/phytase fusion were grown for 3 to 5 days on *Trichoderma* minimal medium plates with no glucose and supplemented with 1% sodium phytate (Sigma, St. Louis, MO, USA), 1% Solka Floc and 1% proteose peptone (Difco). When the construct containing the phytase promoter was used for transformation, screening of high phytase producers was carried out on plates containing 1% sodium phytate and 1% proteose peptone but no sodium phosphate.

For phytase production *A. niger* ALKO 243 was grown for 5 days in a soy flour medium containing glucose and mineral salts (all from Merck.

- 53 -

Darmstadt, FRG); the pH was adjusted to 5.0. For phytase expression from the *cbh1* promoter, *T. reesei* transformants were grown for 7 days (250 rpm) in a lactose based cultivation medium. For growing the *T. reesei* transformed with the fragment containing the phytase promoter, *Trichoderma* minimal medium was supplemented with 50 g/l soy flour and no sodium phosphate was added.

The contents of the soy flower medium are as follows (per liter): 50 g of soy flower, 30 g glucose, 5.0 g NH_4NO_3 , 0.5 g $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 0.5 g KCl, 0.183 g $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, at pH 5.0. The lactose based cultivation medium contains: 4% whey, 1.5% complex nitrogen source, 1.5% KH_2PO_4 , 0.5% $(\text{NH}_4)_2\text{SO}_4$, at pH 5.5.

3. DNA preparations

Plasmid DNA from *E. coli* (large scale) was isolated by using Qiagen columns (Diagen GmbH, Dusseldorf, FRG) according to the manufacturer's protocol. For rapid screening the method of Holmes and Quigley (*Anal. Biochem.* 114:193-197 (1981)) was used. Chromosomal DNA from *Aspergillus* was isolated from lyophilized mycelia as described in Clements and Roberts (*Curr. Genet.* 9:293-298 (1986)) and in Raeder and Broda (*Lett. Appl. Microbiol.* 1:17-20 (1985)).

4. Cloning procedures

The standard DNA methods described by Maniatis *et al.* (*Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA (1982)) were mainly used. The restriction enzymes, T4-DNA-ligase, Klenow fragment of DNA polymerase I, T4 DNA polymerase, polynucleotide kinase and *Eco*RI methylase used in the DNA manipulations were from Boehringer (Mannheim, FRG) and New England Biolabs (Beverly, MA, USA). Mung bean nuclease was from BRL (Gaithersburg, MD, USA) and *Exo*III from Pharmacia (Uppsala, Sweden). Each enzyme was used according to the supplier's instructions.

- 54 -

For making the gene bank the chromosomal DNA was partially digested with *Hae*III. *Eco*RI methylase treatment, size fractionation and packaging were done as in Paloheimo *et al.* (Paloheimo, M., *et al.*, *Appl. Microbiol. Biotechnol.* 36:584-591 (1992)). Fragments of a size of 2-8 kb
5 were used for construction of the gene bank.

Subcloning into the plasmid vector was done by using standard DNA methods (Maniatis, T., *et al.*, *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA (1982)). DNA fragments for cloning or transformations were isolated from low-melting-point
10 agarose gels (FMC Bioproducts, Rockland, ME, USA) by the freeze-thaw-phenol method (Benson, S.A., *Bio/Techniques* 2:66-68 (1984)) or by using the GeneClean® or Mermaid™ Kits (BIO 101 Inc., La Jolla, CA, USA) according to the supplier's instructions.

Sequencing was carried out directly from the plasmids by the Sanger
15 method (Sanger, F., *et al.*, *Proc. Natl. Acad. Sci. USA* 74:5463-5467 (1977)) by means of SP6, T7, pUC/M13 primers and extension primers and the Promega Sequenase sequencing kit (United States Biochemical Corporation, Cleveland, OH, USA). Fusions between the *cbh1* promoter and the phytase gene were sequenced by automated sequencer (Applied Biosystems 373A,
20 Foster City, CA, USA) using Taq DyeDeoxy™ Terminator Cycle Sequencing Kit (Applied Biosystems). The oligonucleotides used were synthesized by an Applied Biosystems 381A Synthesizer except the pUC primers that were purchased from the United States Biochemical Corporation.

DNA probes were labeled by using the non radioactive DIG-DNA
25 Labelling and Detection Kit by Boehringer according to the supplier's instructions.

Hybridizations were done at 68°C as in supplier's instructions (Boehringer). Amersham's Hybond N nylon filters were used in the plaque screenings and in the Southern blot hybridizations.

30 When the plaques were screened with an antiserum, a phytase specific polyclonal antiserum KH1236 was used. KH1236 was made against purified and deglycosylated phytase preparation (M. Turunen, Alko Ltd.) in the

- 55 -

National Public Health Institute (Helsinki, Finland). Anti-rabbit-IgG alkaline phosphate conjugate and color development substrates from ProtoBlot™ Immunoblotting system (Promega) were used to detect the immunocomplexes.

5. Transformations

5 *E. coli* strains were transformed according to the method of Hanahan ("Techniques for transformation of *E. coli*," in *DNA Cloning*, vol. 1. Glover, D.M., ed., IRL Press, Oxford, pp. 109-135 (1985)), and *T. reesei* strains as in Penttilä *et al.* (*Gene* 61:155-164 (1987)). When the ligated fragments were transformed (the D-transformant in Table 7), the ligation mixture was not
10 further purified but was used as such in the transformations. Prior to sporulating on potato dextrose agar (PD) slants *T. reesei* transformants were transferred on the selective medium and purified through conidia.

6. Enzyme and protein measurements

For the enzyme assays *T. reesei* mycelium was separated from the
15 culture medium by centrifuging for 15 to 30 min at 5,000 to 10,000 rpm (Sorvall SS-34, Dupont Company, Wilmington, Delaware, USA). *A. niger* cultures were centrifuged for 40 min at 10,000 rpm (Sorvall SS-34). The phytase activity was measured from the culture supernatant as the amount of inorganic phosphate released by enzymatic hydrolysis of sodium phytate
20 substrate at 37°C as described earlier. One phytase normalized unit (PNU) is defined as the amount of phytase activity produced by the *A. niger* ALKO 243 strain under the cultivation conditions used.

The phytase production on the sodium phytate assay plates was visualized by pouring the reagent C (3:1:1 ratio of 1 M H₂SO₄, 2.5% ammonium molybdate, 10% ascorbic acid) on the plates and incubating them
25 at 50°C for 15 minutes. The reduction of the phosphomolybdate complex leads to bluish color.

Amyloglucosidase activity (AGU) was measured by using 1% Zulkowsky starch (Merck) as a substrate and measuring the amount of the
30 released glucose units by boiling with DNS reagent (see below) after 10 min

- 56 -

of reaction at 60°C at pH 4.8. Proteases (HUT) were measured at pH 4.7 as in Food Chemicals Codex (1981) by using 2% haemoglobin (Sigma) as a substrate. Endoglucanase (ECU) and cellobiohydrolase (FPU) activities were measured as in IUPAC's Measurement of Cellulase Activities (IUPAC Commission on Biotechnology, *Measurement of Cellulase Activities*, Biochemical Engineering Research Centre, Indian Institute of Technology, Delhi, India, pp. 5-7 and 10-11 (1981)). 1% hydroxyethylcellulose (Fluka AG) in 50 mM sodium-citrate buffer (pH4.8) and Whatman no. 1 paper were used as substrates, respectively. DNS used differed from that described at the IUPAC's protocol and was made by first diluting 50.0 g 2-hydroxy-3,5-dinitrobenzoic acid (Merck) into 4 l of deionized water. Then, 80.0 g NaOH was added slowly by using the magnetic stirrer and 1.500 g sodium-potassium tartrate (Merck) was added and diluted by heating the solution (maximum temperature 45°C). The total volume was adjusted to 5 l, the solution was filtered through Whatman no. 1 and was protected from light.

CBHI protein was measured from the culture supernatant by running a SDS-polyacrylamide gel and detecting the CBHI protein band (*T. reesei* ALKO 233 and ALKO 2221 strains) or by dot blotting samples using the Schleicher & Schuell's (Dassel, FRG) Minifold™ Micro-Sample Filtration Manifold (*T. reesei* ATCC56765). CBHI protein was detected by using CBHI specific monoclonal antibody CI-89 (Aho, S., *et al.*, *Eur. J. Biochem.* 200:643-649 (1991)) and anti-mouse-IgG alkaline phosphate conjugate (Promega). Visualization of the immunocomplexes was done as in the plaque screening.

- 57 -

7. SDS-PAGE and Western blot analysis

Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis were done as in Laemmli (Laemmli, U.K., *Nature* 227:680-685 (1970)) and as in Towbin *et al.* (Towbin, H., *et al.*, *Proc. Natl. Acad. Sci. USA* 76:4350-4354 (1979)). Visualization of the phytase protein in Western blots was done by using the polyclonal rabbit antiserum KH1236. Visualization of the immunocomplexes was done as in the plaque screening.

8. Polymerase Chain Reaction (PCR)

The PCR reactions were performed by Techne Thermal Cycler PHC-2 (Techne Ltd., Cambridge, UK) in 100 μ l volumes. The reaction mixtures contained 0.2 mM of each dNTP (3'-deoxynucleoside-5'-triphosphate, Pharmacia) in 10 mM Tris buffer (pH 8.3), 50 mM KCl, 1.5-2.0 mM MgCl₂ and 0.01 % (w/v) gelatin. The protocol used was the following: 95°C (plasmid) or 100°C (chromosomal DNA)/5 min before adding the Taq DNA polymerase (1-2 units, Cetus Corp., Emeryville, CA, USA) and 100 μ l overlay of paraffin oil, denaturation 95°C/1 min, annealing 60°C/1 min (in the inverse PCR 52°C), extension 72°C/2 min (in the inverse PCR 2.5 min) for 30 cycles. The final extension time was 9 min to ensure completion of the strand synthesis.

When a plasmid or DNA fragment was used as a template, the amount of the template used was 5-10 ng and 20-50 pmol of each primer was added. When chromosomal DNA was used as a template, the corresponding amounts used were 100 ng and 50-100 pmol. The circular template for the inverse PCR was done from the digested chromosomal DNA as in Innis *et al.* (Ochman, H., *et al.*, "Amplification of flanking sequences by inverse PCR." in *PCR Protocols, A Guide to Methods and Applications*, Innis, M.A., *et al.*, eds., Academic Press, San Diego, pp. 219-227 (1990)). PCR fragments were purified by GeneClean® or Mermaid™ Kit (from an agarose gel if needed) or by Qiagen tips. The ends of the fragments were filled by using the DNA polymerase I Klenow fragment.

II. RESULTS

A. Molecular cloning of the *Aspergillus niger* phytase

1. Production of the phytase probe by nested PCR amplification

5 The oligonucleotide primers used in the PCR reactions and the corresponding amino acid sequences of the phytase ALKO 243 peptides #792 (15 phy) and #420 (10 phy) (Table 3, as described earlier) are shown in Figure 3 (nucleotides 1409-1480 and 1727-1762 in the phytase sequence, see Figure 5). Two primary PCR reactions were done. In reaction A, sense
10 oligonucleotide 1 (#792) and antisense oligonucleotide 4 (#420) were used; in reaction B, sense oligonucleotide 3 (#420) and antisense oligonucleotide 2 (#792) were used. Primary PCR reaction A gave a single band of about 400 bps while PCR amplification from the reaction B gave no product. Thus it was concluded that the region coding for the peptide #792 was located on the 5'-
15 side in the phytase sequence compared to that coding for the peptide #420. The primary PCR fragment (A) was used as a template for the second PCR with internal primers from the peptide sequences: sense oligonucleotide 2 and antisense oligonucleotide 3. PCR amplification from the second PCR reaction gave a specific product of about 350 bps. The PCR fragment was cloned to
20 *Sma*I digested pUC9 and sequenced. The amino acid sequence deduced from the DNA sequence contained also the known amino acids from the peptide #792 and #420 that were not coded by the primer sequences. The approximately 350 bp PCR fragment was used to probe the DNA bank.

- 59 -

2. Screening of the DNA bank

The gene bank contained approximately 1.9×10^6 pfu (plaque forming units)/ml. of which approximately 99.5% had an insert. From about 80,000 plaques that were screened, two positive clones *Hae2-6* and *Hae1-5* were found. The clones were isolated, purified and the inserts (5.6 and 5.2 kb) were subcloned to *EcoRI* cut pALK307. The clones also reacted with the phytase antiserum KH1236. The inserts were restriction mapped and the PCR fragment was found to hybridize to the about 1 kb *BamHI-SphI* restriction fragment of the clones (see Figure 4 for the hybridization area in the phytase sequence). The sequence of the clone *Hae2-6* that contained more of the 5'-sequence coded for 15 internal tryptic peptide sequences but the N-terminal amino acid sequence was not found. The N-terminal and the promoter area containing phage clones were screened from the gene bank by using a 5'-probe made by inverse PCR (Ochman, H., *et al.*, "Amplification of flanking sequences by inverse PCR," in *PCR Protocols, A Guide to Methods and Applications*, Innis, M.A., *et al.*, eds., Academic Press, San Diego, pp. 219-227 (1990)).

3. Amplification of the 5'-end and the promoter sequence of the phytase gene by inverse PCR

Restriction enzyme digestions of the genomic DNA and Southern hybridizations with the 350 bp PCR probe showed that digestions of the genomic DNA with *Sall* produced fragments of suitable size (1-3 kb) for circularization and amplification with PCR. The primers used for inverse PCR were from bases 1243-1257 (antisense primer) and 1304-1321 (sense primer) areas of the phytase sequence (see Figure 5). Inverse PCR with *Sall* digested ALKO 243 DNA created a PCR band of about 1.2 kb. The 350 bp PCR fragment hybridized to the inverse PCR fragment and by sequencing the subcloned fragment it was confirmed that it contained the upstream parts of the phytase gene and also the N-terminal peptide sequence was included.

- 60 -

4. Isolation of the complete phytase gene

The 1.2 kb PCR fragment obtained from the inverse PCR was used as a probe to screen 80,000 plaques from which seven positive plaques could be identified. The complete phytase gene was isolated on an about 6 kb insert of a phage clone.

The about 2.4 kb *SphI* fragment containing the phytase gene and the promoter area was subcloned into pALK307 (cut with *SphI*) to give pALK169 (Figure 4). The restriction map of the phytase containing *SphI* fragment and the location of the phytase gene in the fragment are shown in the plasmid map.

The phytase sequence is shown in Figure 5. The sequence coding for the phytase protein corresponds to the phytase sequence of *Aspergillus ficuum* published in the Gist brochades (Delft, Netherlands) PCT patent application (EP420,358 or WO91/05053) with 12 differences in the deduced amino acids. Each difference in the deduced amino acid was due to one nucleotide's change and might be due to differences between the strains. Also, in the sequence coding for the structural gene, 33 nucleotide differences were found that did not lead to differences in the deduced amino acid sequence. In the signal sequence, there were differences in two nucleotides (the other lead to a difference in the deduced amino acid) and in the proposed intron area 8 differences could be found. The overall match per length (nucleotide sequences from the first ATG to the STOP codon TAG) between the two sequences was 96.3%. The differences found between the two phytase sequences. Gist-brochades and Alko's, are shown in the Table 5.

- 61 -

Table 5. Nucleotide and amino acid differences between Gist's and Alko's phytase sequences.

area	nt no	aa no	Gist's nt(s)	Alko's nt(s)	Gist's aa	Alko's aa
signal sequence	39 40	(-7) (-6)	CTG TCT	CTA GCT	Leu Ser	Leu Ala
proposed intron	59 61 65 72 85 86 88 136	(-) (-) (-) (-) (-) (-) (-) (-)	A A A A C C T T	G T T G T T G A	(-) (-) (-) (-) (-) (-) (-) (-)	(-) (-) (-) (-) (-) (-) (-) (-)
structural gene	191 210 258 287 300 312 369 419 369 501 549 565 570 613 624 669 756 809 846 849 976 997	11 17 33 43 47 51 70 87 91 114 127 136 137 152 155 170 199 217 229 230 273 280	AGT CAG GCA GTC GAG GGA GAC GCG GAC GAA CGG GTT CCA AAG ATC CCC TTC GTC TCC GGT AAC TTG	ACT CAA GCG GCC GAT GGT GAG GTG GAT GAG CGA ATT CCG GAG ATT CCG TTT GCC TCT GGC CAC CTG	Ser Gln Ala Val Glu Gly Asp Ala Asp Glu Arg Val Pro Lys Ile Pro Phe Val Ser Gly Asn Leu	Thr Gln Ala Ala Asp Gly Glu Val Asp Glu Arg Ile Pro Glu Ile Pro Phe Ala Ser Gly His Leu

5

- 62 -

structural gene (cont'd)	1005	282	AAG	AAA	Lys	Lys
	1008	283	TAT	TAC	Tyr	Tyr
	1020	287	GGT	GGC	Gly	Gly
	1083	308	CTG	CTC	Leu	Leu
	1113	318	AGT	AGC	Ser	Ser
	1125	322	ACT	ACC	Thr	Thr
	1136	326	AGC	AAC	Ser	Asn
	1140	327	CCG	CCA	Pro	Pro
	1149	330	TTT	TTC	Phe	Phe
	1182	341	TCG	TCC	Ser	Ser
	1185	342	CAT	CAC	His	His
	1188	343	GAC	GAT	Asp	Asp
	1203	348	TCC	TCT	Ser	Ser
	1206	349	ATT	ATC	Ile	Ile
	1218	353	TTA	TTG	Leu	Leu
	1245	362	CTA	CTG	Leu	Leu
	1284	375	GGA	GGG	Gly	Gly
	1321	388	TTG	CTG	Leu	Leu
	1344	395	TGT	TGC	Cys	Cys
	1350	397	GCG	GCC	Ala	Ala
	1413	418	CCG	CCA	Pro	Pro
	1414	419	GTT	ATT	Val	Ile
	1499	447	TTT	TCT	Phe	Ser

Table 5. Nucleotide and amino acid differences between Gist's and Alko's phytase sequences. The nucleotide numbers are counted from the first Met (ATG) in the signal sequence and amino acid numbers from the N-terminal Leu (see Figure 5). The amino acids, if different between the two sequences, are written by bold letters.

B. Construction of the plasmids for overexpression of phytase in *Trichoderma reesei*

1. The PCR fragments for the precise *cbh1* - phytase fusions

The fusions between the *cbh1* promoter and the phytase signal sequence, and between the *cbh1* signal sequence and the phytase gene were done by PCR. The phytase signal sequence or the phytase protein N-terminal sequence start precisely where the corresponding *cbh1* sequences would start (for the *cbh1* sequence, see Shoemaker, S., *et al.*, *Bio/Technology* 1:691-696 (1983)). The primers used for the PCR fragments are shown in Figure 6. To construct pALK171 (phytase signal sequence), we made use of the *SacII* site in the *cbh1* promoter area in the 5'-PCR primer. The *XhoI* site (14 nucleotides from the N-terminal of the phytase gene) was used in the 3'-primer. The 5'-primer was a 39-mer that contained a "tail" of 19 nucleotides of the *cbh1* promoter sequence (preceding the signal sequence) and 20

- 63 -

nucleotides from the phytase signal sequence. The 3'-primer was a 22-mer. In the construction of pALK172 (*cbh1* signal sequence), we made use of the *SfiI* site in the *cbh1* signal sequence in the 5'-primer and *Sall* site of the phytase (762 nucleotides from the N-terminal) in the 3'-primer. In this case, the 5'-primer was a 46-mer containing a "tail" of 28 nucleotides and 18 nucleotides of the phytase N-terminal sequence; the 3'-primer was a 24-mer. In all the primers, three to five extra nucleotides were added to the ends of the PCR fragments after the restriction site sequences to ensure a correct cut. pALK169 was used as a template in the PCR reactions.

10 Fragments of the expected lengths were obtained from the PCR reactions: fragment containing the wanted fusion was 202 bps for pALK171 and 800 bps for pALK172.

- 15 2. Construction of plasmids with the *cbh1* promoter: pALK171 (phytase signal sequence) and pALK172 (*cbh1* signal sequence)

20 The plasmid pALK170L was made by cutting the phytase gene from pALK169 as an *SphI-XhoI* fragment and ligating it to *SphI-XhoI* cut pALK307. The 202 bp PCR fragment containing the *cbh1* promoter and phytase signal sequence was cut with *XhoI* and ligated to pALK170L that had been cut with *XbaI*, treated with the DNA polymerase I Klenow fragment and cut with *XhoI* (pALK170X, Figure 7). The fusion and the PCR fragment areas were sequenced to ensure that no mistakes had occurred in the PCR amplification. Phytase fragment containing the fusion was isolated as an *SphI* (treated with the T4 DNA polymerase)- *SacII* fragment and was inserted between the *cbh1* promoter and terminator areas of the plasmid pAMH110 previously digested with *NdeI* (filled in with the DNA polymerase I Klenow fragment) and *SacII*. The plasmid obtained (pALK171X, Figure 7) contains the phytase gene precisely fused to the *cbh1* promoter. To construct pALK171, the *amdS* gene (selectable marker) was isolated from p3SR2 as a *SphI-KpnI* fragment, the ends were treated by the T4 DNA polymerase, and *amdS* was then ligated to

25

30

- 64 -

the *SphI* site of pALK171X (treated with the T4 DNA polymerase). The approximately 7.5 kb linear fragment that contained no bacterial sequences was isolated from pALK171 by cutting with *XbaI* and was used for the transformations.

5 pALK172 was constructed essentially the same way as pALK171 (see Figure 8). The 800 bp PCR fragment was cut with *SalI* and ligated to *XbaI* (filled in with the DNA polymerase I Klenow fragment), *SalI* cut pALK170L. Also in this case, the fusions and the sequence of the PCR fragment were checked by sequencing. Phytase-PCR fragment fusion was isolated from
10 pALK170S as an *SphI* (treated with the T4 DNA polymerase)-*SfiI* fragment and ligated to pAMH110 that had been cut with *NdeI* (filled in with the DNA polymerase I Klenow fragment)-*SfiI*. To construct pALK172, the fragment containing the *amdS* gene was ligated to pALK172S in the same way as when constructing pALK171. *XbaI* was used also in this case to cut out from the
15 vector backbone the linear fragment that was used in the transformations.

3. Construction of the plasmids with the phytase promoter: pALK173A and pALK173B

The phytase gene with its own promoter was isolated as an *SphI* fragment from pALK169 and ligated into the *KpnI* site of p3SR2 (in both cases
20 the ends of the fragments were filled in by the T4-polymerase) resulting in about 11.2 kb plasmids pALK173A and pALK173B (see Figure 4 for pALK169 and Figures 7 and 8 for p3SR2 map). In pALK173A the two genes, phytase and *amdS* are in a parallel orientation. in pALK173B, they are in opposite orientations (Figure 9). *EcoRI* was used to linearize pALK173A and
25 pALK173B when linearized plasmids were used for transformations.

- 65 -

C. Transformation of *Trichoderma reesei* and screening of the transformants

T. reesei ATCC56765, ALKO 233 and ALKO 2221 strains were transformed with circular plasmids and with the *Xba*I fragments from the plasmids pALK171 and pALK172 (*cbh*1 promoter). *T. reesei* ALKO 233 and 2221 strains were also transformed with the linearized pALK171 and pALK172 plasmids as well as with circular and linear pALK173A and pALK173B (phytase promoter) plasmids. Transformation frequencies (transformants/ μ g of DNA) varied from 3 to 60 when the fragments isolated from pALK171 or pALK172 were used. When pALK171 or pALK172 circular plasmids were used in transformations, the frequencies were about 50/ μ g for *T. reesei* ALKO 233 and ALKO 2221 and about 100/ μ g for *T. reesei* ATCC56765. Transformation frequencies obtained when linearized plasmids were used were about 100/ μ g. When pALK173A or pALK173B were used in transformations the frequencies were from 6 to 26 for the linear plasmid and from 6 to 20 for the circular plasmid.

Regeneration frequency of the sphaeroplasts varied from 4.5% to 13.2% for *T. reesei* ALKO 233 and ALKO 2221 strains and was 1-2% for the *T. reesei* ATCC56765 strain.

The amount of the transformants that were screened for the phytase production on plates are shown in Table 6. Those clones that clearly produced a blue colored halo around the colony were counted as positive clones.

Table 6. Plate assay positive transformants and total number of tested clones			
Plasmid	ALKO 233	ALKO 2221	ATCC56765
pALK171 fragment	49% (47/96)	46% (33/71)	23% (15/66)
circular plasmid	35% (6/17)	23% (5/22)	32% (22/68)
linear plasmid	41% (29/71)	49% (27/55)	ND
pALK172 fragment	47% (48/103)	30% (34/113)	11% (8/72)
circular plasmid	17% (4/23)	13% (2/15)	12% (12/104)
linear plasmid	37% (22/59)	24% (11/45)	ND
pALK173A circular plasmid	75% (9/12)	70% (14/20)	ND
linear plasmid	67% (10/15)	64% (14/22)	ND
pALK173B circular plasmid	40% (4/10)	63% (15/24)	ND
linear plasmid	63% (10/16)	67% (8/12)	ND

Table 6. Plate assay positive transformants and total number of tested clones. The number of the plate assay positive transformants and the total number of phytase plate assay tested transformants are shown. Only those transformant strains that grew well both on the selection slant and on the plate assay are included. As positive phytase producers are counted those strains that clearly showed phytase activity on the plate assay.

The transformants that seemed to be the best producers on the plate assay were grown on shake flasks. Inocula were taken either directly from acetamide slants or from PD slants after purification through conidia. Of the *T. reesei* ATCC56765, ALKO 233 and ALKO 2221, transformed with the fragments from pALK171 and pALK172, from 7 to 16 clones from each set of transformants were purified and the phytase production was tested in shake flask cultivations. When circular plasmids pALK171 or pALK172 had been used in transformations, 13 and 12 purified *T. reesei* ATCC56765, and from four to seven *T. reesei* ALKO 233 and ALKO 2221 transformant strains were grown, respectively. When linearized pALK171 or pALK172 plasmids were

- 67 -

used, about 20 transformant strains from each were grown in shake flasks. Of the *T. reesei* ALKO 233 clones transformed with the linear pALK173A/B plasmids, seven pALK173A and two pALK173B (and with the circular plasmids four pALK173A and three pALK173B) transformants indicating phytase activity on plates were purified and tested in shake flask cultivations. For the *T. reesei* ALKO 2221 transformants the corresponding amounts tested in shake flask cultivations were as follows: for the linear plasmids, three pALK173A and five pALK173B and for the circular plasmids six pALK173A and six pALK173B transformants.

D. Phytase production by the *Trichoderma* transformants

The best phytase production levels from transformants of *T. reesei* ATCC56765, ALKO 233 and ALKO 2221, without *E. coli* sequences, when the *cbh1* promoter (pALK171 and pALK172 fragments) was used are shown in Table 7.

Table 7. Phytase production and enzyme profiles of the best <i>T. reesei</i> phytase producing transformants with no <i>E. coli</i> sequences								
Strain	Fragment	Transformant	PNU/ml	CBHI	AGU/ml	HUT/ml	ECU/ml	FPU/ml
ALKO 233	none pALK171	E16	<	(+)	79	170	690	3.2
		A53	3,590	(-)	ND	ND	ND	ND
		D1	2,820	(+)	91	140	385	2.1
		A52	2,740	(+)	ND	ND	ND	ND
		A13	2,580	(+)	88	190	505	3.0
	pALK172	E101	2,570	(+)	82	215	905	1.1
		A12	2,000	(+)	ND	ND	ND	ND
		D4	1,900	(+)	104	ND	<1.000	ND
		E70	1,570	(+)	ND	ND	ND	ND
		E80	1,460	(+)	ND	ND	ND	ND
ALKO 2221	none pALK171	D2	<	(+)	<10	<15	740	3.5
		A9	3,200	(+)	32	42	460	2.4
		A24	2,840	(+)	<10	<20	480	2.6
		E3	2,760	(+)	<10	<20	340	1.5
		D1	2,670	(-)	ND	ND	ND	ND
	pALK172	B17	2,390	(+)	<10	32	410	2.5
		E6	3,480	(+)	ND	ND	ND	ND
		D4	2,860	(+)	ND	ND	ND	ND
		E8	2,590	(+)	27	29	360	1.4
		A96	2,480	(+)	ND	ND	ND	ND
ATCC56765	none pALK171	B1	<	(+)	<16	31	430	2.6
		A11	1,620	(+)	1.1	57	200	0.8
		A21	1,300	(+)	<1.0	55	145	<1.0
		B25	1,280	(+)	<1.0	58	145	<1.0
		B19	1,090	(+)	<1.0	ND	120	ND
	pALK172	B1	1,780	(+)	<1.0	ND	60	ND
		B11	1,180	(+)	<1.0	52	120	<1.0
			1,080	(+)	<1.0	53	120	<1.0
				(+)	<1.0	ND	100	ND
				(+)	<1.0	ND	100	ND
<i>A. niger</i> ALKO 243	none		1	ND	46	31	35	0.0

Table 7. Phytase production and enzyme profiles of the best *T. reesei* phytase producing transformants with no *E. coli* sequences. Phytase activities as PNU/ml, background activities (AGU, HUT, ECU and FPU/ml) and the production of CBHI protein (+/-) in the supernatant are shown. *T. reesei* ATCC56765, ALKO 233 and ALKO 2221 strains were transformed with the *Xba*I fragment from the plasmid pALK171 or pALK172 (*trbA* promoter, no *E. coli* sequences). Strains were purified through conidia before cultivations. The values shown are averages from two shake flask cultivations. A "less than" sign (<) means that the value was below the detection level. ND = not determined.

- 69 -

About 3600 PNU/ml was obtained with the best transformant. About the same level of production could be achieved by using both the strains *T. reesei* ALKO 233 and ALKO 2221. The best phytase producing *T. reesei* ATCC56765 transformant produced about 1.800 PNU/ml. Both the phytase and the *cbh1* signal sequence seemed to work equally well and the same levels in phytase production could be achieved when using *T. reesei* ALKO 2221 or ATCC56765 as a host strain. In *T. reesei* ALKO 233 the level of phytase activity produced was higher when the phytase signal sequence was used.

Some of the transformants did not produce any detectable CBHI protein which most probably indicates integration of the transforming DNA to the *cbh1* locus. The absence of the CBHI protein did not affect the production levels in the screened transformants, i.e., good producers were found both among the transformants producing normal amounts of CBHI as well as among CBHI negative strains (ALKO 233, ALKO 2221).

The best phytase production levels obtained by the use of pALK171 and pALK172 circular and linear plasmid are shown in the Table 8. The best production yields were obtained with the *T. reesei* ALKO 2221 that had been transformed with the linear plasmid pALK171 (phytase signal sequence).

- 70 -

Table 8. Phytase production by the <i>T. reesei</i> strains transformed with circular or linear plasmid pALK171 or pALK172				
Strain	Plasmid	Plasmid form	Transformant	PNU/ml
ALKO 233	pALK171	circular	C13	650
			C23	530
			C4	240
		linear	A22	1.610
			A21	1.270
			A17	1.180
	pALK172	circular	C13	1.360
			C21	540
			C1	500
		linear	A20	1.420
			A27	1.330
			A32	980
ALKO 2221	pALK171	circular	C2	1.630
			C8	1.290
			C32	810
		linear	A14	3.800
			A8	3.660
			B14	3.610
	pALK172	circular	C3	480
			C4	190
			C6	170
		linear	B18	2.060
			A36	1.790
			B9	1.390
ATCC56765	pALK171	circular	A74	2.030
			A75	1.980
			B11	1.870
	pALK172	circular	B3	2.250
			B23	1.970
			B1	1.030

Table 8. Phytase production by the *T. reesei* strains transformed with circular or linear plasmids pALK171 and pALK172. Phytase activities as PNU/ml in the culture supernatants of the three best phytase producing transformants of each type are shown. *T. reesei* ATCC56765 transformants were purified through conidia before cultivations and the results are averages from two shake flask cultivations. Inocula for cultivations of the *T. reesei* ALKO 233 and ALKO 2221 transformants were taken from the acetamide slants and the results shown are from one shake flask cultivation.

- 71 -

Also the *A. niger* phytase promoter can promote the expression of the gene in *Trichoderma*. However, the enzyme yields obtained are much lower than with the *cbh1* promoter homologous to *T. reesei*: the activities obtained from the culture supernatants of transformants containing the phytase's own promoter were from about 1 to about 14 PNU/ml for the *T. reesei* ALKO 233 transformants and from about 6 to about 120 PNU/ml for the *T. reesei* ALKO 2221 transformants (Table 9).

Table 9. Phytase production by the <i>T. reesei</i> strains transformed with circular or linear plasmid pALK173A or pALK173B				
Strain	Plasmid	Plasmid form	Transformant	PNU/ml
ALKO 233	pALK173A	circular	C25	14.2
			C29	6.6
			C23	1.2
		linear	D4	8.8
			D18	5.8
			D6	3.9
	pALK173B	circular	C8	3.5
			C6	<
			E10	<
		linear	D13	5.5
			D31	<
ALKO 2221	pALK173A	circular	E3	32.5
			E5	31.7
			C22	25.0
		linear	D24	37.5
			D36	8.3
			D17	5.8
	pALK173B	circular	C13	115.8
			C28	65.0
			C27	50.8
		linear	D9	36.7
			D26	22.5
			D21	18.3

Table 9. Phytase production by *T. reesei* transformants transformed with circular or linear plasmid pALK173A or pALK173B (phytase promoter). Phytase activities as PNU/ml in the culture supernatants of the transformants are shown. Transformants have been purified through conidia before cultivation. The results shown are from one shake flask cultivation. A "less than" sign (<) means that the value was below the detection level.

- 72 -

E. The enzyme background in the phytase preparations produced by *T. reesei*

Phytase is expressed in the *T. reesei* strains in high amounts and the background of other enzyme activities in the supernatants of *T. reesei* transformants is different from those in the *Aspergillus* supernatant (Table 7). Both endoglucanase and cellobiohydrolase activities are substantially higher when *T. reesei* is used as a production host compared to *A. niger*. The *T. reesei* strains used also produced proportionally less glucoamylase activity than the *A. niger* ALKO 243 strain.

F. Phytase protein produced by the *Trichoderma* transformants

Samples from the growth media of the transformants (pALK171 fragment) and the nontransformed *T. reesei* strains ATCC56765, ALKO 233 and ALKO 2221 were analyzed in Western blots (Figure 10). Briefly, the following samples were analyzed: Lane 1: 50 ng of purified *Aspergillus* ALKO 243 phytase; Lane 2: 15 ng of endoF-treated *Aspergillus* ALKO 243 phytase; Lanes 3 and 10: *T. reesei* ALKO 233; Lanes 4-5 and 11-12: *T. reesei* ALKO 233 transformant 171FR/ A4 and A13, respectively; Lanes 6 and 13: *T. reesei* ALKO 2221; Lanes 7-8 and 14-15: *T. reesei* ALKO 2221 transformant 171FR/A5 and A9, respectively; Lane 9: *T. reesei* ALKO 2221 transformant D2; Lane 16: *T. reesei* ATCC56765; Lanes 17, 18, 19: *T. reesei* ATCC56765 transformants 171FR/A21, A11, and A23, respectively. In each case, 2 μ l of 1:10 dilution of the culture supernatant were run on the gel. 171FR is the host transformed with the *Xba*I fragment from the plasmid pALK171.

The molecular weight of the phytase produced by *Trichoderma* differed from that produced by *Aspergillus* and the difference seemed to be due to differences in the glycosylation level. The phytase secreted by *T. reesei* ALKO 233 was visible in the Western blots as three and that secreted by *T. reesei* ALKO 2221 as 6 to 9 major protein bands of sizes of about 45-65 kDa, the lowest of which corresponded in size the deglycosylated *Aspergillus* phytase (45-48 kDa in SDS-PAGE). The phytase secreted by *T. reesei* ATCC56765

- 73 -

was of a size of 65-80 kDal and consisted of three to five protein bands. The molecular weight of the native *Aspergillus* phytase run in SDS-PAGE is about 80-85 kDal. The phytase protein produced by the transformants that had been transformed with pALK172 fragment or pALK173A/B showed the same kind of banding pattern.

III. Conclusions

The production level of *Aspergillus* phytase obtained when *T. reesei* was used as a production host was surprisingly high. By using *T. reesei*, the phytase is produced in a novel background differing from that of *Aspergillus* and containing enzymes important eg. in feed applications. The molecular weight of the *Aspergillus* phytase protein produced in *Trichoderma* is different from that of *Aspergillus*. This difference in size seemed to be due to different glycosylation but did not affect the enzyme activity.

EXAMPLE 7

Production of *Aspergillus niger* pH 2.5 Acid Phosphatase in *Trichoderma reesei*

I. EXPERIMENTAL PROTOCOLS

1. Strains and plasmids

E. coli strains XL1 -Blue (Bullock, W.O. *et al.*, *Biotechniques* 5:376-379 (1987); Stratagene, La Jolla, CA, USA) and Sure™ (Greener, A., *Strategies* 3:5-6 (1990); Stratagene, La Jolla, CA, USA) were used as hosts for constructions made of plasmids pALK601 (Figure 12 and 13) and pAP-1 (Figure 12 and 13). The plasmid pALK601 contains the *T. reesei cbh1* promoter and terminator sequences and the *Aspergillus nidulans* acetamidase gene. The plasmid pAP-1 contains pH 2.5 acid phosphatase gene from *Aspergillus niger* var. *awamori* ALKO 243 (ATCC 38854).

Trichoderma reesei strain ALKO 2221, a low aspartyl protease mutant derived from the *T. reesei* strain ALKO 233 (VTT-D-79125) by UV-mutagenesis was used as a recipient for the pH 2.5 acid phosphatase gene.

2. Growth media and culture conditions

E. coli strains were grown in L-broth (Maniatis, T., *et al.*, *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA (1982)) supplemented with ampicillin (50 µg/ml) when needed. *E. coli* cultivations were carried out at 37°C overnight.

PD agar slants (Potato Dextrose broth by Difco, Detroit, Michigan, USA) were used for storing the *Trichoderma* strains. The plates and media for *T. reesei* transformations were essentially as in Penttilä *et al.* (Penttilä, M., *et al.*, *Gene* 61:155-164 (1987)). The transformants were purified on selective acetamide-CsCl medium (Penttilä, M. *et al.*, *Gene* 61:155-164 (1987) before transferring to PD slants. *T. reesei* transformants were grown in lactose based medium (see example 6 subparagraph 2) at 30°C (250 rpm) for 7 days for expression of pH 2.5 acid phosphatase under the control of the *cbh1* promoter.

3. Manipulation of DNA

Manipulations of DNA were performed as described above for phytase, mainly by standard methods (Maniatis, T., *et al.*, *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA (1982)). Plasmid DNA from *E. coli* was isolated by using Qiagen columns (Diagen GmbH, Dusseldorf, FRG) according to the supplier's instructions. For rapid screening of the plasmid DNA from *E. coli*, the method of Holmes and Quigley, (Holmes and Quigley, *Anal. Biochem.* 114:193-197 (1981)) was used. The restriction enzymes, T4 DNA ligase, Klenow fragment of DNA polymerase I and T4 DNA polymerase used in the DNA manipulations were from Boehringer (Mannheim, FRG) and New England Biolabs (Beverly, MA, USA). Each enzyme was used according to the supplier's recommendation. DNA fragments for cloning or transformations were isolated from low melting point agarose gels (FMC

- 75 -

Bioproducts, Rockland, ME, USA) by the freeze thaw phenol method (Benson, S.A. *Bio/Techniques* 2:66-68 (1984)) or by using the Mermaid™ Kit (BIO 101 Inc., La Jolla, CA, USA) according to the supplier's instructions.

Sequencing of the fusions between the *cbh1* promoter and pH 2.5 acid phosphatase gene was carried out by means of pUC/M13 primers and extension primers using Taq DyeDeoxy™ Terminator Cycle Sequencing Kit (Applied Biosystems) and the automated sequencer (Applied Biosystems 373A, Foster City, CA, USA).

The oligonucleotides used were synthesized by an Applied Biosystems (Foster City, CA, USA) 381A Synthesizer except the M13 primers that were purchased from the Applied Biosystems.

4. Transformations

Transformations were also performed as described above for phytase. Transformation of *E. coli* strains XL1-Blue or Sure was performed by the supplier's method (Stratagene La Jolla, CA, USA). *T. reesei* strains were transformed essentially according to the method of Penttilä *et al.* (Penttilä, M., *et al.*, *Gene* 61:155-164 (1987)). Novozym 234 used in fungal protoplast preparation for transformations was from Novo Industri AS (Copenhagen, Denmark). Prior sporulating on PD slants *T. reesei* transformants were purified through conidia on the selective acetamide medium.

5. Enzyme activity assays

For the enzyme assays the mycelium was separated from the culture medium by centrifuging for 15 min at 3.000 rpm (Sorvall SS-34, Dupont Company, Wilmington, Delaware, USA). The pH 2.5 acid phosphatase enzyme activity was measured from the culture supernatant using paranitrophenylphosphate (Sigma, St. Louis, USA) as a substrate as described earlier. One pH 2.5 acid phosphatase activity unit releases 1 nmol of inorganic phosphate per minute on the substrate p-nitrophenylphosphate in pH 2.5 at 37°C. One acid phosphatase normalized unit (APNU) is defined as the

- 76 -

amount of acid phosphatase activity produced by the *A. niger* ALKO 243 strain under the cultivation conditions used (see example 6. subparagraph 2).

5 Amyloglucosidase activity (AGU) was measured by using 1% Zulkowsky starch (Merck) as a substrate and measuring the amount of the released glucose units by boiling with DNS reagent (see below) after 10 min of reaction at 60°C at pH 4.8. Proteases (HUT) were measured at pH 4.7 as in Food Chemicals Codex (*Food Chemicals Codex*, National Academy Press, Washington, DC, USA, pp. 496-497 (1981)) by using 2% haemoglobin (Sigma) as a substrate. Endoglucanase (ECU) and cellobiohydrolase (FPU) activities were measured as in IUPAC's Measurement of cellulase activities (IUPAC Commission on Biotechnology, *Measurement of Cellulase Activities*, Biochemical Engineering Research Centre, Indian Institute of Technology, Delhi, India, pp. 5-7 and 10-11 (1981)). 1% hydroxyethylcellulose (Fluka AG) in 50 mM Na-citrate buffer (pH 4.8) and Whatman no. 1 paper were used as substrates, respectively. DNS used differed from that described at the IUPAC's Measurement of cellulase activities (IUPAC Commission on Biotechnology, *Measurement of Cellulase Activities*, Biochemical Engineering Research Centre, Indian Institute of Technology, Delhi, India, pp. 5-7 and 10-11 (1984)) and was made by first diluting 50.0g 2-hydroxy-3,5-dinitrobenzoic acid (Merck) into 4 liters of deionized water. Then 80.0g NaOH was added slowly by using the magnetic stirrer and 1.500g K-Na-tartrate (Merck) was added and diluted by heating the solution (maximum temperature 45°C). The total volume was adjusted to 5 liters, the solution was filtered through Whatman no. 1 and was protected from light.

- 77 -

6. SDS-page and Western blot analysis

Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-page) and Western blot analysis were done according to the methods of Laemmli (Laemmli, U.K., *Nature* 227:680-685 (1970)) and Towbin *et al.* (Towbin, H., *et al.*, *Proc. Natl. Acad. Sci. USA* 76:4350-4354 (1979)). Visualization of the pH 2.5 acid phosphatase protein in Western blots was done by using the polyclonal rabbit antiserum KH1269. KH1269 was made against purified deglycosylated pH 2.5 acid phosphatase protein (M. Turunen, Alko Ltd.) and it was supplied by the National Public Health Institute (Helsinki, Finland). Visualization of the CBHI protein from the pH 2.5 acid phosphatase transformants in Western blots was done by using the mouse monoclonal antibody CI-261 (Aho, S. *et al.*, *Eur. J. Biochem* 200:643-649 (1991)). Anti-rabbit-IgG and anti-mouse-IgG alkaline phosphate conjugate and color development substrates from ProtoBlot™ Immunoblotting system (Promega, Madison, USA) were used to detect the immunocomplexes.

7. PCR

The PCR reactions were performed by a Techne thermal cycler PHC-2 (Techne Ltd., Cambridge, UK) in 100 µl volumes. The reaction mixture contained 0.2 mM of each dNTP (Pharmacia pH 8.3), 20 - 50 pmol of each primer and 10 ng of plasmid template in 10 mM Tris buffer (pH 8.3), 50 mM KCl, 1.5 mM MgCl₂ and 100 µg/ml gelatin. The protocol used was the following: 96°C/ 10 min before adding the Taq DNA polymerase (2 units, Boehringer Mannheim, FRG) and 100 µl of paraffin oil, denaturation 95°C / 1 min, annealing 60°C / 1 min, extension 72°C / 1 min for 30 cycles. The final extension time was 9 min to ensure completion of the strand synthesis. The PCR fragments were purified by Mermaid™ Kit. The ends of the fragments were filled by using the DNA polymerase I Klenow fragment.

II. RESULTS

A. Vector constructions for overexpression of the pH 2.5 acid phosphatase gene in *Trichoderma reesei* ALKO 2221

1. Construction of plasmid pALK533

5 The plasmid pALK533 consists of *Aspergillus niger* var. *awamori* ALKO 243 pH2.5 acid phosphatase gene with its own signal sequence inserted into the *Trichoderma reesei* expression cassette containing the *cbh1* promoter and terminator sequences. pALK533 also contains the *Aspergillus nidulans* amdS gene as a selection marker for transformants.

10 The precise fusion between the *cbh1* promoter and the pH 2.5 acid phosphatase signal sequence was done with PCR. The primers used for the PCR fragments are shown in Figure 11. The *SacII* site in the *cbh1* promoter area was used in the 5'-primer and the *MluI* site of the acid phosphatase gene (374 nucleotides down from the N-terminal of the acid phosphatase gene) was used in the 3'-primer. The 5'-primer was a 39-mer containing a tail of 19 nucleotides of the *cbh1* promoter sequence preceding the signal sequence joining exactly to the first 20 nucleotides of the acid phosphatase signal sequence. The 3'-primer was a 30-mer of pH 2.5 acid phosphatase gene. pAP-1 (Figure 12) was used as a template in the PCR reactions. A fragment of the expected length of 466 bps was obtained from the PCR reaction.

20 The 466 bp PCR fragment containing the pH 2.5 acid phosphatase signal sequence was digested with *MluI* and ligated to pAP-1 that had been digested with *HindIII*, treated with DNA polymerase I Klenow fragment and digested with *MluI* to obtain plasmid p102 (Figure 15). The fusion and the PCR fragment were sequenced to ensure that no mistakes had occurred in the PCR amplification.

25 To construct plasmid pALK533 (Figure 12), a pH 2.5 acid phosphatase gene containing the fusion was isolated from the plasmid p102 as an *SphI* (filled in with DNA polymerase I Klenow fragment) - *SacII* fragment and inserted between the *cbh1* promoter and terminator of the plasmid

30

- 79 -

pALK601($\Delta NdeI$) that had been digested with *NdeI* (filled in with DNA polymerase I Klenow fragment) and *SacII*. In pALK601($\Delta NdeI$), the *NdeI* site in the intron area of the *amdS* gene in pALK601 is inactivated using DNA polymerase I Klenow fragment. The linear fragment used for transformations was digested out from the vector backbone with *XbaI*.

2. Construction of the plasmid pALK532

The plasmid pALK532 consists of the *Aspergillus niger* var. *awamori* ALKO 243 pH 2.5 acid phosphatase gene inserted into the *Trichoderma reesei* CBHI expression cassette containing the *cbh1* promoter and signal sequence and terminator sequences. pALK532 also contains the *Aspergillus nidulans amdS* gene as a selection marker for transformants.

The precise fusion between the *cbh1* signal sequence and the pH 2.5 acid phosphatase gene was done with PCR. The primers used for PCR fragments are shown in Figure 11. The *SfiI* site in the *cbh1* signal sequence was used in the 5'-primer. The 5'-primer was a 46-mer containing a tail of 28 nucleotides joining exactly to the first 18 nucleotides of the acid phosphatase N-terminal sequence. The 3'-primer was the same 30-mer used in the construction of pALK533. pAP-1 was used as a template in the PCR reaction. A fragment of the expected length of 418 bps was obtained from the PCR reaction.

The 418 bp PCR fragment containing the *cbh1* signal sequence was digested with *MluI* and ligated to pAP-1 that had been digested with *HindIII*, treated with DNA polymerase I Klenow fragment and digested with *MluI* to obtain plasmid p51 (Figure 13). The fusion and the PCR fragment were sequenced to ensure that no mistakes had occurred in the PCR amplification. To construct the plasmid pALK532 (Figure 13), a pH 2.5 acid phosphatase fragment containing the fusion was isolated from the plasmid p51 as a *SphI* (filled in with DNA polymerase I Klenow fragment) - *SfiI* fragment and was inserted between the *cbh1* promoter and terminator areas of the plasmid pALK601($\Delta NdeI$). pALK601($\Delta NdeI$) had been digested with *NdeI* and filled in with the DNA polymerase I Klenow fragment and digested with *SfiI*. The

- 80 -

approximately 7.8 kb linear fragment that contained no bacterial sequences was isolated from pALK532 by restricting with *Xba*I and was used for transformations.

5 B. Transformation of *Trichoderma reesei* and screening of the transformants

Trichoderma reesei ALKO 2221 was transformed separately with the linear *Xba*I fragments from the plasmid pALK532 and pALK533. Transformation frequencies (transformants / μ g of DNA) varied from 2 to 30.

10 Forty-four *T. reesei* ALKO 2221/pALK532 transformants and 103 pALK533 transformants were purified through conidia and were cultivated in shake flasks.

 C. pH 2.5 acid phosphatase production by the *Trichoderma* transformants

15 The best transformants based on the pH 2.5 acid phosphatase production are shown in the Table 10. The best enzyme activity level was 240 APNU in shake flask cultivation in lactose based medium.

Table 10.							
Strain	Plasmid	APNU/ml	CBIII(+/-)	AGU/ml	IIUT/ml	ECU/ml	FPU/ml
untransformed ALKO 2221	none	0.2	(+)	48	18	600	3.8
transformed							
SC-9	pAL.K532	240	(+)	53	32	380	2.4
KA-31	pAL.K533	240	(+)	37	19	490	2.0
KA-17	pAL.K533	230	(-)	44	52	760	1.1
KB-44	pAL.K533	230	(+)	37	16	490	ND
KB-18	pAL.K533	220	ND	ND	ND	ND	ND
SB-4	pAL.K532	210	(+)	35	14	590	ND
KA-28	pAL.K533	190	(+)	ND	ND	ND	ND
KB-38	pAL.K533	190	(+)	ND	ND	ND	ND
SC-6	pAL.K532	190	(+)	40	21	520	ND
SC-32	pAL.K532	190	(-)	ND	ND	ND	ND
<i>A. niger</i> ALKO 243	none	1	ND	46	31	35	0.0

Table 10: The best pH 2.5 acid phosphatase producing *T. reesei* ALKO 2221 transformants. pH 2.5 acid phosphatase enzyme activity levels as APNU /ml produced in the 50 ml shake flask cultivations, background activities (AGU, ECU, FPU and IIUT / ml) and the production of CBIII protein (+/-, Western blot) are shown.

Both the acid phosphatase and the *cbh1* signal sequence worked equally well and about the same level of pH 2.5 acid phosphatase activity could be achieved. The best pH 2.5 acid phosphatase activity level was produced by *Trichoderma* transformant SC-9 and was about 250 fold greater than the levels produced by native *Aspergillus niger* var. *awamori* ALKO 243 strain in corresponding conditions.

Two out of the nine best producers did not react with the monoclonal CBHI antibody in Western blot analysis suggesting that the expression cassette had integrated to the *cbh1* locus in those two transformants (Table 10).

D. The enzyme background in the pH 2.5 acid phosphatase preparations produced by *T. reesei*

The pH 2.5 acid phosphatase is expressed in the *T. reesei* transformants in high amounts and the background of some other enzyme activities in the supernatants of *T. reesei* transformants is different from those in the *Aspergillus* supernatant (Table 10). Both endoglucanase and cellobiohydrolase activities are significantly higher when *T. reesei* is used as a production host. The *T. reesei* transformants also produced proportionally less glucoamylase activity than the *A. niger* ALKO 243 strain.

E. Identification of the pH 2.5 acid phosphatase produced by the *Trichoderma* transformants

Samples from the growth media of the transformants and the *T. reesei* ALKO 2221 strain were analyzed in Western blot (Figure 14). The following samples were analyzed: 10ng of purified *Aspergillus* ALKO 243 pH 2.5 acid phosphatase; 10ng of endoF treated *Aspergillus* ALKO 243 pH 2.5 acid phosphatase; and 60ng of protein from the each of the culture supernatants of *Trichoderma reesei* ALKO 2221 transformants SC-9, KA-31, KA-17, KB-44, KB-18, SB-4 and KA-28 (Figure 14).

The pH 2.5 acid phosphatase secreted by *T. reesei* transformants was seen as four protein bands of sizes of about 50 - 66 kD. This is probably due

- 83 -

to the different level of glycolysation of the protein part of the secreted pH 2.5 acid phosphatase. Compared to the size of the pH 2.5 acid phosphatase produced by *Aspergillus niger* var. *awamori* ALKO 243 strain (66 kD) a majority of the pH 2.5 acid phosphatase proteins produced by *T. reesei* are smaller than that produced by *Aspergillus*.

All references are incorporated herein by reference. Having now fully described the invention, it will be understood by those with skill in the art that the scope may be performed with a wide and equivalent range of concentrations, parameters, and the like, without affecting the spirit or scope of the invention or any embodiment thereof.

- 84 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Nevalainen, Helena K.M.
5 Paloheimo, Marja T.
 Miettinen-Oinonen, Arja S.K.
 Torkkeli, Tuula K.
 Cantrell, Michael
 Piddington, Christopher S.
10 Rambosek, John A.
 Turunen, Marja K.
 Fagerström, Richard B.
- (ii) TITLE OF INVENTION: Production of Phytase Degrading Enzymes
 in Trichoderma
- 15 (iii) NUMBER OF SEQUENCES: 66
- (iv) CORRESPONDENCE ADDRESS:
 (A) ADDRESSEE:
 (B) STREET:
20 (C) CITY:
 (D) STATE:
 (E) COUNTRY:
 (F) ZIP:
- (v) COMPUTER READABLE FORM:
25 (A) MEDIUM TYPE: Floppy disk
 (B) COMPUTER: IBM PC compatible
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
30 (A) APPLICATION NUMBER:
 (B) FILING DATE:
 (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 (A) APPLICATION NUMBER: US 07/923,724
 (B) FILING DATE: 31-JUL-1992
- 35 (viii) ATTORNEY/AGENT INFORMATION:
 (A) NAME:
 (B) REGISTRATION NUMBER:
 (C) REFERENCE/DOCKET NUMBER:
- (ix) TELECOMMUNICATION INFORMATION:
40 (A) TELEPHONE:
 (B) TELEFAX:
- (2) INFORMATION FOR SEQ ID NO:1:
- (i) SEQUENCE CHARACTERISTICS:
45 (A) LENGTH: 2071 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: both
- (ix) FEATURE:
50 (A) NAME/KEY: CDS
 (B) LOCATION: join(136..916, 971..1088, 1141..1245, 1305..1737)

- 85 -

x1; SEQUENCE DESCRIPTION: SEQ ID NO:1:

	GCATGCTGGA CCGCAATCTC CGATCGCCGG STATAAAAGG TCGTCCAAAC CCCTCTCGGT	60
	CGATATGTAC CCGGCTCGTC ATCTCCAATC CTCTCGAGAG CACCTTCTCC AGCTTTTGTG	120
5	AATTGTACCT TCGCA ATG CCT CGC ACC TCT CTC CTC ACC CTG GCC TGT GCT Met Pro Arg Thr Ser Leu Leu Thr Leu Ala Cys Ala 1 5 10	171
	CTG GCC ACG GGC GCA TCC GCT TTC TCC TAC GGC GCT GCC ATT CCT CAG Leu Ala Thr Gly Ala Ser Ala Phe Ser Tyr Gly Ala Ala Ile Pro Gln 15 20 25	219
10	TCA ACC CAG GAG AAG CAG TTC TCT CAG GAG TTC CGC GAT GGC TAC AGC Ser Thr Gln Glu Lys Gln Phe Ser Gln Glu Phe Arg Asp Gly Tyr Ser 30 35 40	267
15	ATC CTC AAG CAC TAC GGT GGT AAC GGA CCC TAC TCC GAG CGT GTG TCC Ile Leu Lys His Tyr Gly Gly Asn Gly Pro Tyr Ser Glu Arg Val Ser 45 50 55 60	315
	TAC GGT ATC GCT CGC GAT CCC CCG ACC AGC TGC GAG GTC GAT CAG GTC Tyr Gly Ile Ala Arg Asp Pro Pro Thr Ser Cys Glu Val Asp Gln Val 65 70 75	363
20	ATC ATG GTC AAG CGT CAC GGA GAG CGC TAC CCG TCC CCT TCA GCC GGC Ile Met Val Lys Arg His Gly Glu Arg Tyr Pro Ser Pro Ser Ala Gly 80 85 90	411
	AAG GAC ATC GAA GAG GCC CTG GCC AAG GTC TAC AGC ATC AAC ACT ACT Lys Asp Ile Glu Glu Ala Leu Ala Lys Val Tyr Ser Ile Asn Thr Thr 95 100 105	459
25	GAA TAC AAG GGC GAC CTG GCC TTC CTG AAC GAC TGG ACC TAC TAC GTC Glu Tyr Lys Gly Asp Leu Ala Phe Leu Asn Asp Trp Thr Tyr Tyr Val 110 115 120	507
30	CCT AAT GAG TGC TAC TAC AAC GCC GAG ACC ACC AGC GGC CCC TAC GCC Pro Asn Glu Cys Tyr Tyr Asn Ala Glu Thr Thr Ser Gly Pro Tyr Ala 125 130 135 140	555
	GGT TTG CTG GAC GGC TAC AAC CAT GGC AAC GAT TAC AAG GCT CGC TAC Gly Leu Leu Asp Ala Tyr Asn His Gly Asn Asp Tyr Lys Ala Arg Tyr 145 150 155	603
35	GGC CAC CTC TGG AAC GGT GAG ACG GTC GTG CCC TTC TTT TCT AGT GGC Gly His Leu Trp Asn Gly Glu Thr Val Val Pro Phe Phe Ser Ser Gly 160 165 170	651
	TAC GGA CGT GTC ATC GAG ACG GCC CGC AAG TTC GGT GAG GGT TTC TTT Tyr Gly Arg Val Ile Glu Thr Ala Arg Lys Phe Gly Glu Gly Phe Phe 175 180 185	699
40	GGC TAC AAC TAC TCC ACC AAC GCT GCC CTC AAC ATC ATC TCC GAG TCC Gly Tyr Asn Tyr Ser Thr Asn Ala Ala Leu Asn Ile Ile Ser Glu Ser 190 195 200	747
45	GAG CTC ATG GGC GCG GAC AGC CTC ACG CCC ACC TGT GAC ACC GAC AAC Ile Val Met Gly Ala Asp Ser Leu Thr Pro Thr Cys Asp Thr Asp Asn 205 210 215 220	795
	GAC CAG ACC ACC TGC GAC AAC CTG ACT TAC CAG CTG CCC CAG TTC AAG Asp Gln Thr Thr Cys Asp Asn Leu Thr Tyr Gln Leu Pro Gln Phe Lys 225 230 235	843
50	FTC GCT GCT GCC CGC CTA AAC TCC CAG AAC CCC GGC ATG AAC CTC ACC Val Ala Ala Ala Arg Leu Asn Ser Gln Asn Pro Gly Met Asn Leu Thr 240 245 250	891

- 86 -

	GCA TCT GAT GTC TAC AAC CTG ATG G GTATGTGAT TACGGTACAA TCATTGGCTC Ala Ser Asp Val Tyr Asn Leu Met 255 260	945
5	AAACCTCCAG CTGACAGCAT CCTAG TT ATG GCC TCC TTT GAG CTC AAT GCT Val Met Ala Ser Phe Glu Leu Asn Ala 265	995
	CGT CCC TTC TCC AAC TGG ATC AAC GCC TTT ACC CAG GAC GAA TGG GTC Arg Pro Phe Ser Asn Trp Ile Asn Ala Phe Thr Gln Asp Glu Trp Val 270 275 280 285	1044
10	AGC TTC GGT TAC GTT GAG GAT TTG AAC TAC TAC TAC TGC GCT GG G Ser Phe Gly Tyr Val Glu Asp Leu Asn Tyr Tyr Tyr Cys Ala Gly 290 295 300	1089
15	TGAGTTTACC ATTGATCCA TTATTGTCTT GGATCAGCTA ACGATCGATA G T CCC Pro	1144
	GST GAC AAG AAC ATG GCT GCT GTG GGT GCC GTC TAC GCC AAC GCC AGT Gly Asp Lys Asn Met Ala Ala Val Gly Ala Val Tyr Ala Asn Ala Ser 305 310 315	1192
20	CTC ACC CTC CTG AAC CAG GGA CCC AAG GAA GCC GGC TCC TTG TTC TTC Leu Thr Leu Leu Asn Gln Gly Pro Lys Glu Ala Gly Ser Leu-Phe Phe 320 325 330	1240
	AAC TT GTACGTTCTCG GCAGAATCAG AGTCTCACAA AAAGAAACTC TTCCTAACA Asn Phe 335	1296
25	TATAGTAG T GCC CAC GAC ACC AAC ATC ACC CCC ATC CTC GCC GCC CTA Ala His Asp Thr Asn Ile Thr Pro Ile Leu Ala Ala Leu 340 345	1344
30	GGC GTC CTC ATC CCC AAC GAG GAC CTT CCT CTT GAC CGG GTC GCC TTC Gly Val Leu Ile Pro Asn Glu Asp Leu Pro Leu Asp Arg Val Ala Phe 350 355 360	1392
	GGC AAC CCC TAC TCG ATC GGC AAC ATC GTG CCC ATG GGT GGC CAT CTG Gly Asn Pro Tyr Ser Ile Gly Asn Ile Val Pro Met Gly Gly His Leu 365 370 375 380	1440
35	ACC ATC GAG CGT CTC AGC TGC CAG GCC ACC GCC CTC TCG GAC GAG GGT Thr Ile Glu Arg Leu Ser Cys Gln Ala Thr Ala Leu Ser Asp Glu Gly 385 390 395	1488
	ACC TAC GTG CGT CTG GTG CTG AAC GAG GCT GTA CTC CCC TTC AAC GAC Thr Tyr Val Arg Leu Val Leu Asn Glu Ala Val Leu Pro Phe Asn Asp 400 405 410	1536
40	TGC ACC TCC GGA CCG GGC TAC TCC TGC CCT CTG GCC AAC TAC ACC TCC Cys Thr Ser Gly Pro Gly Tyr Ser Cys Pro Leu Ala Asn Tyr Thr Ser 415 420 425	1584
45	ATC CTG AAC AAG AAT CTG CCA GAC TAC ACG ACC ACC TGC AAT GTC TCT Ile Leu Asn Lys Asn Leu Pro Asp Tyr Thr Thr Thr Cys Asn Val Ser 430 435 440	1632
	GGC TCC TAC CCG CAG TAT CTG AGC TTC TGG TGG AAC TAC AAC ACC ACG Ala Ser Tyr Pro Gln Tyr Leu Ser Phe Trp Trp Asn Tyr Asn Thr Thr 445 450 455 460	1680
50	ACG GAG CTG AAC TAC CGC TCT AGC CCT ATT GCC TGC CAG GAG GGT GAT Thr Glu Leu Asn Tyr Arg Ser Ser Pro Ile Ala Cys Gln Glu Gly Asp 465 470 475	1728

- 87 -

30T ATG GAC TAGATGCAGA GGGGTAGGTC CCGGGATACT TTAGTGATGA
Ala Met Asp

1777

TTGATATTCA AATTTGGTGG TGACGATCAC CTTGTTAATA GTCTTGATCA GTCATACGGT
5 GAATGTAAAT AATGATAATA GCAATGATAC ATGTTGGAAAT CTCGTTTTGT TCTTTGTGTG
CATAGGCGCT TTGGGGGTGT ATTTTATAGGC GTTAGACTTA TTTTCAATTC GTGTATAATG
CGGTCACTAA ATGAATCATC AATTATTCAA ATGCAATGCT GTATACGTGA AACTATTGGG
TTAAGACGCA GCTACTAGCT GACTGCTTGG TTACTTTCTG TGTACACCGC ATGC

1837

1897

1957

2017

2071

(2) INFORMATION FOR SEQ ID NO:2:

- 10 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 479 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
- Met Pro Arg Thr Ser Leu Leu Thr Leu Ala Cys Ala Leu Ala Thr Gly
1 5 10 15
Ala Ser Ala Phe Ser Tyr Gly Ala Ala Ile Pro Gln Ser Thr Gln Glu
20 25 30
20 Lys Gln Phe Ser Gln Glu Phe Arg Asp Gly Tyr Ser Ile Leu Lys His
35 40 45
Tyr Gly Gly Asn Gly Pro Tyr Ser Glu Arg Val Ser Tyr Gly Ile Ala
50 55 60
25 Arg Asp Pro Pro Thr Ser Cys Glu Val Asp Gln Val Ile Met Val Lys
65 70 75 80
Arg His Gly Glu Arg Tyr Pro Ser Pro Ser Ala Gly Lys Asp Ile Glu
85 90 95
Glu Ala Leu Ala Lys Val Tyr Ser Ile Asn Thr Thr Glu Tyr Lys Gly
100 105 110
30 Asp Leu Ala Phe Leu Asn Asp Trp Thr Tyr Tyr Val Pro Asn Glu Cys
115 120 125
Tyr Tyr Asn Ala Glu Thr Thr Ser Gly Pro Tyr Ala Gly Leu Leu Asp
130 135 140
35 Ala Tyr Asn His Gly Asn Asp Tyr Lys Ala Arg Tyr Gly His Leu Trp
145 150 155 160
Asn Gly Glu Thr Val Val Pro Phe Phe Ser Ser Gly Tyr Gly Arg Val
165 170 175
Ile Glu Thr Ala Arg Lys Phe Gly Glu Gly Phe Phe Gly Tyr Asn Tyr
180 185 190
40 Ser Thr Asn Ala Ala Leu Asn Ile Ile Ser Glu Ser Glu Val Met Gly
195 200 205
Ala Asp Ser Leu Thr Pro Thr Cys Asp Thr Asp Asn Asp Gln Thr Thr
210 215 220

- 88 -

Cys Asp Asn Leu Thr Tyr Gln Leu Pro Gln Phe Lys Val Ala Ala Ala
 225 230 235 240
 Arg Leu Asn Ser Gln Asn Pro Gly Met Asn Leu Thr Ala Ser Asp Val
 245 250 255
 5 Tyr Asn Leu Met Val Met Ala Ser Phe Glu Leu Asn Ala Arg Pro Phe
 260 265 270
 Ser Asn Trp Ile Asn Ala Phe Thr Gln Asp Glu Trp Val Ser Phe Gly
 275 280 285
 10 Tyr Val Glu Asp Leu Asn Tyr Tyr Tyr Cys Ala Gly Pro Gly Asp Lys
 290 295 300
 Asn Met Ala Ala Val Gly Ala Val Tyr Ala Asn Ala Ser Leu Thr Leu
 305 310 315 320
 Leu Asn Gln Gly Pro Lys Glu Ala Gly Ser Leu Phe Phe Asn Phe Ala
 325 330 335
 15 His Asp Thr Asn Ile Thr Pro Ile Leu Ala Ala Leu Gly Val Leu Ile
 340 345 350
 Pro Asn Glu Asp Leu Pro Leu Asp Arg Val Ala Phe Gly Asn Pro Tyr
 355 360 365
 20 Ser Ile Gly Asn Ile Val Pro Met Gly Gly His Leu Thr Ile Glu Arg
 370 375 380
 Leu Ser Cys Gln Ala Thr Ala Leu Ser Asp Glu Gly Thr Tyr Val Arg
 385 390 395 400
 Leu Val Leu Asn Glu Ala Val Leu Pro Phe Asn Asp Cys Thr Ser Gly
 405 410 415
 25 Pro Gly Tyr Ser Cys Pro Leu Ala Asn Tyr Thr Ser Ile Leu Asn Lys
 420 425 430
 Asn Leu Pro Asp Tyr Thr Thr Thr Cys Asn Val Ser Ala Ser Tyr Pro
 435 440 445
 30 Gln Tyr Leu Ser Phe Trp Trp Asn Tyr Asn Thr Thr Thr Glu Leu Asn
 450 455 460
 Tyr Arg Ser Ser Pro Ile Ala Cys Gln Glu Gly Asp Ala Met Asp
 465 470 475

(2) INFORMATION FOR SEQ ID NO:3:

- 35 (1) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 17 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

40 TAYTAYGGNC AYGGNGC

17

(2) INFORMATION FOR SEQ ID NO:4:

- 45 (1) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 17 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: both

- 89 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CARGGNGTNG GNTAYGC

17

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

10 TAYGTNGARA TGATGCARAA

20

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

ATGATGCAAA ATCAAGCTGA ACA

23

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2363 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: both

(ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: join(404..447, 550..1906)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CATCCAGGCA CCCTTTCCCA ACGGGGGAAC TTCCGTTGTC CACGTGCCCT GGTTCAGCCA 60

30 ATCAAAGCGT CCCACGGCAA TGCTGGATCA ACGATCAACT TGAATGCAAT AAATGAAGAT 120

GCAACTAACA CCATCTGTTG CCTTTCTCTC GAGAAAGCTC CTCCACTTCT CACACTAGAT 180

TTATCCGTTT CTTGTGCGACT TCCCGTCCCA TTCGGCCTCG TCCACTGAAG ATCTATCCCA 240

CCATTGCACG TGGGCCACCT TTGTGAGCTT CTAACCTGAA CTGGTAGAGT ATCACACAAC 300

ATGCGAAAGT GGGATGAAGG GGTATATGA GGACCGTCCG GTCCGGCGCG ATGGCCGTAG 360

35 CTGCCAATCG CTGCTGTGCA AGAAATTTCT TCTCATAGGC ATC ATG GGC GTC TCT 415
Met Gly Val SerGCT GTT CTA CTT CCT TTG TAT CTC CTA GCT GG GATGCTAAG 457
Ala Val Leu Leu Pro Leu Tyr Leu Leu Ala Gly

40 5 10 15

- 90 -

	CACCGCTATC TAAGTCTGAT AAGGACCCCTC TTTGCCGAGG GCCCCCTGAAG CTCGGACTGT	517
	TTGGGACTAC TGATCGCTGA CAATCTGTGC AG A GTC ACC TCC GGA CTC GCA Val Thr Ser Gly Leu Ala 20	558
5	GTC CCC GCC TCG AGA AAT CAA TCC ACT TGC GAT ACG GTC GAT CAA GGG Val Pro Ala Ser Arg Asn Gln Ser Thr Cys Asp Thr Val Asp Gln Gly 25 30 35	616
10	TAT CAA TGC TTC TCC GAG ACT TCG CAT CTT TGG GGT CAA TAC GCG CCG Tyr Gln Cys Phe Ser Glu Thr Ser His Leu Trp Gly Gln Tyr Ala Pro 40 45 50	664
	TTC TTC TCT CTG GCA AAC GAA TCG GCC ATC TCC CCT GAT GTG CCC GCC Phe Phe Ser Leu Ala Asn Glu Ser Ala Ile Ser Pro Asp Val Pro Ala 55 60 65	712
15	GGT TGC AGA GTC ACT TTC GCT CAG GTC CTC TCC CGT CAT GGA GCG CGG Gly Cys Arg Val Thr Phe Ala Gln Val Leu Ser Arg His Gly Ala Arg 70 75 80 85	760
	TAT CCG ACC GAG TCC AAG GGC AAG AAA TAC TCC GCT CTC ATT GAG GAG Tyr Pro Thr Glu Ser Lys Gly Lys Lys Tyr Ser Ala Leu Ile Glu Glu 90 95 100	808
20	ATC CAG CAG AAC GTG ACC ACC TTT GAT GGA AAA TAT GCC TTC CTG AAG Ile Gln Gln Asn Val Thr Thr Phe Asp Gly Lys Tyr Ala Phe Leu Lys 105 110 115	856
25	ACA TAC AAC TAC AGC TTG GGT GCA GAT GAC CTG ACT CCC TTC GGA GAG Thr Tyr Asn Tyr Ser Leu Gly Ala Asp Asp Leu Thr Pro Phe Gly Glu 120 125 130	904
	CAG GAG CTA GTC AAC TCC GGC ATC AAG TTC TAC CAG CGA TAC GAA TCG Gln Glu Leu Val Asn Ser Gly Ile Lys Phe Tyr Gln Arg Tyr Glu Ser 135 140 145	952
30	CTC ACA AGG AAC ATC ATT CCG TTC ATC CGA TCC TCT GGC TCC AGC CGC Leu Thr Arg Asn Ile Ile Pro Phe Ile Arg Ser Ser Gly Ser Ser Arg 150 155 160 165	1000
	GTG ATC GCC TCC GGC GAG AAA TTC ATT GAG GGC TTC CAG AGC ACC AAG Val Ile Ala Ser Gly Glu Lys Phe Ile Glu Gly Phe Gln Ser Thr Lys 170 175 180	1048
35	CTG AAG GAT CCT CGT GCC CAG CCG GGC CAA TCG TCG CCC AAG ATC GAC Leu Lys Asp Pro Arg Ala Gln Pro Gly Gln Ser Ser Pro Lys Ile Asp 185 190 195	1096
40	GTG GTC ATT TCC GAG GCC AGC TCA TCC AAC AAC ACT CTC GAC CCA GGC Val Val Ile Ser Glu Ala Ser Ser Ser Asn Asn Thr Leu Asp Pro Gly 200 205 210	1144
	ACC TGC ACT GTC TTT GAA GAC AGC GAA TTG GCC GAT ACC GTC GAA GCC Thr Cys Thr Val Phe Glu Asp Ser Glu Leu Ala Asp Thr Val Glu Ala 215 220 225	1192
45	AAT TTC ACC GCC ACG TTC GCC CCC TCC ATT CGT CAA CGT CTG GAG AAC Asn Phe Thr Ala Thr Phe Ala Pro Ser Ile Arg Gln Arg Leu Glu Asn 230 235 240 245	1240
	GAC CTG TCT GGC GTG ACT CTC ACA GAC ACA GAA GTG ACC TAC CTC ATG Asp Leu Ser Gly Val Thr Leu Thr Asp Thr Glu Val Thr Tyr Leu Met 250 255 260	1288
50	GAC ATG TGC TCC TTC GAC ACC ATC TCC ACC AGC ACC GTC GAC ACC AAG Asp Met Cys Ser Phe Asp Thr Ile Ser Thr Ser Thr Val Asp Thr Lys 265 270 275	1336

- 91 -

	CTG TCC CCC TTC TGT GAC CTG TTC ACC CAT GAC GAA TGG ATC CAC TAC	1384
	Leu Ser Pro Phe Cys Asp Leu Phe Thr His Asp Glu Trp Ile His Tyr	
	280 285 290	
5	GAC TAC CTC CAG TCC CTG AAA AAA TAC TAC GGC CAT GGC GCA GGT AAC	1432
	Asp Tyr Leu Gln Ser Leu Lys Lys Tyr Tyr Gly His Gly Ala Gly Asn	
	295 300 305	
	CCG CTC GGC CCG ACC CAG GGC GTC GGC TAC GCT AAC GAG CTC ATC GCC	1480
	Pro Leu Gly Pro Thr Gln Gly Val Gly Tyr Ala Asn Glu Leu Ile Ala	
	310 315 320 325	
10	CGT CTC ACC CAC TCG CCT GTC CAC GAT GAC ACC AGC TCC AAC CAC ACC	1528
	Arg Leu Thr His Ser Pro Val His Asp Asp Thr Ser Ser Asn His Thr	
	330 335 340	
15	TTG GAC TCG AAC CCA GCT ACC TTC CCG CTC AAC TCT ACT CTC TAC GCG	1576
	Leu Asp Ser Asn Pro Ala Thr Phe Pro Leu Asn Ser Thr Leu Tyr Ala	
	345 350 355	
	GAC TTT TCC CAC GAT AAC GGC ATC ATC TCT ATC CTC TTT GCT TTG GGT	1624
	Asp Phe Ser His Asp Asn Gly Ile Ile Ser Ile Leu Phe Ala Leu Gly	
	360 365 370	
20	CTG TAC AAC GGC ACT AAG CCG CTG TCT ACC ACG ACC GTG GAG AAT ATC	1672
	Leu Tyr Asn Gly Thr Lys Pro Leu Ser Thr Thr Thr Val Glu Asn Ile	
	375 380 385	
	ACC CAG ACA GAT GGG TTC TCG TCT GCT TGG ACG GTT CCG TTT GCT TCG	1720
	Thr Gln Thr Asp Gly Phe Ser Ser Ala Trp Thr Val Pro Phe Ala Ser	
	390 395 400 405	
25	CGT CTG TAC GTC GAG ATG ATG CAG TGC CAG GCC GAG CAG GAG CCG CTG	1768
	Arg Leu Tyr Val Glu Met Met Gln Cys Gln Ala Glu Gln Glu Pro Leu	
	410 415 420	
30	GTC CGT GTC TTG GTT AAT GAT CGC GTT GTC CCG CTG CAT GGG TGT CCA	1816
	Val Arg Val Leu Val Asn Asp Arg Val Val Pro Leu His Gly Cys Pro	
	425 430 435	
	ATT GAT GCT TTG GGG AGA TGT ACC CGG GAT AGC TTT GTG AGG GGG TTG	1864
	Ile Asp Ala Leu Gly Arg Cys Thr Arg Asp Ser Phe Val Arg Gly Leu	
	440 445 450	
35	AGC TTT GCT AGA TCT GGG GGT GAT TGG GCG GAG TGT TCT GCT	1906
	Ser Phe Ala Arg Ser Gly Gly Asp Trp Ala Glu Cys Ser Ala	
	455 460 465	
	TAGCTGAAC ACCTTGATGG ATGGTATGTA TCAATCAGAG TACATATCAT TACTTCATGT	1966
	ATGTATTTAC GAAGATGTAC ATATCGAAAT ATCGATGATG ACTACTCCGG TAGATATTTG	2026
	GTCCCCTTCT ATCCTTCGTT CCACAACCAT CGCACTCGAC GTACAGCATA ATACAACCTC	2086
40	AGCATTAACA AACGAACAAA TAATATTATA CACTCCTCCC CAATGCAATA ACAACCGCAA	2146
	TTCATACCTC ATATAGATAC AATACAATAC ATCCATCCCT ACCCTCAAGT CCACCCATCC	2206
	CATAATCAAA TCCCTACTTA CTCCTCCCCC TTCCCAGAAC CCACCCCCGA AGGAGTAATA	2266
	TTAGTAGTAG AAGAAGCAGA CGACCTCTCC ACCAACCTCT TCGGCCTCTT ATCCCACATC	2326
	GCTATACACA CACGAACACA CCAAATAGTC AGCATGC	2363

- 92 -

3 INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 467 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met Gly Val Ser Ala Val Leu Leu Pro Leu Tyr Leu Leu Ala Gly Val
 1 5 10 15

10 Thr Ser Gly Leu Ala Val Pro Ala Ser Arg Asn Gln Ser Thr Cys Asp
 20 25 30

Thr Val Asp Gln Gly Tyr Gln Cys Phe Ser Glu Thr Ser His Leu Trp
 35 40 45

15 Gly Gln Tyr Ala Pro Phe Phe Ser Leu Ala Asn Glu Ser Ala Ile Ser
 50 55 60

Pro Asp Val Pro Ala Gly Cys Arg Val Thr Phe Ala Gln Val Leu Ser
 65 70 75 80

Arg His Gly Ala Arg Tyr Pro Thr Glu Ser Lys Gly Lys Lys Tyr Ser
 85 90 95

20 Ala Leu Ile Glu Glu Ile Gln Gln Asn Val Thr Thr Phe Asp Gly Lys
 100 105 110

Tyr Ala Phe Leu Lys Thr Tyr Asn Tyr Ser Leu Gly Ala Asp Asp Leu
 115 120 125

25 Thr Pro Phe Gly Glu Gln Glu Leu Val Asn Ser Gly Ile Lys Phe Tyr
 130 135 140

Gln Arg Tyr Glu Ser Leu Thr Arg Asn Ile Ile Pro Phe Ile Arg Ser
 145 150 155 160

Ser Gly Ser Ser Arg Val Ile Ala Ser Gly Glu Lys Phe Ile Glu Gly
 165 170 175

30 Phe Gln Ser Thr Lys Leu Lys Asp Pro Arg Ala Gln Pro Gly Gln Ser
 180 185 190

Ser Pro Lys Ile Asp Val Val Ile Ser Glu Ala Ser Ser Ser Asn Asn
 195 200 205

35 Thr Leu Asp Pro Gly Thr Cys Thr Val Phe Glu Asp Ser Glu Leu Ala
 210 215 220

Asp Thr Val Glu Ala Asn Phe Thr Ala Thr Phe Ala Pro Ser Ile Arg
 225 230 235 240

Gln Arg Leu Glu Asn Asp Leu Ser Gly Val Thr Leu Thr Asp Thr Glu
 245 250 255

40 Val Thr Tyr Leu Met Asp Met Cys Ser Phe Asp Thr Ile Ser Thr Ser
 260 265 270

Thr Val Asp Thr Lys Leu Ser Pro Phe Cys Asp Leu Phe Thr His Asp
 275 280 285

45 Glu Trp Ile His Tyr Asp Tyr Leu Gln Ser Leu Lys Lys Tyr Tyr Gly
 290 295 300

- 93 -

His Gly Ala Gly Asn Pro Leu Gly Pro Thr Gln Gly Val Gly Tyr Ala
 305 310 315 320
 Asn Glu Leu Ile Ala Arg Leu Thr His Ser Pro Val His Asp Asp Thr
 325 330 335
 5 Ser Ser Asn His Thr Leu Asp Ser Asn Pro Ala Thr Phe Pro Leu Asn
 340 345 350
 Ser Thr Leu Tyr Ala Asp Phe Ser His Asp Asn Gly Ile Ile Ser Ile
 355 360 365
 10 Leu Phe Ala Leu Gly Leu Tyr Asn Gly Thr Lys Pro Leu Ser Thr Thr
 370 375 380
 Thr Val Glu Asn Ile Thr Gln Thr Asp Gly Phe Ser Ser Ala Trp Thr
 385 390 395 400
 Val Pro Phe Ala Ser Arg Leu Tyr Val Glu Met Met Gln Cys Gln Ala
 405 410 415
 15 Glu Gln Glu Pro Leu Val Arg Val Leu Val Asn Asp Arg Val Val Pro
 420 425 430
 Leu His Gly Cys Pro Ile Asp Ala Leu Gly Arg Cys Thr Arg Asp Ser
 435 440 445
 20 Phe Val Arg Gly Leu Ser Phe Ala Arg Ser Gly Gly Asp Trp Ala Glu
 450 455 460
 Cys Ser Ala
 465

(2) INFORMATION FOR SEQ ID NO:9:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 39 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

30 CAACCGCGGA CTGCGCATCA TGGGCGTCTC TGCTGTTCT

39

(2) INFORMATION FOR SEQ ID NO:10:

35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 22 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

ATTTCTCGAG GCGGGGACTG CC

22

(2) INFORMATION FOR SEQ ID NO:11:

40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 46 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: both

- 94 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CTCGGCCTTC TTGGCGAGAG CTCGTGCTCT GGCAGTCCCC GCCTCG

46

(2) INFORMATION FOR SEQ ID NO:12:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

10 TTGGTGTCTGA CGGTGCTGGT GGAG

24

(2) INFORMATION FOR SEQ ID NO:13:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 46 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CTCGGCCTTC TTGGCCACAG CTCGTGCTTT CTCCTACGGC GCTGCC

46

(2) INFORMATION FOR SEQ ID NO:14:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GCCATGGTTG TACGCGTCCA GCAAACCGGC

30

(2) INFORMATION FOR SEQ ID NO:15:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CAACCGCGGA CTGCGCATCA TGCTCGCAC CTCTCTCTCT

39

(2) INFORMATION FOR SEQ ID NO:16:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: both

- 95 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GAATTCGGG GACCTACCCC TGTGCAT

27

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Leu Ala Val Pro Ala Ser Arg Asn Gln Ser Ser Gly Asp Thr
 1 5 10

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Arg His Gly Xaa Arg Xaa Pro
 1 5

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Lys Asp Pro Arg Ala
 1 5

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Tyr Tyr Gly His Leu Gly Ala Gly Asn Pro Leu Gly Pro Thr Gln
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: both

- 96 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Thr Gly Tyr Val Gln Asn Tyr Val Gln Met Gln
 1 5 10

(2) INFORMATION FOR SEQ ID NO:22:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: both

10

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 6..7

(D) OTHER INFORMATION: /label= Peptide

15

/note= "When deduced from the DNA sequence the
 amino acids at positions 6 and 7 were found to be
 serine."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Ala Gln Pro Gly Gln Ala Ala Pro Lys
 1 5

(2) INFORMATION FOR SEQ ID NO:23:

20

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

25

Leu Tyr Val Glu Met Met Gln Asn Gln Ala Glu Gln Thr Pro Leu Val
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:24:

30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Leu Tyr Val Glu Met Met Gln Cys Gln Ala Glu Gln Glu Pro Leu Val
 1 5 10 15

35

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: both

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Phe Ile Glu Gly Phe Gln Ser Asp Lys
 1 5

- 97 -

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Phe Ile Glu Gly Phe Gln Ser Asp Lys
1 5

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Tyr Ala Phe Leu Lys
1 5

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Gly Leu Ser Phe Ala Arg
1 5

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Val Ile Ala Ser Gly Glu Lys
1 5

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Phe Tyr Gln Arg
1

- 98 -

(2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Phe Tyr Gln Arg Asp Ser Phe Val Arg
1 5

(2) INFORMATION FOR SEQ ID NO:32:

10

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

15

Asp Ser Phe Val Arg
1 5

(2) INFORMATION FOR SEQ ID NO:33:

20

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Val Leu Val Asn Asp
1 5

25

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Tyr Glu Ser Leu Gln
1 5

(2) INFORMATION FOR SEQ ID NO:35:

35

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

40

Tyr Glu Ser Leu Thr Arg
1 5

- 99 -

(2) INFORMATION FOR SEQ ID NO:36:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Ser Ala Ala Ser Leu Asn Ser
1 5

(2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

Leu Lys Asp Pro Arg
1 5

(2) INFORMATION FOR SEQ ID NO:38:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

Val Ile Ala Ser Gly Glu Lys
1 5

(2) INFORMATION FOR SEQ ID NO:39:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Tyr Pro Thr Glu Ser Lys
1 5

(2) INFORMATION FOR SEQ ID NO:40:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Tyr Phe Asn Xaa Gly
1 5

- 100 -

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(ix) FEATURE:

- (A) NAME/KEY: Peptide
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /label= Peptide
/note= "The following are alternative amino acids
at these positions: Proline at 3, Phenylalanine
at 4, Serine at 6, Leucine at 7, and Valine at 8."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

Leu Glu Asn Asp Leu Asp Gly Phe Thr Leu
1 5 10

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

Leu Glu Asn Asp Leu Ser Gly Val Thr Leu Thr
1 5 10

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(ix) FEATURE:

- (A) NAME/KEY: Peptide
(B) LOCATION: 17
(D) OTHER INFORMATION: /label= Peptide
/note= "The amino acid at position 17 may also be
Tyrosine."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

Tyr Tyr Gly His Gly Ala Gly Asn Pro Leu Gly Pro Thr Gln Gly Val
1 5 10 15
Gly Ala Asn Glu
20

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

- 101 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

Leu Ile Ala
1

(2) INFORMATION FOR SEQ ID NO:45:

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

10 Val Thr Phe Ala Gln Val Leu Ser
1 5

(2) INFORMATION FOR SEQ ID NO:46:

- 15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

Phe Ile Glu Gly Phe Gln Ser Thr
1 5

20 (2) INFORMATION FOR SEQ ID NO:47:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

25 (ix) FEATURE:

- (A) NAME/KEY: Peptide
(B) LOCATION: 1
(D) OTHER INFORMATION: /label= Peptide
/note= "The amino acid at position 1 may also be
30 Asparagine."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

Asp Tyr Leu Gln Ser Leu Lys
1 5

(2) INFORMATION FOR SEQ ID NO:48:

- 35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

- 102 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

Asn Ile Glu Pro Phe Gln Val Asn
 1 5

(2) INFORMATION FOR SEQ ID NO:49:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 6 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

10 Val Leu Val Asn Asp Arg
 1 5

(2) INFORMATION FOR SEQ ID NO:50:

- 15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

Leu Ala Val Pro Ala Ser Arg Asp Gln Ser Thr Xaa Asp Thr
 1 5 10

20 (2) INFORMATION FOR SEQ ID NO:51:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 3 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: both

25 (ix) FEATURE:

- (A) NAME/KEY: Peptide
 (B) LOCATION: 1
 (D) OTHER INFORMATION: /label= Peptide
 30 /note= "When deduced from the DNA sequence the
 amino acid at position 1 was found to be
 cysteine."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

Arg Ser Ala
 1

35 (2) INFORMATION FOR SEQ ID NO:52:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 17 base pairs
 (B) TYPE: nucleic acid
 40 (C) STRANDEDNESS: single
 (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

CATTTCNC ARTTYAA

- 103 -

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

Phe Ser Tyr Gly Ala Ala Ile Pro Gln Ser Thr Gln Glu Lys
 1 5 10

(2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

Gln Phe Ser Gln Glu Phe Arg Asp Gly Tyr
 1 5 10

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 7 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

Tyr Gly Gly Asn Gly Pro Tyr
 1 5

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 6 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

Val Ser Tyr Gly Ile Ala
 1 5

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 13 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

Arg His Gly Glu Arg Tyr Pro Ser Pro Ser Ala Gly Lys
 1 5 10

- 104 -

(2) INFORMATION FOR SEQ ID NO:58:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

Asp Ile Glu Glu Ala Leu Ala Lys
1 5

(2) INFORMATION FOR SEQ ID NO:59:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

Ala Arg Tyr Gly His Leu Trp Asn Gly Glu Thr
1 5 10

(2) INFORMATION FOR SEQ ID NO:60:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

Val Val Pro Phe Phe Ser Ser Gly
1 5

(2) INFORMATION FOR SEQ ID NO:61:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

Phe Ser Ser Gly Tyr Gly Arg
1 5

(2) INFORMATION FOR SEQ ID NO:62:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

Gln Leu Pro Gln Phe Lys
1 5

- 105 -

(2) INFORMATION FOR SEQ ID NO:63:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

Val Ala Phe Gly Asn Pro Tyr
1 5

(2) INFORMATION FOR SEQ ID NO:64:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both

(ix) FEATURE:

- (A) NAME/KEY: modified_base
(B) LOCATION: 12
(D) OTHER INFORMATION: /mod_base= i

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

20 GTRCCNCTYK CNATRGG

17

(2) INFORMATION FOR SEQ ID NO:65:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

CARCTNCCNC ARTTYAA

17

(2) INFORMATION FOR SEQ ID NO:66:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

GAATTCCGAG TCCGAGGTCA TGGGCGCG

28

- 109 -

24. The host cell of claim 23, wherein said genetic sequence encoding said phytase has the DNA sequence of SEQ ID No. :7:, or encodes an enzymatically active derivative thereof.
- 5 25. The host cell of claim 22, wherein said pH 2.5 acid phosphatase has the amino acid sequence of SEQ ID No. :2:, or an enzymatically active derivative thereof.
26. The host cell of claim 25, wherein said genetic sequence encoding said pH 2.5 acid phosphatase has the DNA sequence of SEQ ID No. :1:, or encodes an enzymatically active derivative thereof.
- 10 27. The host cell of claim 19, wherein said the sequences encoding said phytate degrading enzyme are operably linked to sequences encoding a signal sequence.
28. The host cell of claim 27, wherein said signal sequence is selected from the group consisting of the signal sequence of CHBI, CBHII, 15 EGI, EGII, pH 2.5 acid phosphatase and phytase.
29. The host cell of claim 19, wherein said genetic sequence encoding said phytate degrading enzyme is provided by a vector selected from the group consisting of pALK171, pALK172, pALK173A and pALK173B, pALK532, pALK533 and a fragment thereof that encodes said phytate 20 degrading enzyme.
30. The host cell of claim 19, wherein said host cell is *Trichoderma reesei*.
31. A method for overexpressing phytate degrading enzymes in *Trichoderma*, wherein the method comprises the steps of:
- 25 (a) preparing a recombinant construct, said recombinant construct containing a gene encoding a phytate degrading enzyme:

- 110 -

- (b) transforming a *Trichoderma* host with said construct;
- (c) cultivating the transformed *Trichoderma* under conditions suitable for said *Trichoderma* and for expression of said phytate degrading enzyme.

- 5 32. The method of claim 31, wherein said DNA construct is provided to said *Trichoderma* host in a linear form.
33. The method of claim 31, wherein said DNA construct is provided to said *Trichoderma* host in a circular plasmid form.
- 10 34. The method of claim 32, wherein said linear form lacks bacterial sequences.
35. The method of claim 31, wherein said phytate degrading enzyme is selected from the group consisting of phytase, pH 2.5 acid phosphatase, an enzymatically active derivative of said phytase and an enzymatically active derivative of said pH 2.5 acid phosphatase.
- 15 36. The method of claim 34, wherein said phytase has the amino acid sequence of SEQ ID No. :8:, or an enzymatically active derivative thereof.
- 20 37. The method of claim 35, wherein the genetic sequence encoding said phytase has the DNA sequence of SEQ ID No. :7:, or encodes an enzymatically active derivative thereof.

- 111 -

38. The method of claim 34, wherein said pH 2.5 acid phosphatase has the amino acid sequence of SEQ ID No. :2:, or an enzymatically active derivative thereof.
- 5 39. The method of claim 37, wherein said genetic sequence encoding said pH 2.5 acid phosphatase has the DNA sequence of SEQ ID No. :1:, or encodes an enzymatically active derivative thereof.
40. The method of claim 31, wherein said the genetic sequences encoding said phytate degrading enzyme are operably linked to genetic sequences encoding a signal sequence.
- 10 41. The method of claim 39, wherein said signal sequence is selected from the group consisting of the signal sequence of CHBI, CBHII, EGI, EGII, pH 2.5 acid phosphatase and phytase.
42. The method of claim 31, wherein said recombinant construct is selected from the group consisting of pALK171, pALK172, 15 pALK173A, pALK173B, pALK532, pALK533 and a fragment thereof that encodes said phytate degrading enzyme.
43. The method of claim 14, wherein said host cell is *Trichoderma reesei*.
44. A method of cloning a fusion of the *Trichoderma reesei cbh1* promoter to the *Aspergillus niger* var. *awamori* phytase signal sequence, 20 wherein said method comprises polymerase chain amplification of a fusion of the *cbh1* promoter with phytase signal sequence using a 5' primer having SEQ ID No. :9: and a 3' primer having SEQ ID No. :10:.
45. A method of cloning a fusion of DNA encoding the *Trichoderma reesei* 25 CBH1 signal sequence to the *Aspergillus niger* var. *awamori* mature

- 112 -

- phytase coding sequence, wherein said method comprises polymerase chain amplification of the DNA encoding said CBH1 signal sequence with a 5' primer having SEQ ID No. :11: and polymerase chain amplification of the phytase coding sequence with a 3' primer having SEQ ID No. :12:.
- 5
46. A method of cloning a fusion of the *Trichoderma reesei cbh1* promoter to the *Aspergillus niger* var. *awamori* pH 2.5 acid phosphatase signal sequence, wherein said method comprises polymerase chain amplification of the a sequence encoding a fusion of said *cbh1* promoter and said signal sequence with a 5' primer having SEQ ID No. :15: and a 3' primer having SEQ ID No. :14:.
- 10
47. A method of cloning a fusion of DNA encoding the *Trichoderma reesei* CBH1 signal sequence to the *Aspergillus niger* var. *awamori* coding sequence of the mature pH 2.5 acid phosphatase, wherein said method comprises polymerase chain amplification of the DNA encoding said CBH1 signal sequence with a 5' primer having SEQ ID No. :13: and polymerase chain amplification of said pH 2.5 acid phosphatase coding sequence with a 3' primer having SEQ ID No. :14:.
- 15

1/22

PEPTIDE #816: Arg His Gly Glu Arg Tyr Pro Ser Pro Ser Ala
 OLIGO PHY-31 3' -GTG CCG CTC GCI ATG GG- 5'
 A A T T A
 T
 C

PEPTIDE #1110: Gln Leu Pro Gln Phe Lys
 OLIGO PHY-34 5' - CAA CTG CCG CAA TTT AA -3'
 G A A G C
 T T
 C C

OLIGO PHY-35 5' - CAA TTA CCG CAA TTT AA -3'
 G G A G C
 T
 C

FIG.1

		2/22	
>SphI			
GCATGCTGGA CCGCAATCTC CGATCGCCGG GTATAAAAGG TCCTCCAAAC CCCTCTCGGT	60		
CGATATGTAC CCCGCTCGTC ATCTCCAATC CTCTCGAGAG CACCTTCTCC AGCTTTTGTC	120		
AATTGTACCT TCGCA ATG CCT CGC ACC TCT CTC CTC ACC CTG GCC TGT GCT	171		
Met Pro Arg Thr Ser Leu Leu Thr Leu Ala Cys Ala			
1 5 10			
CTG GCC ACG GGC GCA TCC GCT TTC TCC TAC GGC GCT GCC ATT CCT CAG	219		
Leu Ala Thr Gly Ala Ser Ala Phe Ser Tyr Gly Ala Ala Ile Pro Gln			
15 20 25			
TCA ACC CAG GAG AAG CAG TTC TCT CAG GAG TTC CGC GAT GGC TAC AGC	267		
Ser Thr Gln Glu Lys Gln Phe Ser Gln Glu Phe Arg Asp Gly Tyr Ser			
30 35 40			
ATC CTC AAG CAC TAC GGT GGT AAC GGA CCC TAC TCC GAG CGT GTG TCC	315		
Ile Leu Lys His Tyr Gly Gly Asn Gly Pro Tyr Ser Glu Arg Val Ser			
45 50 55 60			
TAC GGT ATC GCT CGC GAT CCC CCG ACC AGC TGC GAG GTC GAT CAG GTC	363		
Tyr Gly Ile Ala Arg Asp Pro Pro Thr Ser Cys Glu Val Asp Gln Val			
65 70 75			
ATC ATG GTC AAG CGT CAC GGA GAG CGC TAC CCG TCC CCT TCA GCC GGC	411		
Ile Met Val Lys Arg His Gly Glu Arg Tyr Pro Ser Pro Ser Ala Gly			
80 85 90			
AAG GAC ATC GAA GAG GCC CTG GCC AAG GTC TAC AGC ATC AAC ACT ACT	459		
Lys Asp Ile Glu Glu Ala Leu Ala Lys Val Tyr Ser Ile Asn Thr Thr			
95 100 105			
GAA TAC AAG GGC GAC CTG GCC TTC CTG AAC GAC TGG ACC TAC TAC GTC	507		
Glu Tyr Lys Gly Asp Leu Ala Phe Leu Asn Asp Trp Thr Tyr Tyr Val			
110 115 120			
CCT AAT GAG TGC TAC TAC AAC GCC GAG ACC ACC AGC GGC CCC TAC GCC	555		
Pro Asn Glu Cys Tyr Tyr Asn Ala Glu Thr Thr Ser Gly Pro Tyr Ala			
125 130 135 140			
GGT TTG CTG GAC GCG TAC AAC CAT GGC AAC GAT TAC AAG GCT CGC TAC	603		
Gly Leu Leu Asp Ala Tyr Asn His Gly Asn Asp Tyr Lys Ala Arg Tyr			
145 150 155			

FIG.2A

3/22

GGC CAC CTC TGG AAC GGT GAG ACG GTC GTG CCC TTC TTT TCT AGT GGC Gly His Leu Trp Asn Gly Glu Thr Val Val Pro Phe Phe Ser Ser Gly 160 165 170	651
TAC GGA CGT GTC ATC GAG ACG GCC CGC AAG TTC GGT GAG GGT TTC TTT Tyr Gly Arg Val Ile Glu Thr Ala Arg Lys Phe Gly Glu Gly Phe Phe 175 180 185	699
GGC TAC AAC TAC TCC ACC AAC GCT GCC CTC AAC ATC ATC TCC GAG TCC Gly Tyr Asn Tyr Ser Thr Asn Ala Ala Leu Asn Ile Ile Ser Glu Ser 190 195 200	747
GAG GTC ATG GGC GCG GAC AGC CTC ACG CCC ACC TGT GAC ACC GAC AAC Glu Val Met Gly Ala Asp Ser Leu Thr Pro Thr Cys Asp Thr Asp Asn 205 210 215 220	795
GAC CAG ACC ACC TGC GAC AAC CTG ACT TAC CAG CTG CCC CAG TTC AAG Asp Gln Thr Thr Cys Asp Asn Leu Thr Tyr Gln Leu Pro Gln Phe Lys 225 230 235	843
GTC GCT GCT GCC CGC CTA AAC TCC CAG AAC CCC GGC ATG AAC CTC ACC Val Ala Ala Ala Arg Leu Asn Ser Gln Asn Pro Gly Met Asn Leu Thr 240 245 250	891
GCA TCT GAT GTC TAC AAC CTG ATG G <u>GTATGTGAT</u> TACGGTACAA TCATTGGCTC Ala Ser Asp Val Tyr Asn Leu Met 255 260	945
AAACCTCCAG <u>CTGACAGCAT</u> CCTAG TT ATG GCC TCC TTT GAG CTC AAT GCT Val Met Ala Ser Phe Glu Leu Asn Ala 265	996
CGT CCC TTC TCC AAC TGG ATC AAC GCC TTT ACC CAG GAC GAA TGG GTC Arg Pro Phe Ser Asn Trp Ile Asn Ala Phe Thr Gln Asp Glu Trp Val 270 275 280 285	1044
AGC TTC GGT TAC GTT GAG GAT TTG AAC TAC TAC TAC TGC GCT GG <u>G</u> Ser Phe Gly Tyr Val Glu Asp Leu Asn Tyr Tyr Tyr Cys Ala Gly 290 295 300	1089

FIG.2B

SUBSTITUTE SHEET

CATCCAGGCA	CCCTTTCCCA	ACGGGGGAAC	TTCCGTTGTC	CACGTGCCCT	GGTTCAGCCA	60
ATCAAAGCGT	CCCACGGCAA	TGCTGGATCA	ACGATCAACT	TGAATGCAAT	AAATGAAGAT	120
GCAACTAACA	CCATCTGTTG	CCTTTCTCTC	GAGAAAGCTC	CTCCACTTCT	CACACTAGAT	180
TTATCCGTTC	CTTGTCGACT	TCCCGTCCCA	TTCGGCCTCG	TCCACTGAAG	ATCTATCCCA	240
CCATTGCACG	TGGGCCACCT	TTGTGAGCTT	CTAACCTGAA	CTGGTAGAGT	ATCACACAAC	300
ATGCGAAAGT	GGGATGAAGG	GGTTATATGA	GGACCGTCCG	GTCCGGCGCG	ATGGCCGTAG	360
CTGCCAATCG	CTGCTGTGCA	AGAAATTTCT	TCTCATAGGC	ATC	ATG GGC GTC TCT	415
					Met Gly Val Ser	
GCT GTT CTA CTT CCT TTG TAT CTC CTA GCT GG	GTATGCTAAG	CACCGCTATC	467			
Ala Val Leu Leu Pro Leu Tyr Leu Leu Ala Gl						
-15	-10	-5				
TAAGTCTGAT	AAGGACCCTC	TTTGCCGAGG	GCCCCTGAAG	CTCGGACTGT	GTGGGACTAC	527
TGATCGCTGA	CAATCTGTGC	AG A GTC ACC TCC GGA CTG GCA GTC CCC GCC TCG	580			
		y Val Thr Ser Gly Leu Ala Val Pro Ala Ser				
			1		5	
AGA AAT CAA TCC ACT TGC GAT ACG GTC GAT CAA GGG TAT CAA TGC TTC	628					
Arg Asn Gln Ser Thr Cys Asp Thr Val Asp Gln Gly Tyr Gln Cys Phe						
	10	15	20			
TCC GAG ACT TCG CAT CTT TGG GGT CAA TAC GCG CCG TTC TTC TCT CTG	676					
Ser Glu Thr Ser His Leu Trp Gly Gln Tyr Ala Pro Phe Phe Ser Leu						
	25	30	35			
GCA AAC GAA TCG GCC ATC TCC CCT GAT GTG CCC GCC GGT TGC AGA GTC	724					
Ala Asn Glu Ser Ala Ile Ser Pro Asp Val Pro Ala Gly Cys Arg Val						
	40	45	50			
ACT TTC GCT CAG GTC CTC TCC CGT CAT GGA GCG CGG TAT CCG ACC GAG	772					
Thr Phe Ala Gln Val Leu Ser Arg His Gly Ala Arg Tyr Pro Thr Glu						
	55	60	65	70		
TCC AAG GGC AAG AAA TAC TCC GCT CTC ATT GAG GAG ATC CAG CAG AAC	820					
Ser Lys Gly Lys Lys Tyr Ser Ala Leu Ile Glu Glu Ile Gln Gln Asn						
	75	80	85			
GTG ACC ACC TTT GAT GGA AAA TAT GCC TTC CTG AAG ACA TAC AAC TAC	868					
Val Thr Thr Phe Asp Gly Lys Tyr Ala Phe Leu Lys Thr Tyr Asn Tyr						
	90	95	100			
AGC TTG GGT GCA GAT GAC CTG ACT CCC TTC GGA GAG CAG GAG CTA GTC	916					
Ser Leu Gly Ala Asp Asp Leu Thr Pro Phe Gly Glu Gln Glu Leu Val						
	105	110	115			
AAC TCC GGC ATC AAG TTC TAC CAG CGA TAC GAA TCG CTC ACA AGG AAC	964					
Asn Ser Gly Ile Lys Phe Tyr Gln Arg Tyr Glu Ser Leu Thr Arg Asn						
	120	125	130			
ATC ATT CCG TTC ATC CGA TCC TCT GGC TCC AGC CGC GTG ATC GCC TCC	1012					

Figure 5

Ile	Ile	Pro	Phe	Ile	Arg	Ser	Ser	Gly	Ser	Ser	Arg	Val	Ile	Ala	Ser	
135					140					145					150	
GGC	GAG	AAA	TTC	ATT	GAG	GGC	TTC	CAG	AGC	ACC	AAG	CTG	AAG	GAT	CCT	1060
Gly	Glu	Lys	Phe	Ile	Glu	Gly	Phe	Gln	Ser	Thr	Lys	Leu	Lys	Asp	Pro	
				155					160					165		
CGT	GCC	CAG	CCG	GGC	CAA	TCG	TCG	CCC	AAG	ATC	GAC	GTG	GTC	ATT	TCC	1108
Arg	Ala	Gln	Pro	Gly	Gln	Ser	Ser	Pro	Lys	Ile	Asp	Val	Val	Ile	Ser	
			170					175					180			
GAG	GCC	AGC	TCA	TCC	AAC	AAC	ACT	CTC	GAC	CCA	GGC	ACC	TGC	ACT	GTC	1156
Glu	Ala	Ser	Ser	Ser	Asn	Asn	Thr	Leu	Asp	Pro	Gly	Thr	Cys	Thr	Val	
		185					190					195				
TTT	GAA	GAC	AGC	GAA	TTG	GCC	GAT	ACC	GTC	GAA	GCC	AAT	TTC	ACC	GCC	1204
Phe	Glu	Asp	Ser	Glu	Leu	Ala	Asp	Thr	Val	Glu	Ala	Asn	Phe	Thr	Ala	
	200					205					210					
ACG	TTC	GCC	CCC	TCC	ATT	CGT	CAA	CGT	CTG	GAG	AAC	GAC	CTG	TCT	GGC	1252
Thr	Phe	Ala	Pro	Ser	Ile	Arg	Gln	Arg	Leu	Glu	Asn	Asp	Leu	Ser	Gly	
215					220					225					230	
GTG	ACT	CTC	ACA	GAC	ACA	GAA	GTG	ACC	TAC	CTC	ATG	GAC	ATG	TGC	TCC	1300
Val	Thr	Leu	Thr	Asp	Thr	Glu	Val	Thr	Tyr	Leu	Met	Asp	Met	Cys	Ser	
				235				240						245		
TTC	GAC	ACC	ATC	TCC	ACC	AGC	ACC	GTC	GAC	ACC	AAG	CTG	TCC	CCC	TTC	1348
Phe	Asp	Thr	Ile	Ser	Thr	Ser	Thr	Val	Asp	Thr	Lys	Leu	Ser	Pro	Phe	
			250					255					260			
TGT	GAC	CTG	TTC	ACC	CAT	GAC	GAA	TGG	ATC	CAC	TAC	GAC	TAC	CTC	CAG	1396
Cys	Asp	Leu	Phe	Thr	His	Asp	Glu	Trp	Ile	His	Tyr	Asp	Tyr	Leu	Gln	
	265						270					275				
TCC	CTG	AAA	AAA	TAC	TAC	GGC	CAT	GGC	GCA	GGT	AAC	CCG	CTC	GGC	CCG	1444
Ser	Leu	Lys	Lys	Tyr	Tyr	Gly	His	Gly	Ala	Gly	Asn	Pro	Leu	Gly	Pro	
	280					285					290					
ACC	CAG	GGC	GTC	GGC	TAC	GCT	AAC	GAG	CTC	ATC	GCC	CGT	CTC	ACC	CAC	1492
Thr	Gln	Gly	Val	Gly	Tyr	Ala	Asn	Glu	Leu	Ile	Ala	Arg	Leu	Thr	His	
295					300				305						310	
TCG	CCT	GTC	CAC	GAT	GAC	ACC	AGC	TCC	AAC	CAC	ACC	TTG	GAC	TCG	AAC	1540
Ser	Pro	Val	His	Asp	Asp	Thr	Ser	Ser	Asn	His	Thr	Leu	Asp	Ser	Asn	
				315				320						325		
CCA	GCT	ACC	TTC	CCG	CTC	AAC	TCT	ACT	CTC	TAC	GCG	GAC	TTT	TCC	CAC	1588
Pro	Ala	Thr	Phe	Pro	Leu	Asn	Ser	Thr	Leu	Tyr	Ala	Asp	Phe	Ser	His	
			330					335					340			
GAT	AAC	GGC	ATC	ATC	TCT	ATC	CTC	TTT	GCT	TTG	GGT	CTG	TAC	AAC	GGC	1636
Asp	Asn	Gly	Ile	Ile	Ser	Ile	Leu	Phe	Ala	Leu	Gly	Leu	Tyr	Asn	Gly	
		345					350					355				
ACT	AAG	CCG	CTG	TCT	ACC	ACG	ACC	GTG	GAG	AAT	ATC	ACC	CAG	ACA	GAT	1684
Thr	Lys	Pro	Leu	Ser	Thr	Thr	Thr	Val	Glu	Asn	Ile	Thr	Gln	Thr	Asp	
	360					365					370					

Figure 5

GGG TTC TCG TCT GCT TGG ACG GTT CCG TTT GCT TCG CGT CTG TAC GTC 1732
 Gly Phe Ser Ser Ala Trp Thr Val Pro Phe Ala Ser Arg Leu Tyr Val
 375 380 385 390

GAG ATG ATG CAG TGC CAG GCC GAG CAG GAG CCG CTG GTC CGT GTC TTG 1780
 Glu Met Met Gln Cys Gln Ala Glu Gln Glu Pro Leu Val Arg Val Leu
 395 400 405

GTT AAT GAT CGC GTT GTC CCG CTG CAT GGG TGT CCA ATT GAT GCT TTG 1828
 Val Asn Asp Arg Val Val Pro Leu His Gly Cys Pro Ile Asp Ala Leu
 410 415 420

GGG AGA TGT ACC CGG GAT AGC TTT GTG AGG GGG TTG AGC TTT GCT AGA 1876
 Gly Arg Cys Thr Arg Asp Ser Phe Val Arg Gly Leu Ser Phe Ala Arg
 425 430 435

TCT GGG GGT GAT TGG GCG GAG TGT TCT GCT TAGCTGAACT ACCTTGATGG 1926
 Ser Gly Gly Asp Trp Ala Glu Cys Ser Ala
 440 445

ATGGTATGTA TCAATCAGAG TACATATCAT TACTTCATGT ATGTATTTAC GAAGATGTAC 1986

ATATCGAAAT ATCGATGATG ACTACTCCGG TAGATATTTG GTCCCCTTCT ATCCTTCGTT 2046

CCACAACCAT CGCACTCGAC GTACAGCATA ATACAACTTC AGCATTAACA AACGAACAAA 2106

TAATATTATA CACTCCTCCC CAATGCAATA ACAACCGCAA TTCATACCTC ATATAGATAC 2166

AATACAATAC ATCCATCCCT ACCCTCAAGT CCACCCATCC CATAATCAAA TCCCTACTTA 2226

CTCCTCCCCC TTCCCAGAAC CCACCCCCGA AGGAGTAATA GTAGTAGTAG AAGAAGCAGA 2286

CGACCTCTCC ACCAACCTCT TCGGCCTCTT ATCCCCATAC GCTATACACA CACGAACACA 2346

CCAAATAGTC AGCATGC

pALK171 fusion

5'-primer (39-mer) [SEQ ID No. 9]

5'- C AAC GGC GGA CTG GCG ATC ATG GGC GTC TCT GCT GTT CT
SacI19 nts "tail" of *cbh1*
(promoter sequence)

20 nts of the phytase signal sequence

3'-primer (22-mer)

5'- A TTT CTC GAG GCG GGG ACT GGC [SEQ ID No. 10]
XhoI
phytase sequencepALK172 fusion

5'-primer (46-mer) [SEQ ID No. 11]

5'- CTC GCG CTT CTT GCG CAC AGC TCG TGCT CTG GCA GTC CCC GCC TCG
SfiI28 nts "tail" of *cbh1*
(signal sequence)18 nts of the phytase N-terminal
sequence

3'-primer (24-mer) [SEQ ID No. 12]

5'- TTG GTG TCG ACG GTG CTG GTG GAG
SalI
phytase sequence

FIGURE 6

4/22

TGAGTTTACC ATTTGATCCA TTATTGTCTT GGATCAGCTA ACGATCGATA G T CCC	1144
Pro	
GGT GAC AAG AAC ATG GCT GCT GTG GGT GCC GTC TAC GCC AAC GCC AGT	1192
Gly Asp Lys Asn Met Ala Ala Val Gly Ala Val Tyr Ala Asn Ala Ser	
305 310 315	
CTC ACC CTC CTG AAC CAG GGA CCC AAG GAA GCC GGC TCC TTG TTC TTC	1240
Leu Thr Leu Leu Asn Gln Gly Pro Lys Glu Ala Gly Ser Leu Phe Phe	
320 325 330	
AAC TT GTACGTTCTCG GCAGAATCAG AGTCTCACAA AAAGAACTC TTCACTAACA	1296
Asn Phe	
335	
TATAGTAG T GCC CAC GAC ACC AAC ATC ACC CCC ATC CTC GCC GCC CTA	1344
Ala His Asp Thr Asn Ile Thr Pro Ile Leu Ala Ala Leu	
340 345	
GGC GTC CTC ATC CCC AAC GAG GAC CTT CCT CTT GAC CGG GTC GCC TTC	1392
Gly Val Leu Ile Pro Asn Glu Asp Leu Pro Leu Asp Arg Val Ala Phe	
350 355 360	
GGC AAC CCC TAC TCG ATC GGC AAC ATC GTG CCC ATG GGT GGC CAT CTG	1440
Gly Asn Pro Tyr Ser Ile Gly Asn Ile Val Pro Met Gly Gly His Leu	
365 370 375 380	
ACC ATC GAG CGT CTC AGC TGC CAG GCC ACC GCC CTC TCG GAC GAG GGT	1488
Thr Ile Glu Arg Leu Ser Cys Gln Ala Thr Ala Leu Ser Asp Glu Gly	
385 390 395	
ACC TAC GTG CGT CTG GTG CTG AAC GAG GCT GTA CTC CCC TTC AAC GAC	1536
Thr Tyr Val Arg Leu Val Leu Asn Glu Ala Val Leu Pro Phe Asn Asp	
400 405 410	
TGC ACC TCC GGA CCG GGC TAC TCC TGC CCT CTG GCC AAC TAC ACC TCC	1584
Cys Thr Ser Gly Pro Gly Tyr Ser Cys Pro Leu Ala Asn Tyr Thr Ser	
415 420 425	
ATC CTG AAC AAG AAT CTG CCA GAC TAC ACG ACC ACC TGC AAT GTC TCT	1632
Ile Leu Asn Lys Asn Leu Pro Asp Tyr Thr Thr Thr Cys Asn Val Ser	
430 435 440	

FIG.2C

SUBSTITUTE SHEET

5 / 22

GCG TCC TAC CCG CAG TAT CTG AGC TTC TGG TGG AAC TAC AAC ACC ACG 1680
Ala Ser Tyr Pro Gln Tyr Leu Ser Phe Trp Trp Asn Tyr Asn Thr Thr
445 450 455 460

ACG GAG CTG AAC TAC CGC TCT AGC CCT ATT GCC TGC CAG GAG GGT GAT 1728
Thr Glu Leu Asn Tyr Arg Ser Ser Pro Ile Ala Cys Gln Glu Gly Asp
465 470 475

GCT ATG GAC TAGATGCAGA GGGGTAGGTC CCGGGATACT TTAGTGATGA 1777
Ala Met Asp

TTGATATTCA AGTTTGGTGG TGACGATCAC CTTGTTAATA GTCTTGTA CA GTCATACGGT 1837

GAATGTAAT AATGATAATA GCAATGATAC ATGTTGGAAT CTCGTTTTGT TCTTTGTGTG 1897

CATAGGCGCT TTGGGGGTGT ATTTTAGGC GTTAGACTTA TTTTCAATTC GTGTATAATG 1957

CGGTCAGTAA ATGAATCATC AATTATTCAA ATGCAATGCT GTATACGTGA AACTATTGGG 2017

TTAAGACGCA GCTACTAGCT GACTGCTTGG TTA[^]CTTTCTG TGTACACCGC ATGC 2071
 >SphI

FIG. 2D

6/22

PEPTIDE # 792

1	2	3	4	5	6	7	8	9	10	11	12
Tyr	Tyr	Gly	His	Gly	Ala	Gly	Asn	Pro	Leu	Gly	Pro -

OLIGONUCLEOTIDE 1

TAT	TAT	GGT	CAT	GGT	GC
C	C	C	C	C	
		G		G	
		A		A	

13	14	15	16	17	18	19	20	21	22	23	24
- Thr	Gln	Gly	Val	Gly	Tyr	Ala	Asn	Glu	Leu	Ile	Ala -

OLIGONUCLEOTIDE 2

CAA	GGT	GTT	GGT	TAT	GC
G	C	C	C	C	
	G	G	G		
	A	A	A		

PEPTIDE # 420

1	2	3	4	5	6	7	8	9	10	11
Leu	Tyr	Val	Glu	Met	Met	Gln	(Asn)	Gln	Ala	(Glu)
12	13	14	15	16						
Gln	(Thr)	Pro	Leu	Val						

OLIGONUCLEOTIDE 3

TAT	GTT	GAA	ATG	ATG	CAA	AA
C	C	G			G	
	G					
	A					

OLIGONUCLEOTIDE 4

ATG	ATG	CAA	AAT	CAA	GCT	GAA	CA
-----	-----	-----	-----	-----	-----	-----	----

FIG.3

SUBSTITUTE SHEET

7/22




FIG.4

8/22

CATCCAGGCA CCCTTTCCCA ACGGGGGAAC TTCCGTTGTC CACGTGCCCT GGTTCAGCCA	60
ATCAAAGCGT CCCACGGCAA TGCTGGATCA ACGATCAACT TGAATGCAAT AAATGAAGAT	120
GCAACTAACA CCATCTGTTG CCTTTCTCTC GAGAAAGCTC CTCCACTTCT CACACTAGAT	180
TTATCCGTTG CTTGTGCACT TCCCGTCCCA TTCGGCCTCG TCCACTGAAG ATCTATCCCA	240
CCATTGCACG TGGGCCACCT TTGTGAGCTT CTAACCTGAA CTGGTAGAGT ATCACACAAC	300
ATGCGAAAGT GGGATGAAGG GGTATATGA GGACCGTCCG GTCCGGCGCG ATGGCCGTAG	360
CTGCCAATCG CTGCTGTGCA AGAAATTCT TCTCATAGGC ATC ATG GGC GTC TCT	415
Met Gly Val Ser	
GCT GTT CTA CTT CCT TTG TAT CTC CTA GCT GG GTATGCTAAG	457
Ala Val Leu Leu Pro Leu Tyr Leu Leu Ala Gly	
-15 - 10 -5	
CACCGCTATC TAAGTCTGAT AAGGACCCTC TTTGCCGAGG GCCCCTGAAG CTCGGACTGT	517
GTGGGACTAC TGATCGCTGA CAATCTGTGC AG A GTC ACC TCC GGA CTG GCA	568
Val Thr Ser Gly Leu Ala	
1	
GTC CCC GCC TCG AGA AAT CAA TCC ACT TGC GAT ACG GTC GAT CAA GGG	616
Val Pro Ala Ser Arg Asn Gln Ser Thr Cys Asp Thr Val Asp Gln Gly	
5 10 15	
TAT CAA TGC TTC TCC GAG ACT TCG CAT CTT TGG GGT CAA TAC GCG CCG	664
Tyr Gln Cys Phe Ser Glu Thr Ser His Leu Trp Gly Gln Tyr Ala Pro	
20 25 30	
TTC TTC TCT CTG GCA AAC GAA TCG GCC ATC TCC CCT GAT GTG CCC GCC	712
Phe Phe Ser Leu Ala Asn Glu Ser Ala Ile Ser Pro Asp Val Pro Ala	
35 40 45 50	
GGT TGC AGA GTC ACT TTC GCT CAG GTC CTC TCC CGT CAT GGA GCG CGG	760
Gly Cys Arg Val Thr Phe Ala Gln Val Leu Ser Arg His Gly Ala Arg	
55 60 65	

FIG.5A

SUBSTITUTE SHEET

9/22

TAT CCG ACC GAG TCC AAG GGC AAG AAA TAC TCC GCT CTC ATT GAG GAG Tyr Pro Thr Glu Ser Lys Gly Lys Lys Tyr Ser Ala Leu Ile Glu Glu 70 75 80	808
ATC CAG CAG AAC GTG ACC ACC TTT GAT GGA AAA TAT GCC TTC CTG AAG Ile Gln Gln Asn Val Thr Thr Phe Asp Gly Lys Tyr Ala Phe Leu Lys 85 90 95	856
ACA TAC AAC TAC AGC TTG GGT GCA GAT GAC CTG ACT CCC TTC GGA GAG Thr Tyr Asn Tyr Ser Leu Gly Ala Asp Asp Leu Thr Pro Phe Gly Glu 100 105 110	904
CAG GAG CTA GTC AAC TCC GGC ATC AAG TTC TAC CAG CGA TAC GAA TCG Gln Glu Leu Val Asn Ser Gly Ile Lys Phe Tyr Gln Arg Tyr Glu Ser 115 120 125 130	952
CTC ACA AGG AAC ATC ATT CCG TTC ATC CGA TCC TCT GGC TCC AGC CGC Leu Thr Arg Asn Ile Ile Pro Phe Ile Arg Ser Ser Gly Ser Ser Arg 135 140 145	1000
GTG ATC GCC TCC GGC GAG AAA TTC ATT GAG GGC TTC CAG AGC ACC AAG Val Ile Ala Ser Gly Glu Lys Phe Ile Glu Gly Phe Gln Ser Thr Lys 150 155 160	1048
CTG AAG GAT CCT CGT GCC CAG CCG GGC CAA TCG TCG CCC AAG ATC GAC Leu Lys Asp Pro Arg Ala Gln Pro Gly Gln Ser Ser Pro Lys Ile Asp 165 170 175	1096
GTG GTC ATT TCC GAG GCC AGC TCA TCC AAC AAC ACT CTC GAC CCA GGC Val Val Ile Ser Glu Ala Ser Ser Ser Asn Asn Thr Leu Asp Pro Gly 180 185 190	1144
ACC TGC ACT GTC TTT GAA GAC AGC GAA TTG GCC GAT ACC GTC GAA GCC Thr Cys Thr Val Phe Glu Asp Ser Glu Leu Ala Asp Thr Val Glu Ala 195 200 205 210	1192
AAT TTC ACC GCC ACG TTC GCC CCC TCC ATT CGT CAA CGT CTG GAG AAC Asn Phe Thr Ala Thr Phe Ala Pro Ser Ile Arg Gln Arg Leu Glu Asn 215 220 225	1240
GAC CTG TCT GGC GTG ACT CTC ACA GAC ACA GAA GTG ACC TAC CTC ATG Asp Leu Ser Gly Val Thr Leu Thr Asp Thr Glu Val Thr Tyr Leu Met 230 235 240	1288

FIG.5B

SUBSTITUTE SHEET

10/22

GAC ATG TGC TCC TTC GAC ACC ATC TCC ACC AGC ACC GTC GAC ACC AAG Asp Met Cys Ser Phe Asp Thr Ile Ser Thr Ser Thr Val Asp Thr Lys 245 250 255	1336
CTG TCC CCC TTC TGT GAC CTG TTC ACC CAT GAC GAA TGG ATC CAC TAC Leu Ser Pro Phe Cys Asp Leu Phe Thr His Asp Glu Trp Ile His Tyr 260 265 270	1384
GAC TAC CTC CAG TCC CTG AAA AAA TAC TAC GGC CAT GGC GCA GGT AAC Asp Tyr Leu Gln Ser Leu Lys Lys Tyr Tyr Gly His Gly Ala Gly Asn 275 280 285 290	1432
CCG CTC GGC CCG ACC CAG GGC GTC GGC TAC GCT AAC GAG CTC ATC GCC Pro Leu Gly Pro Thr Gln Gly Val Gly Tyr Ala Asn Glu Leu Ile Ala 295 300 305	1480
CGT CTC ACC CAC TCG CCT GTC CAC GAT GAC ACC AGC TCC AAC CAC ACC Arg Leu Thr His Ser Pro Val His Asp Asp Thr Ser Ser Asn His Thr 310 315 320	1528
TTG GAC TCG AAC CCA GCT ACC TTC CCG CTC AAC TCT ACT CTC TAC GCG Leu Asp Ser Asn Pro Ala Thr Phe Pro Leu Asn Ser Thr Leu Tyr Ala 325 330 335	1576
GAC TTT TCC CAC GAT AAC GGC ATC ATC TCT ATC CTC TTT GCT TTG GGT Asp Phe Ser His Asp Asn Gly Ile Ile Ser Ile Leu Phe Ala Leu Gly 340 345 350	1624
CTG TAC AAC GGC ACT AAG CCG CTG TCT ACC ACG ACC GTG GAG AAT ATC Leu Tyr Asn Gly Thr Lys Pro Leu Ser Thr Thr Thr Val Glu Asn Ile 355 360 365 370	1672
ACC CAG ACA GAT GGG TTC TCG TCT GCT TGG ACG GTT CCG TTT GCT TCG Thr Gln Thr Asp Gly Phe Ser Ser Ala Trp Thr Val Pro Phe Ala Ser 375 380 385	1720
CGT CTG TAC GTC GAG ATG ATG CAG TGC CAG GCC GAG CAG GAG CCG CTG Arg Leu Tyr Val Glu Met Met Gln Cys Gln Ala Glu Gln Glu Pro Leu 390 395 400	1768
GTC CGT GTC TTG GTT AAT GAT CGC GTT GTC CCG CTG CAT GGG TGT CCA Val Arg Val Leu Val Asn Asp Arg Val Val Pro Leu His Gly Cys Pro 405 410 415	1816

FIG.5C

SUBSTITUTE SHEET

11/22

ATT GAT GCT TTG GGG AGA TGT ACC CGG GAT AGC TTT GTG AGG GGG TTG	1864
Ile Asp Ala Leu Gly Arg Cys Thr Arg Asp Ser Phe Val Arg Gly Leu	
420 425 430	
AGC TTT GCT AGA TCT GGG GGT GAT TGG GCG GAG TGT TCT GCT	1906
Ser Phe Ala Arg Ser Gly Gly Asp Trp Ala Glu Cys Ser Ala	
435 440 445	
TAGCTGAAC ACCTTGATGG ATGGTATGTA TCAATCAGAG TACATATCAT TACTTCATGT	1966
ATGTATTTAC GAAGATGTAC ATATCGAAAT ATCGATGATG ACTACTCCGG TAGATATTTG	2026
GTCCCCTTCT ATCCTTCGTT CCACAACCAT CGCACTCGAC GTACAGCATA ATACAACTTC	2086
AGCATTAAACA AACGAACAAA TAATATTATA CACTCCTCCC CAATGCAATA ACAACCGCAA	2146
TTCATACCTC ATATAGATAC AATACAATAC ATCCATCCCT ACCCTCAAGT CCACCCATCC	2206
CATAATCAAA TCCCTACTTA CTCCTCCCC TTCCCAGAAC CCACCCCGA AGGAGTAATA	2266
GTAGTAGTAG AAGAAGCAGA CGACCTCTCC ACCAACCTCT TCGGCCTCTT ATCCCCATAC	2326
GCTATACACA CACGAACACA CCAAATAGTC AGCATGC	2363

FIG.5D

12/22

pALK171 FUSION

5' -PRIMER (39-mer)

5' - C AAC CGC GGA CTG CGC ATC ATG GGC GTC TCT GCT GTT CT

SacII

19 nts "tail" of cbh1
(PROMOTER SEQUENCE)20 nts OF THE PHYTASE SIGNAL
SEQUENCE

3' -PRIMER (22-mer)

5' - A TTT CTC GAG GCG GGG ACT GCC

XhoI

PHYTASE SEQUENCE

pALK172 FUSION

5' -PRIMER (46-mer)

5' - CTC GGC CTT CTT GGC CAC AGC TCG TGCT CTG GCA GTC CCC GCC TCG

SfiI

28 nts "tail" of cbh1
(SIGNAL SEQUENCE)18 nts OF THE PHYTASE
N-TERMINAL SEQUENCE

3' -PRIMER (24-mer)

5' - TTG GTG TCG ACG GTG CTG GTG GAG

SalI

PHYTASE SEQUENCE

FIG.6

13/22




FIG.7




FIG.7(Cont.)

15/22




FIG.8

16/22




FIG.8(Cont.)

17/22





FIG.9

18/22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Kdal

200-

97.4-

69-

46-

30-

FIG. 10

SUBSTITUTE SHEET

19/22

pALK532 FUSION

5'-PRIMER (46-mer)

5'- CTC GGC CTT CTT GGC CAC AGC TCG TGC TTT CTC CTA CGG CGC
TGC C

SfiI

28nts tail of cbh1
(SIGNAL SEQUENCE)

18nts OF THE ACID PHOSPHATASE
N-TERMINAL SEQUENCE

3'- PRIMER (30-mer)

5'- GCC ATG GTT GTA CGC GTC CAG CAA ACC GGC

MluI

pH 2.5 ACID PHOSPHATASE SEQUENCE

pALK533 FUSION

5'-PRIMER (39-mer)

5'- CAA CCG CGG ACT GCG CAT CAT GCC TCG CAC CTC TCT CCT

SacII

19nts tail of cbh1
(PROMOTER SEQUENCE)

20nts OF THE ACID PHOSPHATASE
SIGNAL SEQUENCE

3'- PRIMER (30-mer)

5'- GCC ATG GTT GTA CGC GTC CAG CAA ACC GGC

MluI

pH 2.5 ACID PHOSPHATASE SEQUENCE

Fig. 11

466 bp PCR FRAGMENT
(cbh1 PROMOTER + pH 2.5
ACID PHOSPHATASE SIGNAL SEQUENCE)




FIG.12

418 bp PCR FRAGMENT
(cbh1 SIGNAL SEQUENCE + pH 2.5
ACID PHOSPHATASE FUSION)

21/22





FIG.13

22/22

**FIG. 14**

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 5 C12N15/55 C12N15/62 A23K1/165 C12N1/15 //(C12N1/15,
 C12R1:885)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C12N A23K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,91 05053 (GIST-BROCADES, N.V.) 18 April 1991	1,2,8,9, 19,31, 33,35
Y	cited in the application see the whole document, and especially page 16, line 6 - page 17, line 23, and figure 8	19-22, 27-30, 32,34, 40-43
Y	---	19-22, 32,34
A	WO,A,92 01797 (OY ALKO AB) 6 February 1992 cited in the application see page 25, line 6 - page 26, line 19 see examples 6,11,12 ---	7,8
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- * "A" document defining the general state of the art which is not considered to be of particular relevance
- * "E" earlier document but published on or after the international filing date
- * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- * "O" document referring to an oral disclosure, use, exhibition or other means
- * "P" document published prior to the international filing date but later than the priority date claimed

* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* "&" document member of the same patent family

Date of the actual completion of the international search

22 November 1993

Date of mailing of the international search report

10 -12- 1993

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+ 31-70) 340-3016

Authorized officer

ANDRES, S

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JOURNAL OF BIOTECHNOLOGY vol. 17, no. 1 , January 1991 , AMSTERDAM NL pages 35 - 50 UUSITALO, J. ET AL. 'Enzyme production by recombinant Trichoderma reesei strains' cited in the application	1,2,8, 27-30, 40-43
A	see the whole document ---	11-15
Y	APPLIED MICROBIOLOGY AND BIOTECHNOLOGY vol. 35, no. 5 , August 1991 , SPRINGER INTERNATIONAL pages 611 - 614 MULLANEY, E. ET AL. 'Positive identification of a lambda gt11 clone containing a region of fungal phytase gene by immunoprobe and sequence verification' see the whole document ---	1,2,8
A	BIOTECHNOLOGY vol. 9 , October 1991 , NEW YORK US pages 987 - 990 SALOHEIMO, M. & NIKU-PAAVOLA, M.-J. 'Heterologous production of a ligninolytic enzyme: expression of the Phlebia radiata laccase gene in Trichoderma reesei' cited in the application see the whole document ---	
P,X	GENE vol. 127, no. 1 , 15 May 1993 , AMSTERDAM NL pages 87 - 94 VAN HARTINGSVELDT, W. ET AL. 'Cloning, characterization and overexpression of the phytase-encoding gene (phyA) of Aspergillus niger' see the whole document ---	10,11,14
T	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS vol. 195, no. 1 , 31 August 1993 , DULUTH, MINNESOTA US pages 53 - 57 EHRlich, K. ET AL. 'Identification and cloning of a second phytase gene (phyB) from Aspergillus niger (ficuum)' see the whole document -----	16-18

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9105053	18-04-91	AU-B- 636673	06-05-93
		AU-A- 6501190	28-04-91
		CN-A- 1051058	01-05-91
		EP-A- 0420358	03-04-91
		JP-T- 4506007	22-10-92

WO-A-9201797	06-02-92	AU-A- 8093891	18-02-92
		EP-A- 0539395	05-05-93
